

F3

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 May 2001 (25.05.2001)

PCT

(10) International Publication Number  
WO 01/36408 A1

(51) International Patent Classification<sup>7</sup>: C07D 401/02,  
401/14, 405/12, 498/06, 215/56, A61K 31/495, 31/5383,  
31/47, A61P 33/00, 31/04

(21) International Application Number: PCT/SE00/02217

(22) International Filing Date:  
13 November 2000 (13.11.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9904108-9 15 November 1999 (15.11.1999) SE

(71) Applicant (for all designated States except US): NEW  
PHARMA RESEARCH SWEDEN AB [SE/SE]; Ideon  
Research Park, Ole Römers väg 12, S-223 70 Lund (SE).

(72) Inventor; and

(75) Inventor/Applicant (for US only): ABDUL-RAHMAN,  
Shoaá [JO/SE]; Kämpagränden 23 B, 2 tr, S-224 76 Lund  
(SE).

(74) Agent: AWAPATENT AB; Box 5117, S-200 71 Malmö  
(SE).

(81) Designated States (national): AE, AG, AL, AM, AT, AT  
(utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,  
CH, CN, CR, CU, CZ, CZ (utility model), DE, DE (utility  
model), DK, DK (utility model), DM, DZ, EE, EE (utility  
model), ES, FI, FI (utility model), GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KR (utility  
model), KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,  
MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TR, TT,  
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published:

- With international search report.
- With amended claims.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS WITH ANTIBACTERIAL AND ANTIPARASITIC PROPERTIES

WO 01/36408 A1



(I)

(57) Abstract: There are provided novel compounds which have both antibacterial and antiparasitic properties, thereby reducing the need for using several compounds in combined antibacterial and antiparasitic treatment of livestock. The present novel compounds are especially well suited for treatment of coccidiosis, and they are represented by general formula (I) wherein R<sub>1</sub>-R<sub>6</sub>, X and A are as defined in the specification.

## COMPOUNDS WITH ANTIBACTERIAL AND ANTIPARASITIC PROPERTIES.

Field of the Invention

The present invention relates to novel compounds, pharmaceutical compositions containing the same as well  
5 as a method for treatment of bacterial and parasitic disorders, wherein said compounds are administered.

Background of the Invention

The coccidia are intracellular protozoan parasites which are prevalent in all domestic animals as well as in  
10 man. They are the cause of coccidiosis, which is characterized by enteritis. Coccidia of the genus *Eimeria* cause severe intestinal infections in poultry and ruminants (cattle, sheep e.t.c.). In fact, coccidiosis is one of the most frequently occurring diseases of poultry  
15 (see *inter alia* "Poultry Diseases" by Jordan, F.T.W. and Pattison, M., 4<sup>th</sup> ed., pp. 261-276, 1996, W.B. Saunders Co. Ltd., London, UK). It deserves mentioning that the annual costs for anticoccidial medication is about £5 million in the UK only. In poultry, most cases of  
20 coccidiosis are caused by protozoa belonging to the genus *Eimeria*, such as e.g. *E. maxima*, *E. tenella*, *E. acervulina*, *E. necatrix*, *E. hagani*, *E. praecox*, *E. mitis* and *E. brunetti*. Other examples of infectious *Eimeria* protozoa are *E. gallopavonis*, *E. meleagrimitis*, *E.*  
25 *adenoeides*, *E. meleagridis*, *E. dispersa*, *E. innocua*, *E. subrotunda*, *E. truncata*, *E. anseris*, *E. bovis*, *E. zurnii*, *E. alabamansis*, *E. auburnensis*, *E. ashata*, *E. parva*, *E. faurei*, *E. arloingi*, *E. debliciecki* and *E. spinosa*.

In poultry, e.g. chickens and turkeys, an outbreak  
30 of coccidiosis may with little or no forewarning lead to a serious infection, and unless the birds are promptly treated, the result may be a very high mortality. Animals that survive these types of infections are usually of reduced economical value, since they become less

efficient in converting feed to weight gain, grow much more slowly than normal animals and frequently appear listless. A similar disease scenario may also occur upon coccidia infection of larger animals, e.g. ruminants and  
5 pigs, albeit the problem is in general more severe in poultry.

In the treatment of coccidiosis, a recognized problem is the development of resistance to known anticoccidial agents. This problem has been addressed in  
10 numerous publications, such as in Stephen B. et al., *Vet. Parasitol.*, 69(1-2), pp 19-29, 1997.


Thus, there is a general need in the art for both new and improved antiparasitic compounds, particularly for the treatment of coccidiosis.

15 Furthermore, antibacterial agents such as enrofloxacin (US 4 670 444) are often added to animal feed, and this often leads to resistance problems. Indeed, new antibacterial compounds is an ongoing need in the art.

20 Moreover, there is a general public demand to reduce the number of added drugs in animal feed.

Disclosure of the Invention

There are now provided novel compounds which surprisingly have both antibacterial and antiparasitic properties, thereby reducing the need for using several prior art compounds in e.g. combined antibacterial and antiparasitic treatment of livestock. Furthermore, the present novel compounds are especially well suited for treatment of coccidiosis (*vide infra*). More specifically, the present invention relates to a compound having the general formula (I):



wherein

- X is selected from F, Cl, I, CN, SH, NO<sub>2</sub>, CF<sub>3</sub>, COOR<sub>1</sub>, CONR<sub>7</sub>R<sub>8</sub>, NH-aryl, NHSO<sub>2</sub>R<sub>15</sub> and (CH<sub>2</sub>)<sub>1-5</sub>NHSO<sub>2</sub>R<sub>15</sub>, wherein R<sub>1</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>15</sub> and aryl are as defined hereinbelow;
- R<sub>2</sub>-R<sub>3</sub> are independently selected from a group of substituents (a)-(h) consisting of
- (a) H;
  - (b) straight chain, branched or cyclic saturated or unsaturated alkyl, mono-, di- or trifluoroalkyl, hydroxyalkyl or alkoxyalkyl having 1-6 carbon atoms;
  - (c) (O-alkyl)<sub>z</sub>, (alkyl-O)<sub>z</sub>-alkyl, (S-alkyl)<sub>z</sub>, (alkyl-S)<sub>z</sub>-alkyl, (alkyl-S-S)<sub>z</sub>-alkyl, N-(alkyl)<sub>n</sub>, alkyl-N-(alkyl)<sub>n</sub>, alkyl-NH<sub>2</sub>, alkyl-NHSO<sub>2</sub>-alkyl or alkyl-NHSO<sub>2</sub>-aryl, where alkyl is as defined in (b) and optionally contains at least one substituent X, aryl is as defined in (e), z is an integer from 1 to 5 and n is 1 or 2;
  - (d) (C(O)-alkyl)<sub>z</sub>, (O-C(O)-alkyl)<sub>z</sub>, (S-C(O)-alkyl)<sub>z</sub> or (NH-C(O)-alkyl)<sub>z</sub>, where alkyl is as defined in (b)



and z as defined in (c);


- (e) aryl, condensed aryl or aralkyl, optionally containing at least one heteroatom selected from N, S and O and/or at least one substituent selected from X and (a)-(d);
- (f) O-aryl, C(O)-aryl, C(O)-heteroaryl, O-aralkyl, N-(aryl)<sub>n</sub>, N-(aralkyl)<sub>n</sub> or N-(SO<sub>2</sub>-aryl)<sub>n</sub>, where aryl is as defined in (e) and n is 1 or 2;
- (g) X;
- (h) NR<sub>7</sub>R<sub>8</sub>, wherein R<sub>7</sub> and R<sub>8</sub> independently are selected from the substituents (a)-(f), wherein NR<sub>7</sub>R<sub>8</sub> optionally may form a five- or six-membered saturated or unsaturated ring;
- R<sub>1</sub> is selected from the substituents (a)-(b);
- A is a radical selected from -N- and -CR<sub>9</sub>-, wherein R<sub>9</sub> is selected from the substituents (a)-(h) or is a C-Y bond to a radical -YCR<sub>10</sub>R<sub>11</sub>CR<sub>12</sub>R<sub>13</sub>-, wherein R<sub>10</sub>-R<sub>13</sub> are independently selected from the substituents (a)-(h) and Y is selected from S, O and NR<sub>14</sub>,
- wherein R<sub>14</sub> is selected from the substituents (a)-(h);
- R<sub>4</sub> is selected from the substituents (a)-(h) or may optionally be a C-C bond to said radical -YCR<sub>10</sub>R<sub>11</sub>CR<sub>12</sub>R<sub>13</sub>-;
- R<sub>5</sub> and R<sub>6</sub> are either independently selected from the substituents (a)-(h) and a group of substituents (i)-(m) consisting of
- (i) furanyl, furyl, pyranal, piperidinyl, morpholinyl, pyridinyl, pyrazinyl, piperazinyl and pyrrolidinyl, optionally containing at least one substituent selected from X and (a)-(d);
- (j) alkylfuranyl, -furyl, -pyranal, -piperidinyl, -morpholinyl, -pyridinyl, -pyrazinyl, -piperazinyl, and -pyrrolidinyl, optionally containing at least one substituent selected from X and (a)-(d);
- (k) SO<sub>2</sub>R<sub>15</sub>, where R<sub>15</sub> is selected from the substituents (a)-(f) and (h)-(j);
- (l) C(S)-NR<sub>16</sub>R<sub>17</sub> or C(O)-NR<sub>16</sub>R<sub>17</sub>, where R<sub>16</sub>-R<sub>17</sub> are independently selected from the substituents

(a) - (k) ;

(m) cycloalkyl-NR<sub>16</sub>R<sub>17</sub>, alkylcycloalkyl-NR<sub>16</sub>R<sub>17</sub>,  
cycloalkyl-X or alkylcycloalkyl-X, where R<sub>16</sub> and R<sub>17</sub>  
are as defined in (l) and the cycloalkyl moiety has  
3-7 carbon atoms;

with the proviso that at least one of R<sub>5</sub> and R<sub>6</sub> is  
selected from the substituents (c) - (m) and that R<sub>4</sub> is  
selected from saturated cycloalkyl and aryl, optionally  
containing at least one heteroatom selected from N, S and  
O and/or at least one substituent selected from X and  
(a) - (d) ;


or taken together with the nitrogen atom to which they  
are attached form a group selected from (n) - (p)  
consisting of



wherein

R<sub>18</sub>-R<sub>21</sub> are independently selected from the substituents  
(a) - (b) ;

R<sub>22</sub> is selected from the substituents (c) - (m) ;




wherein

R<sub>23</sub> and R<sub>25</sub> are independently selected from the  
substituents (a) - (f) or may optionally be part of a C=N  
bond;

R<sub>24</sub> and R<sub>26</sub> are independently selected from the group of  
substituents (a) - (m) and a group of substituents (q) - (s)  
consisting of

- (q) alkyl-NR<sub>27</sub>R<sub>28</sub>, where R<sub>27</sub>-R<sub>28</sub> are independently selected from the substituents (a)-(m);
- (r) NR<sub>27</sub>R<sub>28</sub>, where R<sub>27</sub>-R<sub>28</sub> are as defined in (q);
- (s) a =N-O-alkyl radical;
- 5 with the proviso that R<sub>23</sub>-R<sub>25</sub> are not all H when R<sub>26</sub> is NH<sub>2</sub>, X is F, A is -CCl-; R<sub>1</sub>-R<sub>3</sub> are H and R<sub>4</sub> is cyclopropyl;
- with the proviso that at least one of R<sub>27</sub> and R<sub>28</sub> in (q) is selected from the substituents (c)-(m) when X is F, A
- 10 is -COCH<sub>3</sub>- or -N-, R<sub>1</sub>-R<sub>3</sub> are H and R<sub>4</sub> is cyclopropyl;




wherein

- R<sub>27</sub>-R<sub>28</sub> are as defined in (q), with the proviso that at least one of R<sub>27</sub> and R<sub>28</sub> is selected from the substituents (c)-(m);
- 15 tautomers, solvates and radiolabelled derivatives thereof; and
- pharmaceutically acceptable salts thereof.

- As examples of pharmaceutically acceptable salts mention can be made of acid addition salts, e.g. a salt
- 20 formed by reaction with hydrohalogen acids, such as hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, aliphatic, alicyclic, aromatic or heterocyclic sulphonc or carboxylic acids, such as formic acid, acetic acid, propionic acid, succinic acid,
- 25 glycolic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, maleic acid, hydroxymaleic acid, pyruvic acid, p-hydroxybenzoic acid, embonic acid, methanesulphonic acid, ethanesulphonic acid, hydroxy-
- ethanesulphonic acid, halogenbensensulphonic acid,
- 30 toluenesulphonic acid and naphtalenesulphonic acid.

In preferred embodiments of the present invention, R<sub>1</sub> is H. Moreover, X is preferably F.

In one of the most preferred embodiments, a compound according to the present invention has the general formula (II):



5 wherein  $R_3$ ,  $R_4$ ,  $R_9$ ,  $R_{19}$ ,  $R_{21}$  and  $R_{22}$  are as previously defined.

Preferably,  $R_3$  is selected from a group of substituents consisting of H,  $\text{CH}_3$ ,  $\text{NH}_2$ , (6-chloro-2-pyridinyl)amino, (6-chloro-2-pyrazinyl)amino, [(4-fluoro-phenyl)sulfonyl]amino and [(4-nitrophenyl)sulfonyl]amino.

Preferably,  $R_4$  is selected from a group of substituents consisting of cyclopropyl, ethyl, 2-fluoroethyl, 4-fluorophenyl and 2,4-difluorophenyl.

Preferably,  $R_9$  is either H or F.

15 Preferably,  $R_{19}$  and  $R_{21}$  are independently either H or  $\text{CH}_3$ .

Preferably,  $R_{22}$  is selected from a group of substituents consisting of (4-nitroanilino)carbothioyl, anilino-carbothioyl, (4-fluoroanilino)carbothioyl, {4-nitro[(4-nitrophenyl)sulfonyl]anilino}carbothioyl, (4-nitroanilino)carbonyl, (4-fluoroanilino)carbonyl, (4-nitrophenyl)sulfonyl, 6-chloro-2-pyridinyl, 6-chloro-2-pyrazinyl, phenylsulfonyl, (4-methylphenyl)sulfonyl, (4-methoxyphenyl)sulfonyl, 2-naphthylsulfonyl, mesityl-sulfonyl, propylsulfonyl, benzylsulfonyl, methylsulfonyl, (trifluoromethyl)sulfonyl, (5-bromo-2-thienyl)sulfonyl, (3,5-dichloro-2-hydroxyphenyl)sulfonyl, 5-bromo-2-pyridinyl, 3-chloro-2-sulfanyphenyl, (5-chloro-2-thienyl)sulfonyl, 2-pyrazinyl, {4-fluoro[(4-fluoro-phenyl)sulfonyl]anilino}carbothioyl, {4-fluoro[(4-

nitrophenyl)sulfonyl]anilino}carbothioyl, [(6-chloro-2-pyrazinyl)-4-fluoroanilino]carbothioyl, [(6-chloro-2-pyridinyl)-4-fluoroanilino]carbothioyl, (4-fluorophenyl)sulfonyl, 6-{[(4-fluorophenyl)sulfonyl]amino}-2-pyridinyl, 4-pyridinylmethyl, 4-carboxycyclohexyl, 4-carboxybenzyl, tetrahydro-2-furanylmethyl, 4-isopropylphenyl, 2-(1-piperidinyl)ethyl, 2-[(2-{[(4-fluorophenyl)sulfonyl]amino}ethyl)disulfanyl]ethyl, 2-[(2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)disulfanyl]ethyl, 2-[2-(([(4-nitrophenyl)sulfonyl]amino)methoxy)ethoxy]ethyl, 2-(2-{[(6-chloro-2-pyrazinyl)amino]methoxy}ethoxy)ethyl, 2-(1-pyrrolidinyl)ethyl, (4-nitroanilino)carbothioyl, [3-(([(4-fluorophenyl)sulfonyl]amino)methyl)cyclohexyl]methyl, 3-[(3-aminopropyl)(methyl)amino]propyl, 3-amino-propyl, 3-[(trifluoromethyl)sulfonyl]amino}propyl, 3-[[[(4-nitrophenyl)sulfonyl]amino]propyl, 3-(dimethylamino)-2,2-dimethylpropyl, 2-thienylcarboxyl, 2-aminocyclohexyl, 2-[(trifluoromethyl)sulfonyl]amino}ethyl, 2-[[[(4-nitrophenyl)sulfonyl]amino}ethyl, 2,2-dimethyl-3-[(trifluoromethyl)sulfonyl]amino}propyl, phenethylsulfonyl, acetoacetyl, 2-(4-pyridinyl)ethyl, 2-(2-pyridinyl)ethyl and 2-methoxy-1-methylethyl.

Most preferably, a compound according to the formula (II) is selected from the compounds disclosed in the following Table 1, the systematic names of which are also given hereinbelow:

Table 1:

R <sub>3</sub>	R <sub>4</sub>	R <sub>9</sub>	R <sub>19</sub>	R <sub>21</sub>	R <sub>22</sub>	Denoted
H	4-fluoro-phenyl	H	H	H	(4-nitro-anilino) - carbothioyl	B626
H	2-fluoro-ethyl	F	H	H	(4-nitro-anilino) - carbothioyl	B628
CH <sub>3</sub>	cyclo-propyl	H	CH <sub>3</sub>	H	(4-nitro-anilino) - carbothioyl	B629
H	ethyl	F	CH <sub>3</sub>	H	(4-nitro-anilino) - carbothioyl	B630
NH <sub>2</sub>	cyclo-propyl	F	H	H	(4-nitro-anilino) - carbothioyl	B633
H	2,4-di-fluoro-phenyl	H	CH <sub>3</sub>	H	(4-nitro-anilino) - carbothioyl	B634
H	2,4-di-fluoro-phenyl	H	CH <sub>3</sub>	H	{4-nitro[(4-nitrophenyl) sulfonyl] - anilino} - carbothioyl	B635
H	ethyl	F	CH <sub>3</sub>	H	anilino-carbothioyl	B636
H	cyclo-propyl	H	H	H	(4-fluoro-anilino) - carbothioyl	B637
H	ethyl	H	H	H	(4-nitro-anilino) - carbothioyl	B638
H	cyclo-propyl	H	H	H	(4-nitro-anilino) - carbonyl	B700

H	ethyl	F	CH <sub>3</sub>	H	(4-nitro-anilino) - carbonyl	B702
H	4-fluoro-phenyl	H	H	H	(4-nitrophenyl) sulfonyl	JAP 203
H	4-fluoro-phenyl	H	H	H	6-chloro-2-pyridinyl	JAP 204
H	4-fluoro-phenyl	H	H	H	6-chloro-2-pyrazinyl	JAP 205
H	2-fluoro-ethyl	F	H	H	(4-nitrophenyl) sulfonyl	JAP 206
H	2-fluoro-ethyl	F	H	H	6-chloro-2-pyridinyl	JAP 207
H	2-fluoro-ethyl	F	H	H	6-chloro-2-pyrazinyl	JAP 208
CH <sub>3</sub>	cyclopropyl	H	CH <sub>3</sub>	H	(4-nitrophenyl) sulfonyl	JAP 209
CH <sub>3</sub>	cyclopropyl	H	CH <sub>3</sub>	H	6-chloro-2-pyridinyl	JAP 210
CH <sub>3</sub>	cyclopropyl	H	CH <sub>3</sub>	H	6-chloro-2-pyrazinyl	JAP 211
H	ethyl	F	CH <sub>3</sub>	H	(4-nitrophenyl) sulfonyl	JAP 213
H	ethyl	F	CH <sub>3</sub>	H	6-chloro-2-pyridinyl	JAP 214
[(4-nitrophenyl) sulfonyl] amino	cyclopropyl	F	H	H	(4-nitrophenyl) sulfonyl	JAP 221
[(4-nitrophenyl) sulfonyl] amino	cyclopropyl	F	CH <sub>3</sub>	CH <sub>3</sub>	(4-nitrophenyl) sulfonyl	JAP 222
(6-chloro-2-pyridinyl) - amino	cyclopropyl	F	CH <sub>3</sub>	CH <sub>3</sub>	6-chloro-2-pyridinyl	JAP 223

(6-chloro-2-pyrazinyl)-amino	cyclo-propyl	F	CH <sub>3</sub>	CH <sub>3</sub>	6-chloro-2-pyrazinyl	JAP 224
H	2,4-difluorophenyl	H	CH <sub>3</sub>	H	(4-nitrophenyl) sulfonyl	JAP 225
H	2,4-difluorophenyl	H	CH <sub>3</sub>	H	6-chloro-2-pyrazinyl	JAP 226
H	2,4-difluorophenyl	H	CH <sub>3</sub>	H	6-chloro-2-pyridinyl	JAP 227
H	cyclo-propyl	H	H	H	phenyl-sulfonyl	JA 1
H	cyclo-propyl	H	H	H	(4-methylphenyl)-sulfonyl	JA 2
H	cyclo-propyl	H	H	H	(4-nitrophenyl) sulfonyl	JA 3
H	cyclo-propyl	H	H	H	(4-methoxyphenyl)-sulfonyl	JA 4
H	cyclo-propyl	H	H	H	2-naphthyl-sulfonyl	JA 5
H	cyclo-propyl	H	H	H	mesityl-sulfonyl	JA 6
H	cyclo-propyl	H	H	H	propyl-sulfonyl	JA 7
H	cyclo-propyl	H	H	H	benzyl-sulfonyl	JA 9
H	cyclo-propyl	H	H	H	methyl-sulfonyl	JA 10
H	cyclo-propyl	H	H	H	(trifluoromethyl)-sulfonyl	JA 12



H	cyclo- propyl	H	H	H	(5-bromo-2- thienyl)- sulfonyl	JA 13
H	cyclo- propyl	H	H	H	(3,5-di- chloro-2- hydroxyphe- nyl) sulfonyl	JA 14
H	ethyl	H	H	H	(4-nitrophe- nyl) sulfonyl	JA 20
H	ethyl	H	H	H	(4-methoxy- phenyl)- sulfonyl	JA 21
H	ethyl	H	H	H	benzyl- sulfonyl	JA 26
H	ethyl	H	H	H	(3,5- dichloro-2- hydroxyphe- nyl) sulfonyl	JA 31
H	cyclo- propyl	H	H	H	6-chloro-2- pyrazinyl	JA 39
H	cyclo- propyl	H	H	H	5-bromo-2- pyridinyl	JA 40
H	cyclo- propyl	H	H	H	3-chloro-2- sulfanyl- phenyl	JA 41
H	cyclo- propyl	H	H	H	6-chloro-2- pyridinyl	JA 42
H	cyclo- propyl	H	H	H	(5-chloro-2- thienyl)- sulfonyl	JA 43
H	cyclo- propyl	H	H	H	2-pyrazinyl	JA 46

H	cyclo- propyl	H	H	H	{4-fluoro- [(4-fluoro- phenyl)sulf- onyl]anili- no}carbo- thioyl	JA 53-2
H	cyclo- propyl	H	H	H	{4-fluoro- [(4-nitro- phenyl)sulf- onyl]anili- no}carbo- thioyl	JA 53-3
H	cyclo- propyl	H	H	H	[(6-chloro- 2-pyrazin- yl)-4-fluo- roanilino]- carbothioyl	JA 53-5
H	cyclo- propyl	H	H	H	[(6-chloro- 2-pyridin- yl)-4-fluo- roanilino]- carbothioyl	JA 53-6

B626:

6-fluoro-1-(4-fluorophenyl)-7-{4-[(4-nitroanilino)carbo-  
thioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;

B628:

6,8-difluoro-1-(2-fluoroethyl)-7-{4-[(4-nitroanilino)-  
carbothioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;

B629:

1-cyclopropyl-6-fluoro-5-methyl-7-{3-methyl-4-[(4-  
nitroanilino)carbothioyl]-1-piperazinyl}-4-oxo-1,4-  
dihydro-3-quinolinecarboxylic acid;

B630:

1-ethyl-6,8-difluoro-7-{3-methyl-4-[(4-nitroanilino)carbothioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

5 B633:

5-amino-1-cyclopropyl-6,8-difluoro-7-{4-[(4-nitroanilino)carbothioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

B634:

10 1-(2,4-difluorophenyl)-6-fluoro-7-{3-methyl-4-[(4-nitroanilino)carbothioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

B635:

15 1-(2,4-difluorophenyl)-6-fluoro-7-[3-methyl-4-({4-nitro[(4-nitrophenyl)sulfonyl]anilino)carbothioyl}-1-piperazinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

B636:

20 7-[4-(anilinocarbothioyl)-3-methyl-1-piperazinyl]-1-ethyl-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

B637:

25 1-cyclopropyl-6-fluoro-7-{4-[(4-fluoroanilino)carbothioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

B638:

1-ethyl-6-fluoro-7-{4-[(4-nitroanilino)carbothioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

30 JAP 203:

6-fluoro-1-(4-fluorophenyl)-7-{4-[4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 204:

35 7-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 205:

7-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

5 JAP 206:

6,8-difluoro-1-(2-fluoroethyl)-7-{4[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 207:

10 7-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]-6,8-difluoro-1-(2-fluoroethyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 208:

15 7-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-6,8-difluoro-1-(2-fluoroethyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 209:

20 1-cyclopropyl-6-fluoro-5-methyl-7-{3-methyl-4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 210:

7-[4-(6-chloro-2-pyridinyl)-3-methyl-1-piperazinyl]-1-cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

25 JAP 211:

7-[4-(6-chloro-2-pyrazinyl)-3-methyl-1-piperazinyl]-1-cyclopropyl-6-fluoro-5-methyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 213:

30 1-ethyl-6,8-difluoro-7-{3-methyl-4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 214:

35 7-[4-(6-chloro-2-pyridinyl)-3-methyl-1-piperazinyl]-1-ethyl-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 221:

1-cyclopropyl-6,8-difluoro-5-{[(4-nitrophenyl)sulfonyl]-amino}-7-{4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

5 JAP 222:

1-cyclopropyl-7-{3,5-dimethyl-4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-6,8-difluoro-5-{[(4-nitrophenyl)sulfonyl]amino}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

10 JAP 223:

5-[(6-chloro-2-pyridinyl)amino]-7-[4-(6-chloro-2-pyridinyl)-3,5-dimethyl-1-piperazinyl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 224:

15 5-[(6-chloro-2-pyrazinyl)amino]-7-[4-(6-chloro-2-pyrazinyl)-3,5-dimethyl-1-piperazinyl]-1-cyclopropyl-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 225:

20 1-(2,4-difluorophenyl)-6-fluoro-7-{3-methyl-4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 226:

25 7-[4-(6-chloro-2-pyrazinyl)-3-methyl-1-piperazinyl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 227:

7-[4-(6-chloro-2-pyridinyl)-3-methyl-1-piperazinyl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

30 JA 1:

1-cyclopropyl-6-fluoro-4-oxo-7-[4-(phenylsulfonyl)-1-piperazinyl]-1,4-dihydro-3-quinolinecarboxylic acid;

JA 2:

35 1-cyclopropyl-6-fluoro-7-{4-[(4-methylphenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 3:

1-cyclopropyl-6-fluoro-7-{4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

5 JA 4:

1-cyclopropyl-6-fluoro-7-{4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 5:

10 1-cyclopropyl-6-fluoro-7-[4-(2-naphthylsulfonyl)-1-piperazinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 6:

15 1-cyclopropyl-6-fluoro-7-[4-(mesitylsulfonyl)-1-piperazinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 7:

1-cyclopropyl-6-fluoro-4-oxo-7-[4-(propylsulfonyl)-1-piperazinyl]-1,4-dihydro-3-quinolinecarboxylic acid;

20 JA 9:

7-[4-(benzylsulfonyl)-1-piperazinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 10:

25 1-cyclopropyl-6-fluoro-7-[4-(methylsulfonyl)-1-piperazinyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 12:

30 1-cyclopropyl-6-fluoro-4-oxo-7-{4-[(trifluoromethyl)sulfonyl]-1-piperazinyl}-1,4-dihydro-3-quinolinecarboxylic acid;


JA 13:

7-{4-[(5-bromo-2-thienyl)sulfonyl]-1-piperazinyl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

- JA 14:  
1-cyclopropyl-7-{4-[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]-1-piperazinyl}-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 5 JA 20:  
1-ethyl-6-fluoro-7-{4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 21:  
10 1-ethyl-6-fluoro-7-{4-[(4-methoxyphenyl)sulfonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 26:  
7-[4-(benzylsulfonyl)-1-piperazinyl]-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 15 JA 31:  
7-{4-[(3,5-dichloro-2-hydroxyphenyl)sulfonyl]-1-piperazinyl}-1-ethyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 20 JA 39:  
7-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 40:  
7-[4-(5-bromo-2-pyridinyl)-1-piperazinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 25 JA 42:  
7-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 43:  
30 7-{4-[(5-chloro-2-thienyl)sulfonyl]-1-piperazinyl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 46:  
1-cyclopropyl-6-fluoro-4-oxo-7-[4-(2-pyrazinyl)-1-piperazinyl]-1,4-dihydro-3-quinolinecarboxylic acid.
- 35

In another preferred embodiment of the present invention,  $R_9$  is a C-Y bond and  $R_4$  is a C-C bond to said radical  $-YCR_{10}R_{11}CR_{12}R_{13}-$ . Typically,  $R_{10}$ - $R_{13}$  are H, or  $R_{10}$ - $R_{12}$  are H and  $R_{13}$  is methyl.

5 In another one of the most preferred embodiments, a compound according to the present invention has the general formula (III):



wherein  $R_{12}$ ,  $R_{13}$  and  $R_{22}$  are as previously defined.

10 Preferably, Y is either S or O.

Preferably,  $R_{12}$  and  $R_{13}$  are independently either H or  $CH_3$ .

Preferably,  $R_{22}$  is selected from the same said group of substituents as that preferred in the compound(s) of  
15 the general formula (II) *supra*.

Most preferably, a compound according to the formula (III) is selected from the compounds disclosed in the following Table 2, the systematic names of which are also given hereinbelow:



Table 2:

Y	R <sub>12</sub>	R <sub>13</sub>	R <sub>22</sub>	Denoted
O	H	CH <sub>3</sub>	(4-nitrophenyl) sulfonyl	JAP 215
O	H	CH <sub>3</sub>	6-chloro-2-pyridinyl	JAP 216
O	H	CH <sub>3</sub>	6-chloro-2-pyrazinyl	JAP 217
S	H	H	(4-nitrophenyl) sulfonyl	JAP 218
S	H	H	6-chloro-2-pyridinyl	JAP 219
S	H	H	6-chloro-2-pyrazinyl	JAP 220
O	H	CH <sub>3</sub>	(4-nitroanilino) carbothioyl	B631
S	H	H	(4-nitroanilino) carbothioyl	B632

JAP 215:

- 5 9-fluoro-3-methyl-10-{4-[(4-nitrophenyl) sulfonyl]-1-piperazinyl}-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;

JAP 216:

- 10 10-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;

JAP 217:

- 15 10-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;

JAP 218:

9-fluoro-10-{4-[(4-nitrophenyl) sulfonyl]-1-piperazinyl}-7-oxo-2,3-dihydro-7H-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic acid;

20 JAP 219:

10-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]-9-fluoro-7-oxo-2,3-dihydro-7H-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic acid;

JAP 220:

- 25 10-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-9-fluoro-7-oxo-2,3-dihydro-7H-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic acid;

B631:


9-fluoro-3-methyl-10-{4-[(4-nitroanilino)carbothioyl]-1-piperazinyl}-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;

5 B632:

9-fluoro-10-{4-[(4-nitroanilino)carbothioyl]-1-piperazinyl}-7-oxo-2,3-dihydro-7H-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic acid.

10 In another preferred embodiment of the present invention,  $R_5$  and  $R_6$  are selected from the group of substituents (a)-(m). Here,  $R_4$  is typically cyclopropyl.

In yet another one of the most preferred embodiments, a compound according to the present invention has the general formula (IV):



15

wherein  $R_5$  and  $R_6$  are as previously defined.

20 Preferably,  $R_5$  and  $R_6$  are independently selected from H and at least one of the same said group of substituents as that preferred for  $R_{22}$  in the compound(s) of the general formula (II) *supra*.

Most preferably, a compound according to the formula (IV) is selected from the compounds disclosed in the following Table 3, the systematic names of which are also given hereinbelow:

25

Table 3:

R <sub>5</sub>	R <sub>6</sub>	Denoted
(4-fluorophenyl) - sulfonyl	6- { [(4-fluorophenyl) - sulfonyl] amino } -2-pyridinyl	JA 47-2
H	5-bromo-2-pyridinyl	JA 61
H	4-pyridinylmethyl	JA 68
H	4-carboxycyclohexyl	JA 69
6-chloro-2-pyrazinyl	4-carboxycyclohexyl	JA 69-2
(trifluoromethyl) - sulfonyl	4-carboxycyclohexyl	JA 69-3
H	4-carboxybenzyl	JA 70
H	tetrahydro-2-furanylmethyl	JA 73
H	4-isopropylphenyl	JA 74
H	2-(1-piperidinyl)ethyl	JA 76
(4-nitrophenyl) - sulfonyl	2-(1-piperidinyl)ethyl	JA 76-2
6-chloro-2-pyrazinyl	2-(1-piperidinyl)ethyl	JA 76-3
(4-fluorophenyl) - sulfonyl	2- [(2- { [(4-fluorophenyl) - sulfonyl] amino } ethyl) di-sulfanyl] ethyl	JA 79-2
(4-nitrophenyl) - sulfonyl	2- [(2- { [(4-nitrophenyl) - sulfonyl] amino } ethyl) di-sulfanyl] ethyl	JA 79-3
(4-nitrophenyl) - sulfonyl	2- [2- ( { [(4-nitrophenyl) - sulfonyl] amino } methoxy) - ethoxy] ethyl	JA 82-2

6-chloro-2-pyrazinyl	2-(2-{[(6-chloro-2-pyrazinyl)amino]methoxy}ethoxy)ethyl	JA 82-3
phenylsulfonyl	4-pyridinylmethyl	JA 91
H	2-(1-pyrrolidinyl)ethyl	JA 97
(4-nitroanilino)-carbothioyl	2-(1-pyrrolidinyl)ethyl	JA 97-2
6-chloro-2-pyrazinyl	2-(1-pyrrolidinyl)ethyl	JA 97-3
(4-nitrophenyl)-sulfonyl	2-(1-pyrrolidinyl)ethyl	JA 97-4
(trifluoromethyl)-sulfonyl	2-(1-pyrrolidinyl)ethyl	JA 97-5
(4-fluorophenyl)-sulfonyl	[3-({[(4-fluorophenyl)-sulfonyl]amino}methyl)cyclohexyl]methyl	JA 99-2
H	3-[(3-aminopropyl)(methyl)-amino]propyl	JA 102
H	3-aminopropyl	JA 103
(trifluoromethyl)-sulfonyl	3-{[(trifluoromethyl)sulfonyl]amino}propyl	JA 103-2
(4-nitrophenyl)-sulfonyl	3-{[(4-nitrophenyl)-sulfonyl]amino}propyl	JA 103-3
(trifluoromethyl)-sulfonyl	3-(dimethylamino)-2,2-dimethylpropyl	JA 104-2
2-thienylcarbonyl	3-(dimethylamino)-2,2-dimethylpropyl	JA 104-3
H	2-aminocyclohexyl	JA 105
(trifluoromethyl)-sulfonyl	2-{[(trifluoromethyl)-sulfonyl]amino}ethyl	JA 106-3
(4-nitrophenyl)-sulfonyl	2-{[(4-nitrophenyl)-sulfonyl]amino}ethyl	JA 106-4

(trifluoromethyl)- sulfonyl	2,2-dimethyl-3-{{(trifluoro- methyl)sulfonyl}amino}propyl	JA 107-2
(4-nitrophenyl)- sulfonyl	tetrahydro-2-furanylmethyl	JA 117
2-thienylcarbonyl	2-furylemethyl	JA 124
2-thienylcarbonyl	2-(1-piperidinyl)ethyl	JA 128
(4-methoxyphenyl)- sulfonyl	tetrahydro-2-furanylmethyl	JA 135
2-naphthylsulfonyl	tetrahydro-2-furanylmethyl	JA 136
phenethylsulfonyl	tetrahydro-2-furanylmethyl	JA 137
(trifluoromethyl)- sulfonyl	tetrahydro-2-furanylmethyl	JA 138
phenylsulfonyl	tetrahydro-2-furanylmethyl	JA 139
2-thienylcarbonyl	tetrahydro-2-furanylmethyl	JA 140
6-chloro-2- pyrazinyl	tetrahydro-2-furanylmethyl	JA 141
5-bromo-2- pyridinyl	tetrahydro-2-furanylmethyl	JA 142
6-chloro-2- pyridinyl	tetrahydro-2-furanylmethyl	JA 143
acetoacetyl	tetrahydro-2-furanylmethyl	JA 144
2-(4-pyridinyl)- ethyl	tetrahydro-2-furanylmethyl	JA 145
2-(2-pyridinyl)- ethyl	tetrahydro-2-furanylmethyl	JA 146
acetoacetyl	2-methoxy-1-methylethyl	JA 148
(4-nitrophenyl)- sulfonyl	2-methoxy-1-methylethyl	JA 149

(4-nitrophenyl) - sulfonyl	4-pyridinylmethyl	JA 156
(4-nitrophenyl) - sulfonyl	5-bromo-2-pyridinyl	JA 158
(4-fluorophenyl) - sulfonyl	5-bromo-2-pyridinyl	JA 159
(trifluoromethyl) - sulfonyl	5-bromo-2-pyridinyl	JA 160
2-naphtylsulfonyl	5-bromo-2-pyridinyl	JA 161
2-naphtylsulfonyl	tetrahydro-2-furanylmethyl	JA 162
2-naphtylsulfonyl	4-pyridinylmethyl	JA 163
(trifluoromethyl) - sulfonyl	4-pyridinylmethyl	JA 164
6-chloro-2- pyridinyl	4-pyridinylmethyl	JA 165
6-chloro-2- pyrazinyl	4-pyridinylmethyl	JA 166
5-bromo-2- pyridinyl	4-pyridinylmethyl	JA 167
(4-nitrophenyl) - sulfonyl	4-carboxybenzyl	JA 168
2-naphtylsulfonyl	4-carboxybenzyl	JA 169
(trifluoromethyl) - sulfonyl	4-carboxybenzyl	JA 170
6-chloro-2- pyridinyl	4-carboxybenzyl	JA 171
6-chloro-2- pyrazinyl	4-carboxybenzyl	JA 172
5-bromo-2- pyridinyl	4-carboxybenzyl	JA 173

JA 61:

7-[(5-bromo-2-pyridinyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 68:

- 5 1-cyclopropyl-6-fluoro-4-oxo-7-[(4-pyridinylmethyl)-amino]-1,4-dihydro-3-quinolinecarboxylic acid;

JA 69:

7-[(4-carboxycyclohexyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

- 10 JA 70:

7-[(4-carboxybenzyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 73:

- 15 1-cyclopropyl-6-fluoro-4-oxo-7-[(tetrahydro-2-furanylmethyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid;

JA 74:

1-cyclopropyl-6-fluoro-7-(4-isopropylanilino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

- 20 JA 76:

1-cyclopropyl-6-fluoro-4-oxo-7-{[2-(1-piperidinyl)ethyl]-amino}-1,4-dihydro-3-quinolinecarboxylic acid;

JA 91:

- 25 1-cyclopropyl-6-fluoro-4-oxo-7-[(phenylsulfonyl)(4-pyridinylmethyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid;

JA 103:

7-[(3-aminopropyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

- 30 JA 105:

7-[(2-aminocyclohexyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 117:

- 35 1-cyclopropyl-6-fluoro-7-[(4-nitrophenyl)sulfonyl]-(tetrahydro-2-furanylmethyl)amino]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

- JA 135:  
1-cyclopropyl-6-fluoro-7-[[ (4-methoxyphenyl) sulfonyl] -  
(tetrahydro-2-furanylmethyl) amino] -4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;
- 5 JA 136:  
1-cyclopropyl-6-fluoro-7-[(2-naphthylsulfonyl) (tetra-  
hydro-2-furanylmethyl) amino] -4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;
- JA 137:  
10 1-cyclopropyl-6-fluoro-4-oxo-7-[(phenethylsulfonyl) -  
(tetrahydro-2-furanylmethyl) amino] -1,4-dihydro-3-  
quinolinecarboxylic acid;
- JA 138:  
15 1-cyclopropyl-6-fluoro-4-oxo-7-{ (tetrahydro-2-  
furanylmethyl) [(trifluoromethyl) sulfonyl] amino} -1,4-  
dihydro-3-quinolinecarboxylic acid;
- JA 139:  
20 1-cyclopropyl-6-fluoro-4-oxo-7-[(phenylsulfonyl) -  
(tetrahydro-2-furanylmethyl) amino] -1,4-dihydro-3-  
quinolinecarboxylic acid;
- JA 141:  
7-[(6-chloro-2-pyrazinyl) (tetrahydro-2-furanylmethyl) -  
amino] -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;
- 25 JA 142:  
7-[(5-bromo-2-pyridinyl) (tetrahydro-2-furanylmethyl) -  
amino] -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;
- JA 143:  
30 7-[(6-chloro-2-pyridinyl) (tetrahydro-2-furanylmethyl) -  
amino] -1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;
- JA 144:  
35 7-[acetoacetyl (tetrahydro-2-furanylmethyl) amino] -1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;



- JA 145:  
1-cyclopropyl-6-fluoro-4-oxo-7-[[2-(4-pyridinyl)ethyl]-(  
(tetrahydro-2-furanylmethyl)amino]-1,4-dihydro-3-  
quinolinecarboxylic acid;
- 5 JA 146:  
1-cyclopropyl-6-fluoro-4-oxo-7-[[2-(2-pyridinyl)ethyl]-(  
(tetrahydro-2-furanylmethyl)amino]-1,4-dihydro-3-  
quinolinecarboxylic acid;
- JA 156:  
10 1-cyclopropyl-6-fluoro-7-[[4-(4-nitrophenyl)sulfonyl](4-  
pyridinylmethyl)amino]-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 158:  
7-{(5-bromo-2-pyridinyl)[(4-nitrophenyl)sulfonyl]amino}-  
15 1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 159:  
7-{(5-bromo-2-pyridinyl)[(4-fluorophenyl)sulfonyl]amino}-  
1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
20 carboxylic acid;
- JA 160:  
7-{(5-bromo-2-pyridinyl)[(trifluoromethyl)sulfonyl]-  
amino}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;
- 25 JA 161:  
7-[(5-bromo-2-pyridinyl)(2-naphtylsulfonyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 162:  
30 1-cyclopropyl-6-fluoro-7-[(2-naphtylsulfonyl)(tetrahydro-  
2-furanylmethyl)amino]-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 163:  
1-cyclopropyl-6-fluoro-7-[(2-naphtylsulfonyl)(4-  
35 pyridinylmethyl)amino]-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;

- JA 164:  
1-cyclopropyl-6-fluoro-4-oxo-7-{(4-pyridinylmethyl)-  
[(trifluoromethyl)sulfonyl]amino}-1,4-dihydro-3-  
quinolinecarboxylic acid;
- 5 JA 165:  
7-[(6-chloro-2-pyridinyl)(4-pyridinylmethyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 166:  
10 7-[(6-chloro-2-pyrazinyl)(4-pyridinylmethyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 167:  
15 7-[(5-bromo-2-pyridinyl)(4-pyridinylmethyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 168:  
20 7-{(4-carboxybenzyl)[(4-nitrophenyl)sulfonyl]amino}-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 169:  
7-[(4-carboxybenzyl)(2-naphtylsulfonyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- 25 JA 170:  
7-{(4-carboxybenzyl)[(trifluoromethyl)sulfonyl]amino}-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 171:  
30 7-[(4-carboxybenzyl)(6-chloro-2-pyridinyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 172:  
35 7-[(4-carboxybenzyl)(6-chloro-2-pyrazinyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;


JA 173:

7-[(5-bromo-2-pyridinyl)(4-carboxybenzyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid.

5 In another preferred embodiment of the present invention,  $R_5$  and  $R_6$  form said group (o).

In still another one of the most preferred embodiments, a compound according to the present invention has the general formula (V):

10



wherein  $R_4$ , A and  $R_{23}$ - $R_{26}$  are as previously defined.

Preferably, A is selected from  $-CCl-$ ,  $-COCH_3-$ , and  $-N-$ .

15 Preferably,  $R_4$  is selected from a group of substituents consisting of cyclopropyl, ethyl, 2-fluoroethyl, 4-fluorophenyl and 2,4-difluorophenyl.

Preferably,  $R_{23}$ - $R_{26}$  are independently selected from H and at least one of a group of substituents consisting of  
 20 fluoromethyl, methoxyimino, (6-chloro-2-pyridinyl)amino, (6-chloro-2-pyridinyl)[(4-nitrophenyl)sulfonyl]amino, (6-chloro-2-pyrazinyl)[(4-nitrophenyl)sulfonyl]amino, [(4-nitroanilino)carbothioyl]amino, {[(4-nitrophenyl)sulfonyl]amino}methyl, [(6-chloro-2-pyrazinyl)amino]methyl,  
 25 [(6-chloro-2-pyridinyl)amino]methyl, {[(4-fluoroanilino)carbothioyl]amino}methyl, {(4-fluoro[(4-nitrophenyl)sulfonyl]anilino)carbothioyl}[(4-nitrophenyl)sulfonyl]amino}methyl, {(4-fluoro[(4-methoxyphenyl)sulfonyl]anilino)carbothioyl}[(4-methoxyphenyl)sulfonyl]ami-  
 30 no}methyl and the group of substituents preferred for  $R_{22}$  in the compound(s) of the general formula (II) *supra*.

Most preferably, a compound according to the formula (V) is selected from the compounds disclosed in the following Table 4, the systematic names of which are also given hereinbelow:

5

Table 4:

R <sub>4</sub>	A	R <sub>23</sub>	R <sub>24</sub>	R <sub>25</sub>	R <sub>26</sub>	Denoted
cyclopropyl	-CCl-	H	H	H	(6-chloro-2-pyridinyl)amino	JAP 200
cyclopropyl	-CCl-	H	H	H	(6-chloro-2-pyridinyl) [(4-nitrophenyl) sulfonyl]amino	JAP 201
cyclopropyl	-CCl-	H	H	H	(6-chloro-2-pyrazinyl) [(4-nitrophenyl) sulfonyl]amino	JAP 202
cyclopropyl	-CCl-	H	H	H	[(4-nitroanilino) carbothioyl]amino	B627
cyclopropyl	-COCH <sub>3</sub> -	H	H	CH <sub>2</sub> F	{ [(4-nitrophenyl) sulfonyl]amino }-methyl	JA 1006
cyclopropyl	-COCH <sub>3</sub> -	H	H	CH <sub>2</sub> F	[(6-chloro-2-pyrazinyl)amino]-methyl	JA 1007
cyclopropyl	-COCH <sub>3</sub> -	H	H	CH <sub>2</sub> F	[(6-chloro-2-pyridinyl)amino]-methyl	JA 1008
cyclopropyl	-COCH <sub>3</sub> -	H	H	CH <sub>2</sub> F	{ [(4-fluoroanilino) carbothioyl]amino }methyl	JA 1009
cyclopropyl	-COCH <sub>3</sub> -	H	H	CH <sub>2</sub> F	{ { (4-fluoro[(4-nitrophenyl) sulfonyl]anilino) carbothioyl } [(4-nitrophenyl) sulfonyl]amino }methyl	JA 1010

cyclo- propyl	-N-	=NOCH <sub>3</sub>	H	[(6-chloro-2-pyrazinyl) amino] - methyl	JA 1012
cyclo- propyl	-N-	=NOCH <sub>3</sub>	H	{(4-fluoro[(4-methoxyphenyl) - sulfonyl] anilino) - carbothioyl} [(4-methoxyphenyl) sul- fonyl] amino} methyl	JA 1013

JAP 200:

8-chloro-7-{3-[(6-chloro-2-pyridinyl) amino] -1-pyrrolidinyl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 201:

8-chloro-7-(3-{(6-chloro-2-pyridinyl) [(4-nitrophenyl) sulfonyl] amino}-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JAP 202:

8-chloro-7-(3-{(6-chloro-2-pyrazinyl) [(4-nitrophenyl) sulfonyl] amino}-1-pyrrolidinyl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

B627:

8-chloro-1-cyclopropyl-6-fluoro-7-(3-{[(4-nitroanilino) carbothioyl] amino}-1-pyrrolidinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 1006:

1-cyclopropyl-6-fluoro-7-[3-(fluoromethyl)-3-{[(4-nitrophenyl) sulfonyl] amino} methyl]-1-pyrrolidinyl-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 1007:

7-[3-{[(6-chloro-2-pyrazinyl) amino] methyl}-3-(fluoromethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 1008:

7- [3- { [(6-chloro-2-pyridinyl) amino] methyl} -3- (fluoro-  
methyl) -1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-8-methoxy-  
4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

5 JA 1009:

1-cyclopropyl-6-fluoro-7- [3- ({ [(4-fluoroanilino) carbo-  
thioyl] amino} methyl) -3- (fluoromethyl) -1-pyrrolidinyl] -8-  
methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 1010:

10 1-cyclopropyl-6-fluoro-7- [3- (fluoromethyl) -3- ({ (4-  
fluoro [ (4-nitrophenyl) sulfonyl] anilino} carbothioyl) [(4-  
nitrophenyl) sulfonyl] amino} methyl) -1-pyrrolidinyl] -8-  
methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 1012:


15 7- [3- { [(6-chloro-2-pyrazinyl) amino] methyl} -4- (methoxy-  
imino) -1-pyrrolidinyl] -1-cyclopropyl-6-fluoro-4-oxo-1,4-  
dihydro [1,8] naphthyridine-3-carboxylic acid;

JA 1013:

1-cyclopropyl-6-fluoro-7- [3- ({ (4-fluoro [ (4-methoxy-  
20 phenyl) sulfonyl] anilino} carbothioyl) [(4-methoxyphenyl) -  
sulfonyl] amino} methyl) -4- (methoxyimino) -1-pyrrolidinyl] -  
4-oxo-1,4-dihydro [1,8] naphthyridine-3-carboxylic acid.

In another preferred embodiment of the present  
invention, R<sub>5</sub> and R<sub>6</sub> form said group (p).

25 Furthermore, in yet another one of the most  
preferred embodiments, a compound according to the  
present invention has the general formula (VI):



30 wherein A, R<sub>4</sub>, R<sub>27</sub> and R<sub>28</sub> are as previously defined.

Preferably, A is selected from -CCl-, -COCH<sub>3</sub>-, and -N-.

Preferably, R<sub>4</sub> is selected from a group of substituents consisting of cyclopropyl, ethyl, 2-fluoroethyl, 4-fluorophenyl and 2,4-difluorophenyl.

Preferably, R<sub>27</sub> and R<sub>28</sub> are independently selected from H and at least one of the same said group of substituents as that preferred for R<sub>23</sub>-R<sub>26</sub> in the compound(s) of the general formula (V) *supra*.

Most preferably, a compound according to the formula (VI) is selected from the compounds disclosed in the following Table 5, the systematic names of which are also given hereinbelow:

15

Table 5:

A	R <sub>4</sub>	R <sub>27</sub>	R <sub>28</sub>	Denoted
-N-	2,4-di-fluorophenyl	H	(4-fluorophenyl)-sulfonyl	JA 1000
-N-	2,4-di-fluorophenyl	H	6-chloro-2-pyridinyl	JA 1001
-N-	2,4-di-fluorophenyl	H	6-chloro-2-pyrazinyl	JA 1002
-N-	2,4-di-fluorophenyl	H	(4-fluoroanilino)-carbonyl	JA 1003
-N-	2,4-di-fluorophenyl	H	(4-fluoroanilino)-carbothioyl	JA 1004
-N-	2,4-di-fluorophenyl	(4-nitrophenyl)-sulfonyl	{4-fluoro[(4-nitrophenyl)sulfonyl]anilino}-carbothioyl	JA 1005

JA 1000:

1-(2,4-difluorophenyl)-6-fluoro-7-((1R,5S)-6-{[(4-fluorophenyl)sulfonyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid;

JA 1001:

7-{(1R,5S)-6-[(6-chloro-2-pyridinyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphtyridine-3-carboxylic  
5 acid;

JA 1002:

7-{(1R,5S)-6-[(6-chloro-2-pyrazinyl)amino]-3-azabicyclo[3.1.0]hex-3-yl}-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphtyridine-3-carboxylic  
10 acid;

JA 1003:

1-(2,4-difluorophenyl)-6-fluoro-7-((1R,5S)-6-{[(4-fluoroanilino)carbonyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-4-oxo-1,4-dihydro[1,8]naphtyridine-3-carboxylic acid;

15 JA 1004:

1-(2,4-difluorophenyl)-6-fluoro-7-((1R,5S)-6-{[(4-fluoroanilino)carbothioyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-4-oxo-1,4-dihydro[1,8]naphtyridine-3-carboxylic  
acid;

20 JA 1005:

1-(2,4-difluorophenyl)-6-fluoro-7-((1R,5S)-6-{[(4-fluoro[(4-nitrophenyl)-sulfonyl]anilino)carbothionyl][(4-nitrophenyl)sulfonyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-4-oxo-1,4-dihydro[1,8]naphtyridine-3-carboxylic acid.

25 Furthermore, the present invention relates to a compound as set forth above for use as a pharmaceutical.

Accordingly, the present invention also relates to a pharmaceutical composition comprising a compound as set forth above as active ingredient in association with a  
30 pharmaceutically acceptable adjuvant, diluent or carrier.

Moreover, the present invention relates to an animal feed, food concentrate or drinking water comprising a compound as set forth above.

It should be noted that the composition and animal  
35 feed according to the present invention may optionally include two or more of the above outlined compounds.



In addition, the present invention relates to the use of a compound as defined above for the manufacture of a medicament for treatment of bacterial and parasitic disorders, particularly coccidiosis and disorders related thereto.

The present invention is also concerned with a method for treatment of bacterial and parasitic disorders, particularly coccidiosis and disorders related thereto, wherein said method comprises administering to an animal, preferably poultry, of a therapeutically effective amount of a compound as defined above.

Although the present compounds were shown to be especially suitable for treatment of coccidiosis (*vide infra*), it was anticipated that they are also therapeutically efficient against other protozoa, such as those set forth below as non-limiting examples:

*Trypanosoma*, such as *T. cruzi*, *T. brucei*, *T. congolense*,  
*T. evansi* and *T. simiae*;  
*Toxoplasma*, such as *T. gondii*;  
*Plasmodium*;  
*Babesia* spp.;  
*Theileria* spp.;  
*Leishmania*, such as *L. tropica*, *L. major* and *L. donavani*;  
*Entamoeba histolytica*;  
*Giardia intestinalis*;  
*Hexamita meleagridis*;  
*Trichomonas* spp.

*Trypanosoma* spp. is the cause of sleeping sickness in humans and animals, particularly in Africa. It is transmitted by the bite of the tsetse flies. It is well known that new compounds for treatment of *Trypanosoma* infections are an ongoing demand in the art.

Consequently, the present compounds were evaluated against *Trypanosoma* as well, and it was shown that they are also highly efficient for treatment of *Trypanosoma* parasites (*vide infra*).

Thus, the present invention also specifically relates to the use of the present compounds for the manufacture of a medicament for treatment of parasitic infection caused by *Trypanosoma*.

5       Accordingly, the present invention is also specifically concerned with a method for treatment of parasitic disorders caused by *Trypanosoma*, wherein said method comprises administering to an animal of a therapeutically effective amount of a compound as defined  
10   above.

The present compounds are also anticipated to be active against arthropods or helminth parasites, such as flatworms and nematodes. Typical examples of such parasites are disclosed in US 5 863 775, the entire  
15   teachings of which are incorporated herein by reference.

The typical dosage of the compounds according to the present invention varies within a wide range and will depend on various factors such as the particular requirement of each receiving individual and the route of  
20   administration. The dosage is generally within the range of 0.01-1000 mg/kg animal feed or body weight.

The present invention is further illustrated by the following non-limiting experimental part.

Preparation of the compounds of the present invention

25       General experimental information:

For thin liquid chromatography (TLC) monitoring of reactions, a methanol/benzene/ $\text{NH}_3(\text{aq})$  75:20:5 system was used. The products were recrystallized in acetone or chloroform/methanol (50:50 or 75:25). NMR data are given  
30   below as  $^1\text{H}$  NMR ( $\delta$ , ppm), unless otherwise provided.  
JA 1 ( $\text{C}_{23}\text{H}_{22}\text{FN}_3\text{O}_3\text{S}$ ):

Prepared essentially as JA 2 (*vide infra*), although an excess of benzenesulfonyl chloride was used instead of 4-toluenesulfonyl chloride ( $\text{TsCl}$ ). JA 1 was obtained as a  
35   white powder in a yield of 90%. Compound data:

Molecular Weight: 471.502;

Composition: C(58.59%), H(4.70%), F(4.03%), N(8.91%),

O(16.79%), S(6.80%);

NMR: 14.41, 8.65, 7.86, 7.62, 7.29, 3.95, 3.33, 3.19, 3.14, 1.17, 1.00.

JA 2 ( $C_{24}H_{24}FN_3O_5S$ ):

5 In a round bottomed flask, ciprofloxacin (2 g, 6.04 mmol; see US 4 670 444) was dissolved in dimethylformamide (DMF; 30 ml) followed by addition of pyridine (1.5 ml). An excess of TsCl was added, and the reaction mixture was heated for 5 h at 98°C. The excess of TsCl  
10 was neutralized with 20% NaOH (w/v; aq), and the pH was adjusted to 7. The solvent was evaporated, and addition of cold water gave a precipitate, which was filtered and washed with cold methanol and then dried in an oven at 60°C, thereby giving JA 2 as an off-white powder (53.2%  
15 yield). Compound data:

Molecular Weight: 485.529;

Composition: C(59.37%), H(4.98%), F(3.91%), N(8.65%), O(16.48%);

NMR: 14.41 (s), 8.65 (s), 7.86 (d), 7.78 (d), 7.75 (d),  
20 7.47 (m), 7.35 (m), 3.95 (m), 3.40 (m), 2.40 (m), 1.22, 1.12, 1.03, 1.17, 0.92.

JA 3 ( $C_{23}H_{21}FN_4O_7S$ ):

Prepared in a manner essentially identical to that used for JA 2, although 4-nitrobenzenesulfonyl chloride  
25 (1.6 g, 7.22 mmol) was used instead of TsCl. JA 3 was obtained as a yellowish powder (94% yield). Compound data:

Molecular Weight: 516.5;

Composition: C(53.48%), H(4.1%), F(3.68%), N(10.85%),  
30 O(21.68%), S(6.21%);

NMR: 14.41, 8.65, 8.20, 7.93, 7.91, 7.86, 7.78, 7.75, 3.95, 3.40, 3.33, 3.19, 3.14, 1.22, 1.14, 1.17, 1.03, 1.00, 0.92.

JA 4 ( $C_{24}H_{24}FN_3O_6S$ ):

35 Prepared essentially as JA 2, although 4-methoxybenzenesulfonyl chloride (2.3 g, 10 mmol) was used instead of TsCl. Compound data:

Molecular Weight: 501.528;  
Composition: C(57.48%), H(4.82%), F(3.79%), O(19.14%),  
S(6.39%);  
NMR: 14.41, 8.65, 7.86, 7.84, 7.58, 3.98, 3.84, 1.17.

5 JA 5 ( $C_{27}H_{24}FN_3O_5S$ ):

Prepared essentially as JA 2, although an excess of  
2-naphthalenesulfonyl chloride was used instead. JA 5 was  
obtained in 88% yield as a white powder. Compound data:  
Molecular Weight: 521.561;

10 Composition: C(62.18%), H(4.64%), F(4.64%), N(8.06%),  
O(15.34%), S(6.15%);  
NMR: 14.41, 8.17, 7.86, 7.78, 7.40, 3.95, 3.33, 3.19,  
3.14, 1.17, 1.00.

JA 6 ( $C_{26}H_{28}FN_3O_5S$ ):

15 Prepared essentially as JA 2, although an excess of  
mesitylsulfonyl chloride was used instead of TsCl. JA 6  
was obtained as an off-white powder (85% yield). Compound  
data:

Molecular Weight: 513.582;  
20 Composition: C(60.80%), H(5.5%), F(3.7%), N(88.18%),  
O(15.58%), S(6.24%);  
NMR: 14.41, 8.65, 7.86, 7.84, 7.78, 6.68, 3.96, 1.01.

JA 7 ( $C_{20}H_{24}FN_3O_5S$ ):

25 Prepared essentially as JA 2, but 1-propanesulfonyl  
chloride (5.64 ml, 50.3 mmol) was used instead of TsCl.  
JA 7 was obtained as a white powder (90% yield). Compound  
data:

Molecular Weight: 437.486;  
Composition: C(54.91%), H(5.53%), F(4.34%), N(9.6%),  
30 O(18.29%), S(7.33);  
NMR: 14.40, 8.65, 7.86, 7.78, 3.95, 3.10, 2.59, 1.96,  
1.00, 0.99, 0.96.

JA 9 ( $C_{24}H_{24}FN_3O_5S$ ):

35 Prepared essentially as JA 2, although phenyl-  
methanesulfonyl chloride (1.4 g) was used instead of  
TsCl. JA 9 was obtained as an off-white powder (90%  
yield). Compound data:

Molecular Weight: 485.529;

Composition: C(59.37%), H(4.98%), F(3.91%), N(8.65%),  
O(16.48%), S(6.6%);

NMR: 14.41, 8.65, 7.78, 7.86, 7.50, 7.30, 7.17, 4.17,  
5 3.95, 3.20, 3.12, 1.17, 1.00.

JA 10 ( $C_{18}H_{20}FN_3O_5S$ ):

Prepared essentially as JA 2. An excess of methane-  
sulfonyl chloride was used instead of TsCl. JA 10 was  
obtained in 95% yield as a creamy powder. Compound data:

10 Molecular Weight: 409.433;

Composition: C(52.80%), H(4.92%), F(4.64%), N(10.26%),  
O(19.54%), S(7.83%);

NMR: 14.41, 8.65, 7.86, 7.78, 3.95, 3.13, 2.93, 1.17,  
1.00.

15 JA 12 ( $C_{18}H_{17}F_4N_3O_5S$ ):

Prepared essentially as JA 2, although an excess of  
trifluoromethanesulfonyl chloride was used instead of  
TsCl. The required reaction time was 45 min in DMF. JA 12  
was obtained as a white powder. Compound data:

20 Molecular Weight: 463.404;

Composition: C(46.65%), H(3.7%), F(16.4%), N(9.07%),  
O(17.26%), S(6.92%);

NMR: 14.41, 8.65, 7.86, 7.78, 3.95, 3.32, 3.19, 3.14,  
1.17, 1.00.

25 JA 13 ( $C_{21}H_{19}BrFN_3O_5S_2$ ):

Prepared essentially as JA 2, although 5-bromo-  
thiophene-2-sulfonyl chloride (1.6 g) was used instead of  
TsCl. The yield of JA 13 was 88%. Compound data:

Molecular Weight: 556.427;

30 Composition: C(45.33%), H(3.44%), Br(14.36%), F(3.41%),  
N(7.55%), O(14.38%), S(11.53%);

NMR: 14.41, 7.86, 7.78, 7.03, 6.89, 3.95, 3.20, 1.17,  
1.00.

JA 14 ( $C_{23}H_{20}Cl_2FN_3O_6S$ ):

35 Prepared essentially as JA 2, although an excess of  
3,5-dichloro-2-hydroxybenzenesulfonyl chloride was used

instead of TsCl and the reaction required 24 h for completion. The yield of JA 14 was 63%. Compound data:

Molecular Weight: 556.391;

Composition: C(49.65%), H(3.62%), Cl(12.74%), F(3.41%),

5 N(7.55%), O(17.25%), S(5.76%);

NMR: 10.69, 8.65, 7.98, 7.86, 7.78, 3.95, 3.33, 3.40, 3.19, 3.14, 1.17, 1.03, 1.00.

JA 20 ( $C_{22}H_{21}FN_4O_7S$ ):

Prepared essentially as JA 2, although norfloxacin  
10 (2 g, 6.3 mmol; see US 4 146 719) was used instead of ciprofloxacin and 4-nitrobenzenesulfonyl chloride (1.7 g) was used instead of TsCl as an electrophilic reagent. JA 20 was obtained in 81% yield as a creamy powder. Compound data:

15 Molecular Weight: 504.489;

Composition: C(52.38%), H(4.20%), F(3.77%), N(11.11%), O(22.20%), S(6.36%);

NMR: 14.41, 8.93, 8.20, 7.93, 7.81, 7.43, 4.55, 3.40, 3.33, 3.19, 3.14, 1.40.

20 JA 21 ( $C_{23}H_{24}FN_3O_6S$ ):

Prepared essentially as JA 20, although the electrophilic reagent used was 4-methoxybenzenesulfonyl chloride (2 g, 9.7 mmol). JA 21 was obtained as an off-white powder (96% yield). Compound data:

25 Molecular Weight: 489.518;

Composition: C(56.43%), H(4.94%), F(3.88%), N(8.58%), O(19.61%), S(6.55%);

NMR: 14.41, 8.93, 7.81, 7.56, 7.43, 6.85, 4.55, 3.84, 3.40, 3.33, 3.19, 3.14, 1.40.

30 JA 26 ( $C_{23}H_{24}FN_3O_5S$ ):

Prepared essentially as JA 20, although the electrophilic reagent used was phenylmethanesulfonyl chloride (1.8 g). JA 26 was obtained as a creamy powder (84% yield). Compound data:

35 Molecular Weight: 473.518;

Composition: C(58.34%), H(5.11%), F(4.01%), N(8.87%), O(16.89%), S(6.77%);

NMR: 14.41, 8.93, 7.81, 7.43, 7.31, 7.17, 4.55, 4.17, 3.20, 3.12, 1.40.

JA 31 ( $C_{22}H_{20}Cl_2FN_3O_6S$ ):

Prepared essentially as JA 20, although the  
5 electrophilic reagent used was 3,5-dichloro-2-hydroxy-  
benzenesulfonyl chloride (2.5 g, 9.6 mmol). JA 31 was  
obtained as a creamy powder (75% yield). Compound data:  
Molecular Weight: 544.381;  
Composition: C(48.54%), H(3.70%), Cl(13.02%), F(3.49%),  
10 N(7.72%), O(17.63%), S(5.89%);  
NMR: 10.69, 8.93, 7.98, 7.81, 7.43, 4.55, 3.40, 3.33,  
3.19, 3.14, 1.40.

JA 39 ( $C_{21}H_{19}ClFN_5O_3$ ):

2,6-dichloropyrazine (1 g, 6.7 mmol) was reacted  
15 with ciprofloxacin (2 g, 6 mmol) using DMF (40 ml) as  
solvent in the presence of pyridine (1.5 ml). The  
reaction mixture was refluxed at 123°C for 5 h. Then ice  
water was added, and the precipitated powder product was  
washed with methanol and dried. In an alternative  
20 approach, the DMF was removed in vacuo using a rotary  
evaporator, followed by addition of ice water (50 ml).  
The obtained precipitate was washed with cold water and  
methanol up to a point where no yellowish filtrate was  
observed. JA 39 was obtained as a brown powder (90%  
25 yield). Compound data:  
Molecular Weight: 443.859;  
Composition: C(56.83%), H(4.31%), Cl(7.99%), F(4.28%),  
N(15.78%), O(10.81%);  
NMR: 14.41, 8.65, 8.06, 7.78, 7.54, 3.95, 3.84, 3.32,  
30 3.27, 1.17, 1.00.

JA 40 ( $C_{22}H_{20}BrFN_4O_3$ ):

Prepared essentially as JA 39, but 2,5-dibromo-  
pyridine (1.43 g, 6.04 mmol) was used instead of 2,6-  
dichloropyrazine. JA 40 was obtained in 77% yield.  
35 Compound data:  
Molecular Weight: 487.322;  
Composition: C(54.22%), H(4.14%), Br(16.40%), F(3.90%),

N(11.50%), O(9.85%);

NMR: 14.41, 8.65, 8.09, 7.78, 7.54, 7.24, 6.43, 3.95, 3.84, 3.32, 3.27, 1.17, 1.00.

JA 42 ( $C_{22}H_{20}ClFN_4O_3$ ):

- 5        Prepared essentially as JA 39, although 2,6-dichloropyridine (0.9 g, 6.04 mmol) was used instead of 2,6-dichloropyrazine and the reaction temperature was 120°C. JA 42 was obtained as a white powder (91% yield). Compound data:

10    Molecular Weight: 442.870;

Composition: C(59.66%), H(4.55%), Cl(8.01%), F(4.29%), N(12.65%), O(10.84%);

NMR: 14.41, 8.65, 7.78, 7.54, 7.54, 7.46, 7.01, 6.40, 3.95, 3.84, 3.32, 3.27, 1.17, 1.00.

15    JA 43 ( $C_{21}H_{19}ClFN_3O_5S_2$ ):

Prepared essentially as JA 2, but 5-chlorothiophene-2-sulfonylchloride (1.31 g, 6.03 mmol) was used instead of TsCl. The reaction temperature was 110°C and JA 43 was obtained as a white powder (77.6% yield). Compound data:

20    Molecular Weight: 511.976;

Composition: C(49.26%), H(3.74%), Cl(6.92%), F(3.71%), N(8.21%), O(15.63%), S(12.53%);

NMR: 14.41, 8.65, 7.86, 7.78, 6.95, 6.82, 3.95, 3.20, 1.17, 1.00.

25    JA 46 ( $C_{21}H_{20}FN_5O_3$ ):

Prepared essentially as JA 39, although 2-chloropyrazine was used as electrophilic agent. JA 46 was obtained in 80% yield as a white powder. Compound data:

Molecular Weight: 409.414;

30    Composition: C(61.61%), H(4.92%), F(4.64%), N(17.11%), O(11.72%);

NMR: 14.41, 8.65, 8.08, 7.84, 7.78, 7.54, 3.95, 3.84, 3.32, 3.27, 1.17, 1.00

JA 61 ( $C_{18}H_{13}BrFN_3O_3$ ):

- 35        Prepared essentially as JA 68 (*vide infra*), although 2 g of IM was used, and the nucleophilic reagent was 2-



amino-5-bromopyridine (7 g). JA 61 was obtained as a creamy powder (86% yield). Compound data:

Molecular Weight: 418.217;

Composition: C(51.69%), H(3.13%), Br(19.11%), F(4.54%),

5 N(10.05%), O(11.48%);

NMR: 12.3, 8.65, 8.40, 8.18, 7.55, 7.15, 6.71, 4.11, 1.17, 1.00.

JA 68 ( $C_{19}H_{16}FN_3O_3$ ):

7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-  
10 quinolinecarboxylic acid (4 g, 14.2 mmol; hereinafter denoted "IM") and 4-picolylamine (8 g) as nucleophilic reagent were refluxed overnight in DMF (50 ml) and pyridine (3 ml). After completion of the reaction, the solvents were evaporated and cold water was added,  
15 whereby a precipitate was obtained. The precipitate was washed with water followed by methanol, after which it was filtered and dried. JA 68 was obtained as a pale yellowish powder (73% yield) which was recrystallized from chloroform/acetone 70:30. A TLC spot of JA 68  
20 displays fluorescence when exposed to UV light. Compound data:

Molecular Weight: 353.347;


Composition: C(64.58%), H(4.56%), F(5.38%), N(11.89%), O(13.58%);

25 NMR: 11.77, 8.70, 8.65, 8.08, 7.48, 6.41, 4.33, 4.11, 1.17, 1.00.

IM ( $C_{13}H_9ClFNO_3$ ) was prepared as follows:

Condensation of 2,4-dichloro-5-fluoroacetophenone 2 with  
30 diethyl carbonate in the presence of NaH yielded ethyl 2,4-dichloro-5-fluorobenzoylacetate 3. Treatment of the latter with triethyl orthoformate in acetic anhydride gave the carbon homologue enol ether intermediate 4 which was allowed to react with a slight excess of cyclopropyl-  
35 amine in methylene chloride at room temperature to give the enaminoketoester 5. Cyclization of the latter with 1 molar equivalent of NaH in refluxing dioxane yielded

- ethyl 1,4-dihydro-4-oxo-quinoline-3-carboxylate **6** which was then hydrolysed with aqueous NaOH to give 1-cyclopropyl-6-chloro-7-fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acid (IM) **7**. See also Scheme 1 below (Maurer, F. and Grohe, K., DE 3 435 392 through Chem. Abst., Vol. 105, No.5, 1984, pp. 97158e). Compound data:
- Molecular Weight: 281.667;
- Composition: C(55.43%), H(3.22%), Cl(12.59%), F(6.74%), N(4.97%), O(17.04%);
- 10 NMR ( $\delta$  ppm; relative intensity): 14.41;0.13, 8.65;6.37, 8.22;1.62, 4.11;2.3, 1.22;0.06, 1.12;0.14, 1.03;0.14, 1.17;0.91, 1.00;0.90, 0.92;0.06.



Scheme 1

JA 69 (C<sub>20</sub>H<sub>21</sub>FN<sub>2</sub>O<sub>5</sub>):

Prepared essentially as JA 68 (*vide supra*), although 2 g of IM was used, and the nucleophilic reagent was 4-

aminocyclohexanecarboxylic acid (7 g). JA 69 was obtained as a white powder (86% yield). Compound data:

Molecular Weight: 388.390;

Composition: C(61.85%), H(5.45%), F(4.89%), N(7.21%),

5 O(20.60%);

NMR: 10.34, 8.65, 8.01, 6.31, 4.11, 3.29, 2.75, 2.10,  
1.77, 1.59, 1.17, 1.00.

JA 70 ( $C_{21}H_{17}FN_2O_5$ ):

Prepared essentially as JA 68, although the amount  
10 of IM used was 5.11 g and the nucleophilic reagent was 4-(aminomethyl)benzoic acid (6 g). The reaction temperature was 125°C for 4 h, and JA 70 was obtained as a creamy powder (61.2% yield). Compound data:

Molecular Weight: 396.369;

15 Composition: C(63.63%), H(4.32%), F(4.79%), N(7.07%),  
O(20.18%);

NMR: 12.13, 8.65, 8.08, 7.87, 7.48, 6.41, 4.48, 4.11,  
1.17, 1.00.

JA 73 ( $C_{18}H_{19}FN_2O_4$ ):

20 Prepared essentially as JA 68, although the amount of IM used was 8 g, the nucleophilic reagent was tetrahydrofurfurylamine (12.00 g), and the reaction temperature was 120°C for 3 h. JA 73 was obtained as a white powder (75% yield). Compound data:

25 Molecular Weight: 346.353;

NMR: 10.27, 8.65, 8.06, 6.38, 4.11, 3.89, 3.84, 2.98,  
2.77, 1.11, 1.17, 1.00.

JA 74 ( $C_{20}H_{21}FN_2O_5$ ):

Prepared essentially as JA 68, although 2 g of IM  
30 was used, and the nucleophilic reagent was 4-isopropylaniline (2 g). JA 69 was obtained as a white powder (86% yield). Compound data:

Molecular Weight: 380.412;

Composition: C(69.46%), H(5.56%), F(4.99%), N(7.36%),

35 O(12.62%);

NMR: 12.22, 8.65, 8.18, 7.20, 7.05, 4.11, 3.03, 1.15,  
1.20, 1.00.

JA 76 ( $C_{20}H_{24}FN_3O_3$ ):

Prepared essentially as JA 68, although 2 g of IM was used, and the nucleophilic reagent was 2-(1-piperidiny)-1-ethanamine (6 g). JA 76 was obtained as a

5 white powder (86% yield). Compound data:

Molecular Weight: 373.421;

Composition: C(64.33%), H(6.48%), F(5.09%), N(11.25%), O(12.85%);

NMR: 10.30, 8.65, 7.94, 6.34, 4.11, 3.21, 2.80, 2.47,  
10 2.40, 1.58, 1.48, 1.17, 1.03, 1.00.

JA 91 ( $C_{25}H_{20}FN_3O_5S$ ):

Prepared exactly as JA 2 (*vide supra*), although instead JA 68 (0.8 g, 2.27 mmol) was reacted with benzenesulfonyl chloride (3 g). JA 91 was obtained in 52%

15 yield. Compound data:

Molecular Weight: 493.508;

Composition: C(60.84%), H(4.08%), F(3.85%), O(16.21%), S(6.50%);

NMR: 14.41, 9.01, 8.65, 8.27, 7.81, 7.67, 7.42, 7.08,  
20 4.64, 4.11, 1.17, 1.00.

JA 103 ( $C_{16}H_{18}FN_3O_3$ ):

Prepared essentially as JA 68, although 3 g of IM was used, and the nucleophilic reagent was ethylenediamine (3.5 g). When the reaction was complete, the  
25 solvent was removed in vacuo and acetone (30 ml) was added to the residue. It should be noted that methanol should not be used at all here. An excess of cold water was subsequently added to obtain JA 103 as a suspended powder, which was filtered, dried and recrystallized. JA  
30 103 was obtained as a white powder (84% yield). Compound data:

Molecular Weight: 319.331;

Composition: C(60.18%), H(5.68%), F(5.95%), N(13.16%), O(15.03%);

NMR: 8.65, 7.97, 6.26, 6.12, 4.11, 3.31, 2.26, 1.17,  
35 1.00.

JA 105 ( $C_{19}H_{22}FN_3O_3$ ):

Prepared exactly as JA 103, although 3 g of IM was used, and the nucleophilic reagent was 1,2-diaminocyclohexane (6 g). JA 105 was obtained as a brownish powder (81% yield). Compound data:

5 Molecular Weight: 359.395;  
Composition: C(63.50%), H(6.17%), F(5.29%), N(11.69%),  
O(13.36%);  
NMR: 8.65, 8.01, 6.31, 5.32, 4.11, 2.83, 2.58, 1.92,  
1.46, 1.17, 1.00.

10 JA 117 ( $C_{24}H_{22}FN_3O_8S$ ):

Prepared essentially as JA 2 (*vide supra*), although instead 4-nitrobenzenesulfonyl chloride (0.8 g) was used as electrophile. JA 117 was obtained as a white powder (76% yield). Compound data:

15 Molecular Weight: 531.511;  
Composition: C(54.23%), H(4.17%), F(3.57%), N(7.91%),  
O(24.08%), S(6.03%);  
NMR: 14.41, 8.65, 8.31, 8.12, 7.05, 4.11, 3.89, 3.75,  
3.67, 1.17, 1.00.

20 JA 135 ( $C_{25}H_{25}FN_2O_7S$ ):

Prepared essentially as JA 2, although 1-cyclopropyl-6-fluoro-4-oxo-7-[(tetrahydro-2-furanylmethyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid and an excess of 4-methoxybenzenesulfonyl chloride were used instead. JA

25 135 was obtained in 86% yield as a white powder. Compound data:

Molecular Weight: 516.540;  
Composition: C(58.13%), H(4.68%), F(3.68%), N(5.42%),  
O(21.68%), S(6.21%);

30 NMR: 14.41, 8.65, 8.24, 7.75, 7.05, 6.96, 4.11, 3.84,  
3.89, 3.75, 3.67, 1.17, 1.00.

JA 136 ( $C_{28}H_{25}FN_2O_6S$ ):

Prepared essentially as JA 2, although 1-cyclopropyl-6-fluoro-4-oxo-7-[(tetrahydro-2-furanylmethyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid and an excess of 2-naphthalenesulfonyl chloride were used instead. JA 136

was obtained in 86% yield as a white powder. Compound data:

Molecular Weight: 536.572;

Composition: C(62.68%), H(4.70%), F(3.54%), N(5.22%),

5 O(17.89%), S(5.98%);

NMR: 14.41, 8.65, 8.24, 8.00, 7.76, 7.40, 7.05, 4.11, 3.89, 3.67, 3.75, 1.17, 1.00.

JA 137 (C<sub>26</sub>H<sub>27</sub>FN<sub>2</sub>O<sub>6</sub>S):

Prepared essentially as JA 2, although 1-cycloprop-  
10 yl-6-fluoro-4-oxo-7-[(tetrahydro-2-furanylmethyl)amino]-  
1,4-dihydro-3-quinolinecarboxylic acid and an excess of  
2-phenyl-1-ethanesulfonyl chloride were used instead. JA  
137 was obtained in 86% yield as a white powder. Compound  
data:

15 Molecular Weight: 514.567;

Composition: C(60.69%), H(5.29%), F(3.69%), N(5.44%),  
O(18.66%), S(6.23%);

NMR: 14.41, 8.65, 8.17, 7.39, 7.30, 6.92, 4.11, 3.79,  
3.68, 2.85, 1.17, 1.00.

20 JA 138 (C<sub>19</sub>H<sub>18</sub>F<sub>4</sub>N<sub>2</sub>O<sub>6</sub>S):

Prepared essentially as JA 144 (*vide infra*),  
although trifluoromethanesulfonyl chloride (0.6 g) was  
used as electrophile. JA 138 was obtained as a creamy  
powder (70% yield). Compound data:

25 Molecular Weight: 478.416;

Composition: C(47.70%), H(3.79%), F(15.88%), N(5.88%),  
N(5.86%), O(20.07%), S(6.70%);

NMR: 14.41, 8.65, 8.07, 7.31, 4.11, 3.99, 3.75, 3.61,  
1.17, 1.00.

30 JA 139 (C<sub>24</sub>H<sub>23</sub>FN<sub>2</sub>O<sub>6</sub>S):

Prepared essentially as JA 117, although benzene-  
sulfonyl chloride (0.7 g) was used as electrophile. JA  
139 was obtained in 76% yield. Compound data:

Molecular Weight: 486.514;

35 Composition: C(59.25%), H(4.77%), F(3.91%), N(5.76%),  
O(19.73%), S(6.59%);

NMR: 14.41, 8.65, 8.24, 7.79, 7.42, 7.05, 4.11, 3.89, 3.75, 1.17, 1.00.

JA 141 ( $C_{22}H_{20}ClFN_4O_4$ ):

Prepared essentially as JA 39, although 1-cyclopropyl-6-fluoro-4-oxo-7-[(tetrahydro-2-furanylmethyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead of ciprofloxacin. JA 141 was obtained in 78% yield as a brownish powder. Compound data:

Molecular Weight: 458.870;

Composition: C(57.58%), H(4.39%), Cl(7.73%), F(4.14%), N(12.21%), O(13.95%);

NMR: 14.41, 8.65, 8.15, 7.81, 4.57, 4.38, 4.11, 4.03, 3.89, 3.81, 1.17, 1.00.

JA 142 ( $C_{23}H_{21}BrFN_3O_4$ ):

Prepared essentially as JA 141, although instead 2,5-dibromopyridine (2.85 g) was used as electrophile. JA 142 was obtained as a creamy powder (80% yield). Compound data:

Molecular Weight: 502.333;

Composition: C(54.99%), H(4.21%), Br(15.91%), F(3.78%), N(8.37%), O(12.74%);

NMR: 14.41, 8.65, 8.36, 8.18, 7.51, 6.36, 4.59, 4.41, 4.11, 4.03, 3.89, 3.81, 1.17, 1.00.

JA 143 ( $C_{23}H_{21}ClFN_3O_4$ ):

Prepared essentially as JA 142, although 2,6-dichloropyridine (2.6 g) was used as electrophile. JA 143 was obtained as a creamy powder (72.3% yield). Compound data:

Molecular Weight: 457.882;

Composition: C(60.33%), H(4.62%), Cl(7.74%), F(4.15%), N(9.18%), O(13.98%);

NMR: 14.41, 8.65, 8.18, 7.72, 7.15, 6.33, 4.59, 4.41, 4.11, 4.03, 3.89, 3.81, 1.17, 1.00.

JA 144 ( $C_{22}H_{23}FN_2O_6$ ):

JA 73 (1 g, 2.9 mmol) was dissolved in DMF (40 ml), after which acetoacetic ester (2.5 g; CAS #141979) was added. The reaction mixture was refluxed for 3 h at

125°C, followed by solvent removal *in vacuo* and cold water addition to precipitate the product. Subsequent filtration and recrystallization from acetone gave JA 144 as an off-white powder (55% yield). Compound data:

- 5 Molecular Weight: 430.426;  
Composition: C(61.39%), H(5.39%), F(4.41%), N(6.51%),  
O(22.30%);  
NMR: 14.41, 8.65, 8.16, 7.25, 4.91, 4.53, 4.11, 3.75,  
3.53, 3.61, 1.9, 1.17, 1.00.

- 10 JA 145 (C<sub>25</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>4</sub>):

Prepared essentially as JA 144, although 4-vinylpyridine (2 g) was used as electrophile. JA 145 was obtained as a yellowish to off-white powder (62% yield). Compound data:

- 15 Molecular Weight: 451.490;  
Composition: C(66.51%), H(5.80%), F(4.21%), N(9.31%),  
O(14.17%);  
NMR: 14.41, 8.65, 8.48, 7.89, 7.55, 7.11, 3.95, 3.81,  
3.37, 3.19, 2.67, 1.18, 1.00.

- 20 JA 146 (C<sub>25</sub>H<sub>26</sub>FN<sub>3</sub>O<sub>4</sub>):

Prepared exactly as JA 145, although 2-vinylpyridine (2 g, 19 mmol) was used as electrophile. JA 146 was obtained as a light brown powder (66% yield). Compound data:

- 25 Molecular Weight: 451.490;  
Composition: C(66.51%), H(5.80%), F(4.21%), N(9.31%),  
O(14.17%);  
NMR: 14.41, 8.65, 8.5, 7.89, 7.53, 7.49, 7.25, 3.95,  
3.81, 3.26, 2.83, 1.18, 1.00.

- 30 JA 156 (C<sub>25</sub>H<sub>19</sub>FN<sub>4</sub>O<sub>7</sub>S):

Prepared exactly as JA 91, although instead JA 68 (1 g) was reacted with 4-nitrophenylsulfonyl chloride. JA 156 was obtained in 75% yield. Compound data:

- Molecular Weight: 538.505;  
35 Composition: C(55.76%), H(3.56%), F(3.53%), N(10.40%),  
O(20.80%), S(5.95%);



NMR: 14.41, 9.01, 8.65, 8.31, 8.14, 7.67, 7.08, 4.64, 4.11, 1.17, 1.00.

JA 158 ( $C_{24}H_{16}BrFN_4O_7S$ ):

Prepared essentially as JA 2, although instead JA 61 (1 g, 2.4 mmol) was reacted with 4-nitrobenzenesulfonyl chloride (2.7 g, 12.2 mmol). JA 158 was obtained as a creamy powder (67% yield). Compound data:

Molecular Weight: 603.375;

Composition: C(47.77%), H(2.67%), Br(13.24%), F(3.15%), N(9.29%), O(18.56%), S(5.31%);

NMR: 14.41, 8.65, 8.57, 8.35, 8.16, 7.73, 7.48, 6.80, 4.11, 1.17, 1.00.

JA 159 ( $C_{24}H_{16}BrF_2N_3O_5S$ ):

Prepared essentially as JA 2, although instead JA 61 (1 g, 2.4 mmol) was reacted with 4-fluorobenzenesulfonyl chloride (2.5 g, 11.8 mmol). JA 159 was obtained in a yield of 70%. Compound data:

Molecular Weight: 576.368;

Composition: C(50.01%), H(2.80%), Br(13.86%), F(6.59%), N(7.29%), O(13.88%), S(5.56%);

NMR: 14.41, 8.65, 8.57, 8.49, 7.81, 7.73, 7.48, 6.80, 4.11, 1.17, 1.00.

JA 160 ( $C_{19}H_{12}BrF_4N_3O_5S$ ):

Prepared exactly as JA 159, although instead JA 61 was reacted with trifluoromethylsulfonyl chloride. JA 160 was obtained in a yield of 68%. Compound data:

Molecular Weight: 550.279;

Composition: C(41.47%), H(2.20%), Br(14.52%), F(13.81%), N(7.64%), O(14.54%), S(5.83%);

NMR: 14.41, 8.65, 8.40, 7.74, 7.55, 7.06, 4.11, 1.17, 1.00.

JA 161 ( $C_{28}H_{19}BrFN_3O_5S$ ):

Prepared exactly as JA 159, although instead JA 61 was reacted with 2-naphtalenesulfonyl chloride. JA 161 was obtained in a yield of 66%. Compound data:

Molecular Weight: 608.436;

Composition: C(55.27%), H(3.15%), Br(13.13%), F(3.12%),  
N(6.91%), O(13.15%), S(5.27%);

NMR: 14.41, 8.57, 8.65, 8.04, 7.74, 7.48, 7.40, 6.80,  
4.11, 1.17, 1.00.

5 JA 162 ( $C_{28}H_{25}FN_2O_6S$ ):

Prepared essentially as JA 2, although instead JA 73  
(1 g, 2.9 mmol) was reacted with 2-naphtalenesulfonyl  
chloride (3.27 g, 14.9 mmol). JA 162 was obtained in a  
yield of 69%. Compound data:

10 Molecular Weight: 536.572;

Composition: C(62.68%), H(4.70%), F(3.54%), N(5.22%),  
O(17.89%), S(5.98%);

NMR: 14.41, 8.65, 8.24, 8.00, 7.76, 7.40, 7.05, 4.11,  
3.89, 3.75, 3.67, 1.17, 1.00.

15 JA 163 ( $C_{29}H_{22}FN_3O_5S$ ):

Prepared essentially as JA 2, although instead JA 68  
(1 g) was reacted with 2-naphtalenesulfonyl chloride (3.2  
g). JA 163 was obtained in a yield of 70%. Compound data:  
Molecular Weight: 543.567;

20 Composition: C(64.08%), H(4.08%), F(3.50%), N(7.73%),  
O(14.72%), S(5.90%);

NMR: 14.41, 9.01, 8.65, 8.27, 8.02, 7.67, 7.08, 4.64,  
4.11, 1.17, 1.00.

JA 164 ( $C_{20}H_{15}F_4N_3O_5S$ ):

25 Prepared exactly as JA 163, although instead JA 68  
(1 g) was reacted with trifluoromethanesulfonyl chloride  
(2.4 g, 14.2 mmol). JA 164 was obtained in a yield of  
72%. Compound data:

Molecular Weight: 485.410;

30 Composition: C(49.49%), H(3.11%), F(15.66%), N(8.66%),  
O(16.48%), S(6.61%);

NMR: 14.41, 9.01, 8.65, 8.09, 7.50, 7.33, 4.59, 4.11,  
1.17, 1.00.

JA 165 ( $C_{24}H_{18}ClFN_4O_3$ ):

35 Prepared exactly as JA 163, although instead JA 68  
(1 g) was reacted with 2,6-dichloropyridine (2 g, 13.5

mmol). JA 165 was obtained in a yield of 75%. Compound data:

Molecular Weight: 464.876;

Composition: C(62.01%), H(3.90%), Cl(7.63%), F(4.09%),

5 N(12.05%), O(10.32%);

NMR: 14.41, 8.72, 8.65, 8.20, 7.74, 7.51, 7.15, 6.36, 5.56, 4.11, 1.17, 1.00.

JA 166 ( $C_{23}H_{17}ClFN_5O_3$ ):

Prepared exactly as JA 163, although instead JA 68  
10 (1 g, 2.83 mmol) was reacted with dichloropyrazine (0.6 g, 4.0 mmol). JA 166 was obtained in a yield of 66%.

Compound data:

Molecular Weight: 465.864;

Composition: C(59.30%), H(3.68%), Cl(7.61%), F(4.08%),

15 N(15.03%), O(10.30%);

NMR: 14.41, 8.72, 8.65, 8.16, 7.84, 7.60, 5.54, 4.11, 1.17, 1.00.

JA 167 ( $C_{24}H_{18}BrFN_4O_3$ ):

Prepared exactly as JA 163, although instead JA 68  
20 (1 g, 2.83 mmol) was reacted with 2,5-dibromopyridine. JA 167 was obtained in a yield of 69%. Compound data:

Molecular Weight: 509.327;

Composition: C(56.60%), H(3.56%), Br(15.69%), F(3.73%), N(11.00%), O(9.42%);

25 NMR: 14.41, 8.72, 8.65, 8.38, 8.20, 7.51, 6.37, 5.56, 4.11, 1.17, 1.00.

JA 168 ( $C_{27}H_{20}FN_3O_9S$ ):

Prepared exactly as JA 2, although instead 4-nitrobenzenesulfonyl chloride (2.2 g) was used as  
30 electrophile and reacted with JA 70 (1.0 g). JA 168 was obtained as a creamy powder (72% yield). Compound data:

Molecular Weight: 581.527;

Composition: C(55.77%), H(3.47%), F(3.27%), N(7.23%), O(24.76%), S(5.51%);

35 NMR: 13.63, 8.65, 8.31, 8.14, 8.18, 7.68, 7.08, 4.67, 4.11, 1.17, 1.00.

JA 169 ( $C_{31}H_{23}FN_2O_7S$ ):

Prepared essentially as JA 168, although instead JA 70 (1 g, 2.5 mmol) was reacted with 2-naphtalenesulfonyl chloride (2.3 g). JA 169 was obtained as a white powder (70% yield). Compound data:

5 Molecular Weight: 586.588;  
Composition: C(63.47%), H(3.95%), F(3.24%), N(4.78%),  
O(19.09%), S(5.47%);  
NMR: 13.63, 8.65, 8.18, 7.68, 7.40, 7.08, 4.67, 4.11,  
1.17, 1.00.

10 JA 170 ( $C_{22}H_{16}F_4N_2O_7S$ ):

Prepared exactly as JA 169, although instead trifluoromethanesulfonyl chloride was used as the electrophilic reagent. JA 170 was obtained as a white powder (70% yield). Compound data:

15 Molecular Weight: 528.431;  
Composition: C(50.00%), H(3.05%), F(14.38%), N(5.30%),  
O(21.19%), S(6.07%);  
NMR: 13.63, 8.65, 8.18, 7.51, 7.33, 4.62, 4.11, 1.17,  
1.00.

20 JA 171 ( $C_{26}H_{19}ClFN_3O_5$ ):

Prepared exactly as JA 169, although instead 2,6-dichloropyridine (0.45 g) was used as the electrophilic reagent. JA 171 was obtained in 68% yield. Compound data:

Molecular Weight: 507.897;  
25 Composition: C(61.48%), H(3.77%), Cl(6.98%), F(3.74%),  
N(8.27%), O(15.75%);  
NMR: 13.63, 8.65, 8.20, 7.89, 7.74, 7.53, 7.15, 6.36,  
5.59, 4.11, 1.17, 1.00.

JA 172 ( $C_{25}H_{18}ClFN_4O_5$ ):

30 Prepared exactly as JA 169, although instead dichloropyrazine (0.45 g) was the electrophile used. JA 172 was obtained in 70% yield. Compound data:  
Molecular Weight: 508.885;  
Composition: C(59.00%), H(3.57%), Cl(6.97%), F(3.73%),  
35 N(11.01%), O(15.72%);  
NMR: 13.63, 8.65, 8.16, 7.89, 7.62, 5.56, 4.11, 1.17,  
1.00.

JA 173 ( $C_{26}H_{19}BrFN_3O_5$ ):

Prepared exactly as JA 169, although instead 2,5-dibromopyridine (1 g) was the electrophile used. JA 173 was obtained in 77% yield. Compound data:

5 Molecular Weight: 552.349;

Composition: C(56.54%), H(3.47%), Br(14.47%), F(3.44%), N(7.61%), O(14.48%);

NMR: 13.63, 8.65, 8.38, 7.89, 7.53, 6.37, 5.59, 4.11, 1.17, 1.00.

10 B626 ( $C_{27}H_{21}F_2N_5O_5S$ ):

In a round bottomed flask, 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid (5.56 mmol) was dissolved in a 10% aqueous solution of KOH (7.5 ml), followed by  
15 addition of distilled water (10 ml) in order to obtain a clear solution. A solution of 4-nitrophenylisothiocyanate (1.02 g, 5.56 mmol) in acetone (30 ml) was then added to the clear solution. The reaction mixture was refluxed for 0.5 h, after which distilled water was added and the pH  
20 was adjusted to 7 by using HCl (2N). The resulting precipitate was filtered off, washed with water and recrystallized from chloroform/acetone 70:30. The yield of B626 was 91%. Compound data:

Molecular Weight: 565.549;

25 Composition: C(57.34%), H(3.74%), F(6.72%), N(12.38%), O(14.15%), S(5.67%);

NMR: 12.11, 8.74, 8.04, 7.95, 7.63, 7.16, 6.91, 6.73, 3.34, 3.35, 2.56, 2.60.

B627 ( $C_{24}H_{21}ClFN_5O_5S$ ):

30 Prepared exactly as B626, although 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.56 mmol) was used instead. The yield of B627 was 96%. Compound data:

Molecular Weight: 545.971;

35 Composition: C(52.80%), H(3.88%), Cl(6.49%), F(3.48%), N(12.83%), O(14.65%), S(5.87%);

NMR: 10.29, 8.71, 8.16, 8.09, 6.97, 5.27, 3.99, 3.78,  
3.66, 3.26, 2.00, 1.97, 1.53, 1.17, 1.03, 1.00.

B628 ( $C_{23}H_{20}F_3N_5O_5S$ ):

Prepared exactly as B626, although 6,8-difluoro-1-  
5 (2-fluoroethyl)-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-  
quinolinecarboxylic acid (5.56 mmol) was used instead.  
The yield of B628 was 90%. Compound data:

Molecular Weight: 535.497;

Composition: C(51.59%), H(3.76%), F(10.64%), N(13.08%),  
10 O(14.94%), S(5.99%);

NMR: 12.04, 8.65, 8.04, 7.13, 6.92, 4.11, 3.7, 3.63,  
3.39, 3.29, 2.70, 2.62, 2.09, 1.18, 1.00.

B629 ( $C_{26}H_{26}FN_5O_5S$ ):

Prepared exactly as B626, although 1-cyclopropyl-6-  
15 fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-  
dihydro-3-quinolinecarboxylic acid (5.56 mmol) was used  
instead. The yield of B629 was 91%. Compound data:

Molecular Weight: 539.580;

Composition: C(57.87%), H(4.86%), F(3.52%), N(12.98%),  
20 O(14.83%), S(5.94%);

NMR: 12.04, 8.65, 8.04, 7.13, 6.92, 4.11, 3.70, 3.63,  
3.39, 3.29, 2.70, 2.62, 2.09, 1.18, 1.00.

B630 ( $C_{24}H_{23}F_2N_5O_5S$ ):

Prepared exactly as B626, although 1-ethyl-6,8-  
25 difluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid·HCl (2 g, 5.15 mmol) was used  
instead. The yield of B630 was 93%. Compound data:

Molecular Weight: 531.533;

Composition: C(54.23%), H(4.36%), F(7.15%), N(13.18%),  
30 O(15.05%), S(6.03%);

NMR: 12.04, 9.02, 8.04, 7.85, 6.92, 4.51, 3.66, 3.50,  
3.43, 2.70, 2.60, 1.55, 1.19.

B631 ( $C_{24}H_{22}FN_5O_6S$ ):

Prepared exactly as B626, although 9-fluoro-3-  
35 methyl-7-oxo-10-(1-piperazinyl)-2,3-dihydro-7H-  
[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid (5.56

58 .

mmol) was used instead. The yield of B631 was 92%.

Compound data:

Molecular Weight: 527.526;

Composition: C(54.64%), H(4.20%), F(3.60%), N(13.28%),

5 O(18.20%), S(6.08%);

NMR: 12.11, 8.93, 8.04, 7.35, 6.91, 4.52, 4.49, 4.42,  
3.43, 3.24, 2.95, 2.56, 2.60.

B632 (C<sub>23</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>5</sub>S<sub>2</sub>):

Prepared exactly as B626, although 9-fluoro-7-oxo-  
10 10-(1-piperazinyl)-2,3-dihydro-7H-[1,4]thiazino[2,3,4-  
ij]quinoline-6-carboxylic acid (5.56 mmol) was used  
instead. The yield of B632 was 96%. Compound data:

Molecular Weight: 529.566;

Composition: C(52.16%), H(3.81%), F(3.59%), N(13.22%),

15 O(15.11%), S(12.11%);

NMR: 12.11, 8.93, 8.04, 7.35, 6.91, 4.52, 4.49, 4.42,  
3.43, 3.24, 2.95, 2.56, 2.60.

B633 (C<sub>24</sub>H<sub>22</sub>F<sub>2</sub>N<sub>6</sub>O<sub>5</sub>S):

Prepared exactly as B626, although 5-amino-1-  
20 cyclopropyl-6,8-difluoro-4-oxo-7-(1-piperazinyl)-1,4-  
dihydro-3-quinolinecarboxylic acid (5.56 mmol) having its  
5-amino group acetyl-protected (by previous reaction with  
Ac<sub>2</sub>O) was used instead. The yield of B633 was 96%.

Compound data:

25 Molecular Weight: 544.532;

Composition: C(52.94%), H(4.07%), F(6.98%), N(15.43%),  
O(14.69%), S(5.89%);

NMR: 11.07, 8.84, 8.04, 6.91, 4.26, 3.55, 3.49, 2.60,  
2.56, 1.17, 1.00.

30 B634 (C<sub>28</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>5</sub>S):

Prepared exactly as B626, although 1-(2,4-  
difluorophenyl)-6-fluoro-7-(3-methyl-1-piperazinyl)-4-  
oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.56 mmol)  
was used instead. The yield of B634 was 98%. Compound  
35 data:

Molecular Weight: 597.566;

Composition: C(56.28%), H(3.71%), F(9.54%), N(11.72%),

O(13.39%), S(5.37%);

NMR: 12.04, 8.93, 8.04, 7.59, 7.08, 6.92, 6.79, 6.59,  
3.69, 3.39, 3.32, 2.70, 2.60, 1.19.

B635 ( $C_{34}H_{25}F_3N_6O_9S_2$ ):

- 5        Prepared exactly as JA 2, although 1-(2,4-difluorophenyl)-6-fluoro-7-{3-methyl-4-[(4-nitroanilino)carbothioyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid was reacted with 4-nitrobenzenesulfonyl chloride instead of TsCl. B635 was  
10    obtained as a creamy powder (92% yield). Compound data:  
Molecular Weight: 782.725;  
Composition: C(52.17%), H(3.22%), F(7.28%), N(10.74%),  
O(18.40%), S(8.19%);  
NMR: 14.41, 8.93, 8.26, 7.64, 7.57, 7.08, 6.79, 6.59,  
15    3.53, 3.41, 3.23, 3.11, 2.49, 1.22.

B636 ( $C_{24}H_{24}F_2N_4O_3S$ ):

- Prepared essentially as B626, although 1-ethyl-6,8-difluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid·HCl (2.6 mmol) was instead  
20    reacted with phenylisothiocyanate (3 mmol). B636 was  
obtained in 91% yield as a white powder. Compound data:  
Molecular Weight: 486.535;  
Composition: C(59.25%), H(4.97%), F(7.81%), N(11.52%),  
O(9.87%), S(6.59%);  
25    NMR: 12.04, 9.02, 7.85, 7.61, 7.22, 4.51, 3.66, 3.63,  
3.50, 3.43, 3.24, 2.70, 2.61, 1.55, 1.19.

B637 ( $C_{24}H_{22}F_2N_4O_3S$ ):

- Prepared exactly as B626, although 4-fluorophenyl-isothiocyanate was used instead of 4-nitrophenylisothio-  
30    cyanate. B637 was obtained in 91% yield as a white  
powder. Compound data:  
Molecular Weight: 484.519;  
Composition: C(59.49%), H(4.58%), F(7.84%), N(11.56%),  
O(9.91%), S(6.62%);  
35    NMR: 12.11, 8.65, 7.78, 7.70, 7.57, 7.14, 3.95, 3.43,  
3.35, 2.56, 2.6, 1.17, 1.00.

B638 ( $C_{23}H_{22}FN_5O_5S$ ):



Prepared exactly as B626, although 1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid (5.56 mmol) was used instead. The yield of B638 was 93%. Compound data:

5 Molecular Weight: 499.516;  
Composition: C(55.30%), H(4.44%), F(3.80%), N(14.02%),  
O(16.01%), S(6.42%);  
NMR: 12.11, 8.93, 8.04, 7.81, 7.15, 6.91, 4.55, 3.43,  
3.37, 2.60, 2.56, 1.40.

10 JA 1000 ( $C_{28}H_{18}F_4N_4O_5S$ ):

Prepared essentially as JA 2, although 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophen-yl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (6.3 mmol; see US 5 164 402) and 4-fluorobenz-  
15 enesulfonyl chloride (7 mmol) were used instead. JA 1000 was obtained in 82% yield as a creamy powder. Compound data:

Molecular Weight: 574.505;  
Composition: C(54.36%), H(3.16%), F(13.23%), N(9.75%),  
20 O(13.92%), S(5.58%);  
NMR: 9.36, 8.88, 8.44, 7.64, 7.30, 6.92, 6.72, 3.00,  
2.80, 2.66, 0.96.

JA 1001 ( $C_{25}H_{17}ClF_3N_5O_3$ ):

Prepared essentially as JA 42, although 7-[(1R,5S)-  
25 6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophen-yl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (6.3 mmol) was used instead of ciprofloxacin. JA 1001 was obtained in 90% yield as a creamy powder. Compound data:

30 Molecular Weight: 527.882;  
Composition: C(56.88%), H(3.25%), Cl(6.72%), F(10.80%),  
N(13.27%), O(9.09%);  
NMR: 8.88, 8.77, 8.44, 7.54, 7.08, 6.92, 6.72, 6.30,  
3.19, 2.85, 2.51, 1.14.

35 JA 1002 ( $C_{24}H_{16}ClF_3N_6O_3$ ):

Prepared essentially as JA 39, although 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophen-

yl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (6.3 mmol) was used instead of ciprofloxacin. JA 1002 was obtained in 90% yield as a brownish powder. Compound data:

5 Molecular Weight: 528.870;  
Composition: C(54.50%), H(3.05%), Cl(6.70%), F(10.78%), N(15.89%), O(9.08%);  
NMR: 9.44, 8.88, 8.44, 8.08, 7.82, 7.27, 6.92, 6.72, 3.19, 2.72, 1.14.

10 JA 1003 ( $C_{27}H_{19}F_4N_6O_4$ ):

Prepared exactly as B626, although 7-[(1R,5S)-6-amino-3-azabicyclo[3.1.0]hex-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (5.6 mmol) and 4-fluorophenylthiocyanate (5.6 mmol) were used instead. JA 1003 was obtained in 90% yield as a creamy powder. Compound data:

15 Molecular Weight: 527.882;  
Composition: C(58.59%), H(3.46%), F(13.73%), N(12.65%), O(11.56%);  
20 NMR: 9.06, 8.88, 8.44, 7.27, 7.06, 6.96, 6.72, 3.08, 2.75, 1.64, 1.42.

JA 1004 ( $C_{27}H_{19}F_4N_5O_3S$ ):

Prepared exactly as JA 1003, although 4-fluorophenylisothiocyanate (5.6 mmol) was used instead of 4-fluorophenylthiocyanate. JA 1003 was obtained in 90% yield as a creamy powder. Compound data:

25 Molecular Weight: 569.531;  
Composition: C(56.94%), H(3.36%), F(13.34%), N(12.30%), O(8.43%), S(5.63%);  
30 NMR: 9.73, 8.88, 8.44, 7.81, 7.27, 7.19, 6.92, 6.72, 3.08, 2.73, 1.91, 1.48.

JA 1005 ( $C_{39}H_{25}F_4N_7O_{11}S_3$ ):

Prepared essentially as JA 2, although 1-(2,4-difluorophenyl)-6-fluoro-7-((1R,5S)-6-{[(4-fluoroanilino)carbothioyl]amino}-3-azabicyclo[3.1.0]hex-3-yl)-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (6.3 mmol; see US 5 164 402) and an excess of 4-fluorobenzene-

sulfonyl chloride were used instead. JA 1005 was obtained in 79% yield as a creamy powder. Compound data:

Molecular Weight: 939.848;

Composition: C(49.84%), H(2.68%), F(8.09%), N(10.43%),

5 O(18.73%), S(10.24%);

NMR: 14.41, 8.88, 8.44, 8.35, 7.49, 7.27, 6.92, 6.72, 3.06, 2.76, 1.66.

JA 1006 (C<sub>26</sub>H<sub>26</sub>F<sub>2</sub>N<sub>4</sub>O<sub>8</sub>S):

Prepared exactly as JA 1005, although 7-[3-(amino-  
10 methyl)-3-(fluoromethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (6 mmol; see US 5 677 316) was used instead. JA 1006 was obtained in 72% yield as a creamy powder. Compound data:

15 Molecular Weight: 592.570;

Composition: C(52.70%), H(4.42%), F(6.41%), N(9.45%), O(21.60%), S(5.41%);

NMR: 10.06, 8.61, 8.41, 7.83, 4.22, 4.09, 4.02, 3.61, 3.45, 3.27, 2.90, 2.79, 2.69, 1.89, 1.83, 1.18, 1.00,

20 0.92.

JA 1007 (C<sub>24</sub>H<sub>24</sub>ClF<sub>2</sub>N<sub>6</sub>O<sub>4</sub>):

Prepared essentially as JA 39, although 7-[3-(amino-  
methyl)-3-(fluoromethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-  
fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic  
25 acid (6.3 mmol) was used instead. JA 1007 was obtained in 88% yield as a brownish powder. Compound data:

Molecular Weight: 519.928;

Composition: C(55.44%), H(4.65%), Cl(6.82%), F(7.31%), N(13.47%), O(12.31%);

30 NMR: 9.32, 8.61, 8.08, 7.83, 4.15, 4.02, 3.61, 3.43, 2.77, 1.90, 1.84, 1.22, 1.18, 1.00.

JA 1008 (C<sub>25</sub>H<sub>25</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>4</sub>):

Prepared exactly as JA 1001, although 7-[3-(amino-  
methyl)-3-(fluoromethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-  
35 fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (6.3 mmol) was used instead of ciprofloxacin. JA

1008 was obtained in 86% yield as a brownish powder.

Compound data:

Molecular Weight: 518.940;

Composition: C(57.86%), H(4.86%), Cl(6.83%), F(7.32%),

5 N(10.80%), O(12.33%);

NMR: 9.67, 8.61, 7.83, 7.41, 7.07, 6.31, 4.15, 4.02,

3.61, 3.43, 2.79, 1.90, 1.84, 1.22, 1.18, 1.00.

JA 1009 (C<sub>27</sub>H<sub>27</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S):

Prepared exactly as JA 1004, although 7-[3-(amino-  
10 methyl)-3-(fluoromethyl)-1-pyrrolidinyl]-1-cyclopropyl-6-  
fluoro-8-methoxy-4-oxo-1,4-dihydro-3-quinolinecarboxylic  
acid (6.3 mmol) was used instead. JA 1009 was obtained in  
89% yield as a brownish powder. Compound data:

Molecular Weight: 560.589;

15 Composition: C(57.85%), H(4.85%), F(10.17%), N(9.99%),  
O(11.42%), S(5.72%);

NMR: 10.61, 8.61, 7.83, 7.19, 4.36, 4.22, 4.18, 4.02,

3.61, 3.42, 3.34, 3.23, 2.79, 1.91, 1.85, 1.22, 1.18,  
1.00, 0.92.

20 JA 1010 (C<sub>39</sub>H<sub>33</sub>F<sub>3</sub>N<sub>6</sub>O<sub>12</sub>S<sub>3</sub>):

Prepared essentially as JA 2, although 1-cycloprop-  
yl-6-fluoro-7-[3-({[(4-fluoroanilino)carbothioyl]amino}-  
methyl)-3-(fluoromethyl)-1-pyrrolidinyl]-8-methoxy-4-oxo-  
1,4-dihydro-3-quinolinecarboxylic acid (6.3 mmol) and an  
25 excess of 4-nitrobenzenesulfonyl chloride were used  
instead. JA 1010 was obtained in 82% yield as a creamy  
powder. Compound data:

Molecular Weight: 930.906;

Composition: C(50.32%), H(3.57%), F(6.12%), N(9.03%),

30 O(20.62%), S(10.33%);

NMR: 14.41, 8.61, 8.46, 8.39, 7.83, 7.64, 7.51, 4.43,

4.30, 4.12, 4.02, 3.61, 3.44, 3.26, 2.79, 1.88, 1.18,  
1.00.

JA 1012 (C<sub>22</sub>H<sub>21</sub>ClFN<sub>7</sub>O<sub>4</sub>):

35 Prepared essentially as JA 39, although 7-[3-(amino-  
methyl)-4-(methoxyimino)-1-pyrrolidinyl]-1-cyclopropyl-6-  
fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic

acid (5.6 mmol) was used instead of ciprofloxacin. JA 1012 was obtained in 78% yield as a brownish powder.

Compound data:

Molecular Weight: 501.898;

5 Composition: C(52.65%), H(4.22%), Cl(7.06%), F(3.79%), N(19.54%), O(12.75%).

NMR: 9.77, 8.58, 8.31, 8.08, 7.79, 3.78, 3.64, 3.55, 3.11, 3.17, 1.18, 1.00.

JA 1013 ( $C_{39}H_{36}F_2N_8O_{10}S_3$ ):

10 Prepared essentially as JA 2, although 1-cyclopropyl-6-fluoro-7-[3-({[(4-fluoroanilino)carbothioyl]amino}-methyl)-4-(methoxyimino)-1-pyrrolidinyl]-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (5.7 mmol) and an excess of 4-methoxybenzenesulfonyl chloride were  
15 used instead. JA 1010 was obtained in 68% yield as a creamy powder. Compound data:

Molecular Weight: 882.932;

Composition: C(53.05%), H(4.11%), F(4.30%), N(9.52%), O(18.12%), S(10.90%);

20 NMR: 14.41, 8.58, 8.24, 8.12, 7.64, 7.51, 7.02, 4.74, 4.63, 3.84, 3.78, 3.64, 3.37, 3.15, 1.18, 1.00.

JAP 200 ( $C_{22}H_{19}Cl_2FN_4O_3$ ):

Prepared essentially as JA 42, although 7-(3-amino-1-pyrrolidinyl)-8-chloro-1-cyclopropyl-6-fluoro-4-oxo-  
25 1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead of ciprofloxacin. JAP 200 was obtained in 88% yield as a creamy powder. Compound data:

Molecular Weight: 477.315;

Composition: C(55.36%), H(4.01%), Cl(14.86%), F(3.98%),  
30 N(11.74%), O(10.06%);

NMR: 10.79, 8.71, 8.16, 7.48, 7.02, 6.30, 3.99, 3.81, 3.66, 3.22, 1.98, 1.56, 1.17, 1.00.

JAP 201 ( $C_{28}H_{22}Cl_2FN_5O_7S$ ):

Prepared essentially as JA 2, although 8-chloro-7-  
35 {3-[(6-chloro-2-pyridinyl)amino]-1-pyrrolidinyl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (6.3 mmol) and an excess of 4-nitrobenzenesulfonyl

chloride were used instead. JAP 201 was obtained in 86% yield as a creamy powder. Compound data:

Molecular Weight: 662.474;

Composition: C(50.76%), H(3.35%), F(2.87%), N(10.57%),

5 O(16.91%), S(4.84%);

NMR: 14.41, 8.71, 8.16, 7.96, 7.67, 7.33, 6.63, 3.99,

3.8, 3.68, 3.29, 1.97, 1.53, 1.17, 1.00.

JAP 202 ( $C_{27}H_{21}Cl_2FN_6O_7S$ ):

Prepared essentially as JA 2, although 8-chloro-7-  
10 {3-[(6-chloro-2-pyridinyl)amino]-1-pyrrolidinyl}-1-cyclo-  
propyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic  
acid (5.6 mmol) and an excess of 4-nitrobenzenesulfonyl  
chloride were used instead. JAP 202 was obtained in 86%  
yield as a creamy powder. Compound data:

15 Molecular Weight: 663.462;

Composition: C(48.88%), H(3.19%), Cl(10.69%), F(2.86%),

N(12.67%), O(16.88%), S(4.83%);

NMR: 14.41, 8.74, 8.20, 7.93, 7.16, 6.73, 3.40, 3.33,  
3.19, 3.12.

20 JAP 203 ( $C_{26}H_{20}F_2N_4O_7S$ ):

Prepared essentially as JA 2, although 6-fluoro-1-  
(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-  
quinolinecarboxylic acid (5.6 mmol; see US 4 730 000) and  
an excess of 4-nitrobenzenesulfonyl chloride were used  
25 instead. JAP 203 was obtained in 84% yield as a creamy  
powder. Compound data:

Molecular Weight: 570.523;

Composition: C(54.74%), H(3.53%), F(6.66%), N(9.82%),

O(19.63%), S(5.62%);

30 NMR: 14.41, 8.74, 8.20, 7.93, 7.16, 6.73, 3.40, 3.33,  
3.19, 3.12.

JAP 204 ( $C_{25}H_{19}ClF_2N_4O_3$ ):

Prepared essentially as JA 42, although 6-fluoro-1-  
(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-  
35 quinolinecarboxylic acid (5.5 mmol) was used instead of  
ciprofloxacin. JAP 204 was obtained in 90% yield as a  
creamy powder. Compound data:

Molecular Weight: 496.893;  
Composition: C(60.43%), H(3.85%), Cl(7.13%), F(7.65%),  
N(11.28%), O(9.66%);  
NMR: 14.41, 8.74, 7.95, 7.59, 7.46, 6.73, 6.40, 3.90,  
5 3.32.

JAP 205 ( $C_{24}H_{18}ClF_2N_5O_3$ ):

Prepared essentially as JA 39, although 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP  
10 205 was obtained in 77% yield as a brownish powder.

Compound data:

Molecular Weight: 497.881;  
Composition: C(57.90%), H(3.64%), Cl(7.12%), F(7.63%),  
N(14.07%), O(9.64%);  
15 NMR: 14.41, 8.74, 8.06, 7.95, 7.59, 7.16, 6.73, 3.90,  
3.32.

JAP 206 ( $C_{22}H_{19}F_3N_4O_7S$ ):

Prepared essentially as JA 2, although 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-  
20 dihydro-3-quinolinecarboxylic acid (5.6 mmol; see  
US 4 398 029) and an excess of 4-nitrobenzenesulfonyl  
chloride were used instead. JAP 206 was obtained in 85%  
yield as a creamy powder. Compound data:

Molecular Weight: 540.470;  
25 Composition: C(48.89%), H(3.54%), F(10.55%), N(10.37%),  
O(20.72%), S(5.93%);  
NMR: 14.41, 9.66, 8.20, 7.93, 7.86, 4.77, 4.66, 3.62,  
3.54, 3.40, 3.16, 3.09.

JAP 207 ( $C_{21}H_{18}ClF_3N_4O_3$ ):

Prepared essentially as JA 42, although 6,8-  
30 difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-  
oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was  
used instead. JAP 207 was obtained in 90% yield as a  
creamy powder. Compound data:

35 Molecular Weight: 466.841;  
Composition: C(54.03%), H(3.89%), Cl(7.59%), F(12.21%),  
N(12.00%), O(10.28%);

NMR: 14.41, 9.66, 7.90, 7.46, 7.01, 6.40, 4.77, 4.66, 3.90, 3.85, 3.62, 3.54, 3.44.

JAP 208 ( $C_{20}H_{17}ClF_3N_5O_3$ ):

Prepared essentially as JA 39, although 6,8-difluoro-1-(2-fluoroethyl)-7-(4-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP 208 was obtained in 77% yield as a brownish powder. Compound data:

Molecular Weight: 467.829;

Composition: C(51.35%), H(3.66%), Cl(7.58%), F(12.18%), N(14.97%), O(10.26%);

NMR: 14.41, 9.66, 8.06, 7.90, 4.77, 4.66, 3.90, 3.62, 3.54, 3.44.

JAP 209 ( $C_{25}H_{25}FN_4O_7S$ ):

Prepared essentially as JA 2, although 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol; see US 4 920 120) and an excess of 4-nitrobenzenesulfonyl chloride were used instead. JAP 209 was obtained in 87% yield as a creamy powder. Compound data:

Molecular Weight: 544.553;

Composition: C(55.14%), H(4.63%), F(3.49%), N(10.29%), O(20.57%), S(5.89%);

NMR: 14.41, 8.65, 8.20, 7.90, 7.46, 4.11, 3.46, 3.41, 3.17, 2.58, 2.09, 1.23, 1.17, 1.00.

JAP 210 ( $C_{24}H_{24}ClFN_4O_3$ ):

Prepared essentially as JA 42, although 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead of ciprofloxacin. JAP 210 was obtained in 82% yield as a creamy powder. Compound data:

Molecular Weight: 470.924;

Composition: C(61.21%), H(5.14%), Cl(7.53%), F(4.03%), N(11.90%), O(10.19%);

NMR: 14.41, 8.65, 8.20, 7.90, 7.46, 4.11, 3.46, 3.41, 3.17, 2.58, 2.09, 1.23, 1.17, 1.00.

JAP 211 ( $C_{23}H_{23}ClFN_5O_3$ ):



Prepared essentially as JA 39, although 1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP 211 was obtained in 79% yield as a brownish powder. Compound data:

Molecular Weight: 467.829;  
Composition: C(58.54%), H(4.91%), Cl(7.51%), F(4.03%), N(14.84%), O(10.17%);  
NMR: 14.41, 8.65, 8.04, 7.13, 4.21, 4.00, 4.11, 3.83, 3.24, 2.82, 2.09, 1.33, 1.17, 1.00.  
JAP 213 (C<sub>23</sub>H<sub>22</sub>F<sub>2</sub>N<sub>4</sub>O<sub>7</sub>S):

Prepared essentially as JA 2, although 1-ethyl-6,8-difluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol; see US 4 528 287) and an excess of 4-nitrobenzenesulfonyl chloride were used instead. JAP 213 was obtained in 89% yield as a creamy powder. Compound data:

Molecular Weight: 536.506;  
Composition: C(51.49%), H(4.13%), F(7.08%), N(10.44%), O(20.88%), S(5.98%);  
NMR: 14.41, 9.02, 8.20, 7.90, 7.83, 4.51, 3.46, 3.41, 3.14, 2.55, 1.55, 1.23.  
JAP 214 (C<sub>22</sub>H<sub>21</sub>ClF<sub>2</sub>N<sub>4</sub>O<sub>3</sub>):

Prepared essentially as JA 42, although 1-ethyl-6,8-difluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP 210 was obtained in 85% yield as a creamy powder.

Compound data:  
Molecular Weight: 462.877;  
Composition: C(57.09%), H(4.57%), Cl(7.66%), F(8.21%), N(12.10%), O(10.37%);  
NMR: 14.41, 9.02, 7.85, 7.43, 7.02, 6.38, 4.51, 4.20, 3.97, 3.40, 3.33, 3.22, 2.79, 1.55, 1.33.  
JAP 215 (C<sub>23</sub>H<sub>21</sub>FN<sub>4</sub>O<sub>8</sub>S):

Prepared essentially as JA 2, although 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyl)-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid (5.6 mmol; see

US 4 382 892) and an excess of 4-nitrobenzenesulfonyl chloride were used instead. JAP 215 was obtained in 89% yield as a creamy powder. Compound data:

Molecular Weight: 532.499;

5 Composition: C(51.88%), H(3.97%), F(3.57%), N(10.52%), O(24.04%), S(6.02%);

NMR: 14.41, 8.57, 7.99, 4.42, 3.82, 3.53, 3.40, 3.33, 1.35.

JAP 216 ( $C_{22}H_{20}ClFN_4O_4$ ):

10 Prepared essentially as JA 42, although 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyl)-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid (5.6 mmol) was used instead. JAP 216 was obtained in 86% yield as a creamy powder. Compound data:

15 Molecular Weight: 458.870;

Composition: C(57.58%), H(4.39%), Cl(7.73%), F(4.14%), N(12.21%), O(13.95%);

NMR: 14.41, 8.57, 7.99, 7.46, 7.01, 6.40, 4.42, 3.84, 3.53, 2.86, 1.35.

20 JAP 217 ( $C_{21}H_{19}ClFN_5O_4$ ):

Prepared essentially as JA 39, although 9-fluoro-3-methyl-7-oxo-10-(1-piperazinyl)-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid (5.6 mmol) was used instead. JAP 217 was obtained in 80% yield as a  
25 brownish powder. Compound data:

Molecular Weight: 459.858;

Composition: C(54.85%), H(4.16%), Cl(7.71%), F(4.13%), N(15.23%), O(13.92%);

30 NMR: 14.41, 8.57, 8.06, 7.95, 4.42, 3.82, 3.53, 2.86, 1.35.

JAP 218 ( $C_{22}H_{19}FN_4O_7S_2$ ):

Prepared essentially as JA 2, although 9-fluoro-7-oxo-10-(1-piperazinyl)-2,3-dihydro-7H-[1,4]thiazino[2,3,4-ij]quinoline-6-carboxylic acid (5.6 mmol; see  
35 US 4 684 647) and an excess of 4-nitrobenzenesulfonyl chloride were used instead. JAP 218 was obtained in 89% yield as a creamy powder. Compound data:

Molecular Weight: 534.539;

Composition: C(49.43%), H(3.58%), F(3.55%), N(10.48%),  
O(20.95%), S(12.00%);

NMR: 14.41, 8.93, 8.20, 7.93, 7.35, 4.49, 4.42, 3.40,  
5 3.24, 2.95, 3.12.

JAP 219 ( $C_{21}H_{18}ClFN_4O_3S$ ):

Prepared essentially as JA 42, although 9-fluoro-7-  
oxo-10-(1-piperazinyl)-2,3-dihydro-7H-[1,4]thiazi-  
no[2,3,4-ij]quinoline-6-carboxylic acid (5.6 mmol) was  
10 used instead. JAP 219 was obtained in 84% yield as a  
creamy powder. Compound data:

Molecular Weight: 460.910;

Composition: C(54.72%), H(3.94%), Cl(7.69%), F(4.12%),  
N(12.12%), O(10.41%), S(6.96%);

15 NMR: 14.41, 8.93, 7.46, 7.35, 7.01, 6.40, 4.49, 4.42,  
3.90, 3.24, 2.95.

JAP 220 ( $C_{20}H_{17}ClFN_5O_3S$ ):

Prepared essentially as JA 39, although 9-fluoro-7-  
oxo-10-(1-piperazinyl)-2,3-dihydro-7H-[1,4]thiazi-  
20 no[2,3,4-ij]quinoline-6-carboxylic acid (5.6 mmol) was  
used instead. JAP 220 was obtained in 76% yield as a  
brownish powder. Compound data:

Molecular Weight: 461.898;

Composition: C(52.01%), H(3.71%), Cl(7.68%), F(4.11%),  
25 N(15.16%), O(10.39%), S(6.94%);

NMR: 14.41, 8.93, 8.06, 7.35, 4.49, 4.42, 3.90, 3.24,  
2.95.

JAP 221 ( $C_{29}H_{24}F_2N_6O_{11}S_2$ ):

Prepared essentially as JA 2, although 5-amino-1-  
30 cyclopropyl-6,8-difluoro-4-oxo-7-(1-piperazinyl)-1,4-  
dihydro-3-quinolinecarboxylic acid (5.6 mmol; see  
US 4 795 751) and an excess of 4-nitrobenzenesulfonyl  
chloride were used instead. JAP 221 was obtained in 83%  
yield as a creamy powder. Compound data:

35 Molecular Weight: 734.664;

Composition: C(47.41%), H(3.29%), F(5.17%), N(11.44%),  
O(23.96%), S(8.73%);

NMR: 14.92, 8.84, 8.20, 7.93, 4.26, 3.40, 3.33, 3.16, 3.09, 1.17, 1.00.

JAP 222 ( $C_{31}H_{28}F_2N_6O_{11}S_2$ ):

Prepared essentially as JA 2, although 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol; see US 4 795 751) and an excess of 4-nitrobenzenesulfonyl chloride were used instead. JAP 222 was obtained in 81% yield as a creamy powder. Compound data:

10 Molecular Weight: 762.717;  
Composition: C(48.82%), H(3.70%), F(4.98%), N(11.02%), O(23.07%), S(8.41%);  
NMR: 14.92, 8.84, 8.21, 7.87, 4.26, 3.58, 3.00, 2.52, 1.23, 1.17, 1.00.

15 JAP 223 ( $C_{29}H_{26}Cl_2F_2N_6O_3$ ):

Prepared essentially as JA 42, although 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP 223 was obtained in 80% yield as a creamy powder. Compound data:

20 Molecular Weight: 615.458;  
Composition: C(56.59%), H(4.26%), Cl(11.52%), F(6.17%), N(13.65%), O(7.80%);  
NMR: 14.52, 8.84, 7.79, 7.40, 7.09, 6.36, 4.26, 3.88, 3.20, 2.77, 1.34, 1.17, 1.00.

25 JAP 224 ( $C_{27}H_{24}Cl_2F_2N_8O_3$ ):

Prepared essentially as JA 39, although 5-amino-1-cyclopropyl-7-(3,5-dimethyl-1-piperazinyl)-6,8-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP 220 was obtained in 76% yield as a brownish powder. Compound data:

30 Molecular Weight: 617.434;  
Composition: C(52.52%), H(3.92%), Cl(11.48%), F(6.15%), N(18.15%), O(7.77%);  
NMR: 15.62, 8.84, 8.36, 8.03, 4.26, 3.88, 3.20, 2.77, 1.34, 1.17, 1.00.

JAP 225 ( $C_{27}H_{21}F_3N_4O_7S$ ):

Prepared essentially as JA 2, although 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol; see US 4 730 000) and an excess of 4-nitrobenzenesulfonyl chloride were used instead. JAP 225 was obtained in 81% yield as a creamy powder. Compound data:

Molecular Weight: 602.540;

Composition: C(53.82%), H(3.51%), F(9.46%), N(9.30%), O(18.59%), S(5.32%);

10 NMR: 14.41, 8.93, 8.20, 8.06, 7.90, 7.08, 6.79, 6.59, 3.48, 3.41, 3.17, 2.58, 1.23.

JAP 226 (C<sub>25</sub>H<sub>19</sub>ClF<sub>3</sub>N<sub>5</sub>O<sub>3</sub>):

Prepared essentially as JA 39, although 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP 226 was obtained in 78% yield as a brownish powder. Compound data:

Molecular Weight: 529.898;

20 Composition: C(56.67%), H(3.61%), Cl(6.69%), F(10.76%), N(13.22%), O(9.06%);

NMR: 14.41, 8.93, 8.04, 7.59, 7.08, 6.79, 6.59, 4.24, 4.00, 3.29, 2.82, 1.33.

JAP 227 (C<sub>26</sub>H<sub>20</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>3</sub>):

Prepared essentially as JA 42, although 1-(2,4-difluorophenyl)-6-fluoro-7-(3-methyl-1-piperazinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid (5.6 mmol) was used instead. JAP 227 was obtained in 83% yield as a creamy powder. Compound data:

Molecular Weight: 528.910;

30 Composition: C(59.04%), H(3.81%), Cl(6.70%), F(10.78%), N(10.59%), O(9.07%);

NMR: 14.41, 8.93, 8.05, 7.59, 7.43, 7.02, 6.38, 4.24, 4.00, 3.29, 2.82, 1.33.

As for the preparation of the other compounds according to the present invention, useful general guidance is also provided by the following publications: EP 195 316 A1; US 4 398 029; US 4 528 287; US 4 684 647;

US 4 730 000; US 4 795 751; US 4 920 120; US 5 164 402;  
US 5 677 316; US 5 776 944;  
*Org. Syntheses*, Coll. Vol. 2, 586, pp. 1055-1057 (1943);  
*ibid.*, 34-38, 179-183, 943-946;

- 5 "Advanced Organic Chemistry", March, J., p.445 and  
pp. 802-803, 3<sup>rd</sup> ed.

The synthesis of the required starting substances is  
readily accomplished by a person skilled in the art,  
should they not be commercially available. The additional  
10 compounds listed below were all prepared by using  
essentially the same synthetic protocol as that used for  
the previously disclosed compounds.

B700 ( $C_{24}H_{22}FN_5O_6$ ):

- 1-cyclopropyl-6-fluoro-7-{4-[(4-nitroanilino)carbonyl]-1-  
15 piperazinyl}-4-oxo-1,4-dihydro-3-quinolinecarboxylic  
acid;

B702 ( $C_{24}H_{23}F_2N_5O_6$ ):

- 1-ethyl-6,8-difluoro-7-{3-methyl-4-[(4-nitroanilino)-  
carbonyl]-1-piperazinyl}-4-oxo-1,4-dihydro-3-quinoline-  
20 carboxylic acid;

JA 41 ( $C_{23}H_{21}ClFN_3O_3S$ ):

- 7-[4-(3-chloro-2-sulfanylphenyl)-1-piperazinyl]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;

- 25 JA 47-2 ( $C_{30}H_{21}F_3N_4O_7S_2$ ):

1-cyclopropyl-6-fluoro-7-[[4-(4-fluorophenyl)sulfonyl](6-  
{[(4-fluorophenyl)sulfonyl]amino}-2-pyridinyl)amino]-4-  
oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 53-2 ( $C_{30}H_{25}F_3N_4O_5S_2$ ):

- 30 1-cyclopropyl-6-fluoro-7-[4-({4-fluoro[(4-fluorophenyl)-  
sulfonyl]anilino}carbothioyl)-1-piperazinyl]-4-oxo-1,4-  
dihydro-3-quinolinecarboxylic acid;

JA 53-3 ( $C_{30}H_{25}F_2N_5O_7S_2$ ):

- 1-cyclopropyl-6-fluoro-7-[4-({4-fluoro[(4-nitrophenyl)-  
35 sulfonyl]anilino}carbothioyl)-1-piperazinyl]-4-oxo-1,4-  
dihydro-3-quinolinecarboxylic acid;

- JA 53-5 ( $C_{28}H_{23}ClF_2N_6O_3S$ ):  
7-(4-{[(6-chloro-2-pyrazinyl)-4-fluoroanilino]carbothio-  
yl}-1-piperazinyl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-  
dihydro-3-quinolinecarboxylic acid;
- 5 JA 53-6 ( $C_{29}H_{24}ClF_2N_5O_3S$ ):  
7-(4-{[(6-chloro-2-pyridinyl)-4-fluoroanilino]carbothio-  
yl}-1-piperazinyl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-  
dihydro-3-quinolinecarboxylic acid;
- JA 69-2 ( $C_{24}H_{22}ClFN_4O_5$ ):  
10 7-[(4-carboxycyclohexyl)(6-chloro-2-pyrazinyl)amino]-1-  
cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 69-3 ( $C_{21}H_{20}F_4N_2O_7S$ ):  
7-{(4-carboxycyclohexyl)[(trifluoromethyl)sulfonyl]-  
15 amino}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-  
quinolinecarboxylic acid;
- JA 74-2 ( $C_{21}H_{21}FN_2O_3$ ):  
1-ethyl-6-fluoro-7-(4-isopropylanilino)-4-oxo-1,4-  
dihydro-3-quinolinecarboxylic acid;
- 20 JA 76-2 ( $C_{26}H_{27}FN_4O_7S$ ):  
1-cyclopropyl-6-fluoro-7-{[(4-nitrophenyl)sulfonyl][2-(1-  
piperidinyl)ethyl]amino}-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 76-3 ( $C_{24}H_{25}ClFN_5O_3$ ):  
25 7-{(6-chloro-2-pyrazinyl)[2-(1-piperidinyl)ethyl]amino}-  
1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid;
- JA 79-2 ( $C_{29}H_{26}F_3N_3O_7S_4$ ):  
1-cyclopropyl-6-fluoro-7-{[(4-fluorophenyl)sulfonyl]{2-  
30 [(2-{[(4-fluorophenyl)sulfonyl]amino}ethyl)disulfanyl]-  
ethyl}amino}-4-oxo-1,4-dihydro-3-quinolinecarboxylic  
acid;
- JA 79-3 ( $C_{29}H_{26}FN_5O_{11}S_4$ ):  
1-cyclopropyl-6-fluoro-7-{[(4-nitrophenyl)sulfonyl]{2-  
35 [(2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)disulfanyl]-  
ethyl}amino}-4-oxo-1,4-dihydro-3-quinolinecarboxylic  
acid;

- JA 82-2 ( $C_{30}H_{28}FN_5O_{13}S_2$ ):  
1-cyclopropyl-6-fluoro-7-([(4-nitrophenyl)sulfonyl]{2-[2-([(4-nitrophenyl)sulfonyl]amino)methoxy]ethoxy}ethyl)-amino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 5 JA 82-3 ( $C_{26}H_{24}Cl_2FN_7O_5$ ):  
7-{(6-chloro-2-pyrazinyl)[2-(2-{[(6-chloro-2-pyrazinyl)-amino]methoxy}ethoxy)ethyl]amino}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 96-2 ( $C_{38}H_{32}F_2N_6O_{12}S_2$ ):  
10 1-cyclopropyl-6-fluoro-7-[4-({[(4-fluoro[(4-nitrophenyl)sulfonyl]anilino)carbonyl][(4-nitrophenyl)sulfonyl]amino)methyl]-1-piperidinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 97 ( $C_{19}H_{22}FN_3O_3$ ):  
15 1-cyclopropyl-6-fluoro-4-oxo-7-{[2-(1-pyrrolidinyl)ethyl]amino}-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 97-2 ( $C_{26}H_{26}FN_5O_5S$ ):  
1-cyclopropyl-6-fluoro-7-{[(4-nitroanilino)carbothioyl][2-(1-pyrrolidinyl)ethyl]amino}-4-oxo-1,4-dihydro-3-
- 20 quinolinecarboxylic acid;
- JA 97-3 ( $C_{23}H_{23}ClFN_5O_3$ ):  
7-{(6-chloro-2-pyrazinyl)[2-(1-pyrrolidinyl)ethyl]amino}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 25 JA 97-4 ( $C_{25}H_{25}FN_4O_7S$ ):  
1-cyclopropyl-6-fluoro-7-{[(4-nitrophenyl)sulfonyl][2-(1-pyrrolidinyl)ethyl]amino}-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 97-5 ( $C_{20}H_{21}F_4N_3O_5S$ ):  
30 1-cyclopropyl-6-fluoro-4-oxo-7-{[2-(1-pyrrolidinyl)ethyl][(trifluoromethyl)sulfonyl]amino}-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 99-2 ( $C_{33}H_{32}F_3N_3O_7S_2$ ):  
1-cyclopropyl-6-fluoro-7-([(4-fluorophenyl)sulfonyl]{[3-([(4-fluorophenyl)sulfonyl]amino)methyl]cyclohexyl}methyl]amino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 35



- JA 102 ( $C_{20}H_{27}FN_4O_3$ ):  
7-({3-[(3-aminopropyl)(methyl)amino]propyl}amino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid;
- 5 JA 103-2 ( $C_{18}H_{16}F_7N_3O_7S_2$ ):  
1-cyclopropyl-6-fluoro-4-oxo-7-[[[(trifluoromethyl)sulfonyl](3-{[(trifluoromethyl)sulfonyl]amino}propyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid;
- 10 JA 103-3 ( $C_{28}H_{24}FN_5O_{11}S_2$ ):  
1-cyclopropyl-6-fluoro-7-[[[(4-nitrophenyl)sulfonyl](3-{[(4-nitrophenyl)sulfonyl]amino}propyl)amino]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 15 JA 104-2 ( $C_{21}H_{25}F_4N_3O_5S$ ):  
1-cyclopropyl-7-{[3-(dimethylamino)-2,2-dimethylpropyl] [(trifluoromethyl)sulfonyl]amino}-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 20 JA 104-3 ( $C_{25}H_{28}FN_3O_4S$ ):  
1-cyclopropyl-7-[[3-(dimethylamino)-2,2-dimethylpropyl]-(2-thienylcarbonyl)amino]-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 25 JA 106-3 ( $C_{17}H_{14}F_7N_3O_7S_2$ ):  
1-cyclopropyl-6-fluoro-4-oxo-7-[[[(trifluoromethyl)sulfonyl](2-{[(trifluoromethyl)sulfonyl]amino}ethyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid;
- 30 JA 106-4 ( $C_{27}H_{22}FN_5O_{11}S_2$ ):  
1-cyclopropyl-6-fluoro-7-[[[(4-nitrophenyl)sulfonyl](2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)amino]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- 35 JA 107-2 ( $C_{20}H_{20}F_7N_3O_7S_2$ ):  
1-cyclopropyl-7-{(2,2-dimethyl-3-{[(trifluoromethyl)sulfonyl]amino}propyl) [(trifluoromethyl)sulfonyl]amino}-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;
- JA 110 ( $C_{28}H_{27}FN_4O_3S$ ):  
7-(4-{[(anilino-carbothioyl)amino]methyl}-1-piperidinyl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-carboxylic acid;

JA 124 ( $C_{23}H_{17}FN_2O_5S$ ):

1-cyclopropyl-6-fluoro-7-[(2-furylmethyl)(2-thienylcarbonyl)amino]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 128 ( $C_{25}H_{26}FN_3O_4S$ ):

- 5 1-cyclopropyl-6-fluoro-4-oxo-7-[[2-(1-piperidinyl)ethyl]-(2-thienylcarbonyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid;

JA 140 ( $C_{23}H_{21}FN_2O_5S$ ):

- 10 1-cyclopropyl-6-fluoro-4-oxo-7-[(tetrahydro-2-furanylmethyl)(2-thienylcarbonyl)amino]-1,4-dihydro-3-quinolinecarboxylic acid;

JA 148 ( $C_{21}H_{23}FN_2O_6$ ):

- 15 7-[acetoacetyl(2-methoxy-1-methylethyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

JA 149 ( $C_{23}H_{22}FN_3O_8S$ ):

- 20 1-cyclopropyl-6-fluoro-7-[(2-methoxy-1-methylethyl)[(4-nitrophenyl)sulfonyl]amino]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

#### Biological evaluation of the present compounds

##### Antibacterial testing against gram-positive and gram-negative bacteria:

- 25 The antibacterial activity of the present compounds was investigated by *in vitro* evaluation of their M.I.C. (Minimum Inhibitory Concentration) values. The evaluation was conducted in complete accordance with the "Broth dilution method", as outlined by the US National Committee for Clinical Laboratory Standards "NCCLS 1988".

- 30 Solutions of the present compounds were prepared by dissolving 0.01 g of a test compound in either 10% KOH (aq) or a 10% KOH/DMF mixture, after which sterile, distilled  $H_2O$  was added up to a total volume of 10 ml, thereby yielding a test compound concentration of 1 000  
35  $\mu g/ml$ . The volume (ml) used of 10% KOH and DMF for dissolution of each respective test compound is given in Table 1 below.

In this evaluation, the antibacterial activity of the present compounds and enrofloxacin as reference compound was tested against seven strains of gram-positive bacteria, namely *Bacillus subtilus* (ATCC 6633),  
5 *Bacillus cereus*, *Streptococcus faecium*, *Micrococcus Luteus* (ATCC 9341), *Staph. aureus* (ATCC 29737), *Staph. epidermidis* (ATCC 12228) and *Staphylococcus* (ATCC 6538). The results are presented in the following Table 6.

Table 6: M.I.C. values for compounds tested

Compound tested	KOH/DMF (ml)	<i>Bacillus subtilus</i>	<i>Bacillus cereus</i>	<i>Streptoc. faecium</i>	<i>Microc. Luteus</i>	<i>Staph. aureus</i>	<i>Staph. epidermidis</i>	<i>Staph. (ATCC 6538)</i>
Enrofloxacin	0.10/0.10	0.500	0.250	1.000	2.000	0.250	0.120	0.120
JA 1	0.14/1.50	0.060	0.060	0.500	0.500	0.120	0.060	0.060
JA 2	0.10/0.70	0.120	0.060	0.500	0.500	0.120	0.060	0.030
JA 3	0.10/-	0.060	0.060	0.250	1.000	0.060	0.010	0.060
JA 4	0.10/0.10	0.010	0.010	0.060	0.250	0.060	0.030	0.010
JA 5	0.10/0.50	0.008	0.030	0.120	0.500	0.060	0.010	0.060
JA 9	0.14/0.50	0.250	0.250	1.000	1.000	≥0.120	0.120	0.060
JA 10	0.10/-	0.500	0.120	1.000	2.000	0.250	0.250	0.250
JA 12	0.10/0.50	0.120	0.060	1.000	0.500	0.120	0.120	0.030
JA 21	0.10/-	0.250	0.010	0.500	2.000	0.250	0.060	0.060
JA 39	0.10/0.50	0.060	0.010	0.250	1.000	0.120	0.010	0.030
JA 40	0.12/1.00	0.120	0.060	1.000	2.000	0.250	0.120	0.060
JA 41	0.16/1.70	0.500	0.250	1.000	2.000	0.250	0.250	0.250
JA 42	0.10/1.70	0.010	0.060	0.250	1.000	0.030	0.008	0.060
JA 43	0.10/1.00	0.250	0.120	1.000	1.000	0.120	0.250	0.030
JA 46	0.14/1.00	0.120	0.060	0.500	1.000	0.120	0.120	0.120
JA 68	0.10/1.00	0.120	0.060	1.000	2.000	0.120	0.250	0.120

Table 6 (cont.):

Compound tested	KOH/DMF (ml)	<i>Bacillus subtilus</i>	<i>Bacillus cereus</i>	<i>Streptoc. faecium</i>	<i>Microc. Luteus</i>	<i>Staph. aureus</i>	<i>Staph. epidermidis</i>	<i>Staph. (ATCC 6538)</i>
JA 69	0.16/1.00	0.120	0.060	2.000	2.000	0.120	0.120	0.120
JA 70	0.10/0.50	0.250	0.120	2.000	1.000	0.120	0.250	0.120
JA 73	0.16/1.00	0.120	0.060	0.500	2.000	0.120	0.120	0.060
JA 74	0.14/1.00	0.120	0.120	2.000	2.000	0.120	0.120	0.120
JA 76	0.10/1.00	0.120	0.120	1.000	2.000	0.120	0.120	0.060
JA 102	0.14/1.00	0.120	0.060	1.000	2.000	0.060	0.120	0.120
JA 124	0.10/1.00	0.120	0.120	1.000	2.000	0.120	0.120	0.120
JA 128	0.10/1.20	0.120	0.060	1.000	2.000	0.120	0.060	0.120
JA 135	0.14/1.50	0.120	0.060	0.500	2.000	0.120	0.120	0.120
JA 136	0.10/1.50	0.120	0.060	0.500	2.000	0.120	0.120	0.120
JA 137	0.10/0.10	0.120	0.250	1.000	2.000	0.500	0.250	0.120
JA 138	0.10/1.00	0.120	0.060	1.000	2.000	0.250	0.120	0.120
JA 140	0.10/1.00	0.060	0.060	0.500	1.000	0.120	0.120	0.060
JA 141	0.10/-	0.120	0.120	1.000	2.000	0.250	0.120	0.120
JA 143	0.10/0.10	0.120	0.120	1.000	>2.000	0.250	0.120	0.120
JA 144	0.10/1.00	0.120	0.120	0.500	1.000	0.120	0.120	0.060
JA 145	0.16/1.30	0.120	0.120	1.000	2.000	0.120	0.120	0.120
JA 146	0.10/1.00	0.120	0.120	1.000	2.000	0.120	0.120	0.120

Table 6 (cont.):

Compound tested	KOH/DMF (ml)	Bacillus subtilis	Bacillus cereus	Streptoc. faecium	Microc. Luteus	Staph. aureus	Staph. epidermidis	Staph. (ATCC 6538)
JA 148	0.10/0.50	0.120	0.060	1.000	2.000	0.120	0.120	0.120
JA 149	0.10/0.50	0.120	0.120	2.000	2.000	0.120	0.120	0.120

As is evident from Table 6 above, the compounds according to the present invention have excellent antibacterial properties. Indeed, the antibacterial activity of the present compounds against gram-positive bacteria is at least equal, and in some instances even clearly superior (e.g. JA 4 and JA 39), to that of enrofloxacin.

In the same manner as above, the M.I.C. values of the present compounds JA 3, JA 5, JA 12, JA 42, JA 73 and enrofloxacin as reference compound were investigated also on gram-negative bacteria. The gram-negative bacteria used were *E. coli* (ATCC 25922), *E. Coli* (ATCC 8739), *E. Coli* (ATCC 10536), *E. Coli* Pathogenic, *KL. Pneumonia* (ATCC 10031), *Bordetella bronchiseptic* (ATCC 4617), *Salmonella typhi*, *Salmonella spp.*, *Proteus spp.*, *Pasterulla Duck* and *Pasterulla Camel*. In summary, it was found that all of said present compounds have antibacterial activity against gram-negative bacteria, and that their activity is roughly equal to that of enrofloxacin.

Antibacterial testing against *Mycoplasma*:

As is well known, *Mycoplasma* are bacteria which often cause severe respiratory tract infections in both humans and animals. As typical examples, an infection of *M. pneumoniae* in humans causes pneumonia, whereas an infection of *M. gallisepticum* in avians, especially chickens, normally causes chronic respiratory disease or sinusitis.

The M.I.C. values of the compounds JA 1, JA 3, JA 5, JA 12, JA 42 and JA 43 were determined *in vitro* against *M. gallisepticum*. Enrofloxacin, tylosin and oxytetracyclin were used as reference compounds. The tested compounds were all stored and applied as solutions in distilled water. The M.I.C. evaluation was performed in microtitre plates, and the methodology employed was basically that of Tanner and Wu (Avian Disease, 36:714-717 (1992)). The results are presented in Table 7 below:

Table 7: M.I.C. values against *M. gallisepticum*

Compound tested	M.I.C. values
JA 1	0.03
JA 3	0.06
JA 5	0.12
JA 12	0.12
JA 42	0.25
JA 43	0.25
Enrofloxacin	0.06
Tylosin	0.06
Oxytetracyclin	0.12

5        As can be seen in Table 7, the present compounds have antibacterial activity against *M. gallisepticum* as well, and the high antibacterial activity of JA 1 is noteworthy.

Antiparasitic testing against *Coccidia*:

10        The anticoccidial activity of the present compounds as prophylactic agents was evaluated *in vivo* on 60 one day old (1 day after hatch) chickens of Habbared X breed. The chickens were divided into four groups of 20 birds each, and each group was located in a separate pen (1 m x 15    1 m). The chickens were then fed with unmedicated food up to day 7 after hatch. Fresh water was supplied *ad libitum*.

On day 8 after hatch, the four groups were fed as follows (1 ppm=1 mg drug/kg feed):

- 20        Group #1: feed containing JA 39 (100 ppm);  
Group #2: feed containing JA 42 (100 ppm);  
Group #3: feed containing Coxistac (60 ppm), a known anticoccidial agent (see US 3 857 948);  
Group #4: feed containing no drug (control group).

25

The chickens were fed as above on day 8 and 9 after hatch. On day 10 after hatch, each chicken was infected



orally by 6 000-7 000 oocysts containing a mixture of 5  
mature sporulated strains, namely *Eimeria acervulina*,  
*E. maxima*, *E. necatrix*, *E. tenella* and *E. brunetti*. The  
groups #1-3 received drug as above from day 10 to 21  
5 after hatch.

From day 14 to 21 after hatch, fresh fecal droplets  
were collected and examined daily. The average number of  
oocysts/g faeces was then calculated in accordance with  
the so-called Mc-Master technique (Soulsby, E.J.,  
10 *Helminths, Arthropods & Protozoa of domesticated animals*,  
p. 789, 6<sup>th</sup> Ed., Williams & Wilkins Co. Baltimore (USA),  
Tindall & Cassell Ltd., London, 1968). The final weight  
of and mean total amount of feed consumed by each bird  
were also examined, and the results are summarized in  
15 Table 8 hereinbelow.

Table 8: Anticoccidial effect of JA 39 and JA 42 on chicken

Group (drug)	Average number of <i>Eimeria</i> spp. oocysts/g faeces										Mean body weight (g)	Mean amount of feed consumed (g)
	Day after hatch									Total		
	14	15	16	17	18	19	20	21	22			
#1 (JA 39)	0.0	4000	5000	3000	0.0	0.0	0.0	0.0	0.0	12000	68.2	81
#2 (JA 42)	0.0	4000	6000	3000	0.0	0.0	0.0	0.0	0.0	13000	73.7	91
#3 (Coxistac)	0.0	3000	4000	7000	2000	2000	2000	0.0	0.0	18000	62.0	120
#4 (no drug)	0.0	15000	24000	1.3x10 <sup>6</sup>	174000	0.0	0.0	0.0	0.0	1.4x10 <sup>6</sup>	57.3	120

As is evident from Table 8 above, the compounds JA 39 and JA 42 have excellent anticoccidial effect. This is also manifested in the higher mean body weight and lower amount of feed consumed as compared to both the  
5 Coxistac and the non-treated group.

Moreover, the prophylactic anticoccidial effect of JA 12, JA 39 and JA 42 was also evaluated in chickens of Arbor Aker breed. These trials were conducted by using basically the same test protocol as that used for the  
10 chickens of Habbared X breed, albeit with the following modifications:

- i) On day 3 after hatch, the tested groups of chickens received feed containing 100 ppm of JA 12, JA 39, JA 42 or Coxistac (60 ppm);
- 15 ii) On day 7 after hatch, the chickens were infected orally by oocysts containing a mixture of 8 mature sporulated strains, namely *E. mitis*, *E. hagani*, *E. praecox*, *E. acervulina*, *E. maxima*, *E. necatrix*, *E. tenella* and *E.*  
20 *brunetti*.

For JA 39 and JA 42, the results were essentially the same as those reported for the trials with the chickens of Habbared X breed (*vide supra*), whereas the antiparasitic efficacy of JA 12 was very similar to that  
25 of JA 39.

In yet another evaluation of the prophylactic anticoccidial effect of the present compounds, additional trials on chickens of Habbared X breed were performed. The same test protocol as the one previously employed for  
30 this breed of chickens was used, albeit with the following following modifications:

- i) On day 8 after hatch, the chickens received feed containing B700 (100 ppm), JA 3 (200 ppm) or Coxistac (100 ppm);
- 35 ii) On day 11 after hatch, the chickens were infected orally by oocysts containing a mixture

of 8 mature sporulated strains, namely *E. mitis*, *E. hagani*, *E. praecox*, *E. acervulina*, *E. maxima*, *E. necatrix*, *E. tenella* and *E. brunetti*.

- 5 The results of this evaluation were slightly unexpected. Both B700 and JA 3 displayed a significant anticoccidial activity, albeit the total number of oocysts during the treatment was higher than for the group treated with Coxistac. However, despite the said higher number of  
10 oocysts, the chickens treated with B700 or JA 3 experienced an approximately 10% increased body weight gain as compared to the Coxistac treated group. Moreover, a similar or even lowered (up to about 10%) feed consumption was observed in the chickens treated with  
15 B700 or JA 3. In short, the net effect of the treatment with B700 or JA 3 was clearly beneficial to the chickens.

Antiparasitic testing against *Trypanosoma*:

- The antitrypanosomal activity of the present compounds was evaluated *in vivo* on 40 white albino rats.  
20 The rats were divided into 4 groups of 10 rats each. The rats were then inoculated intraperitoneally with  $10^3$  organisms of *T. evansi* (isolated from blood of naturally infected camels) in accordance with known methodology (see Kolmer, J.A., *J. Infect. Dis.*, 17:78-95 (1915)). The  
25 progress of the infection was monitored with the aid of standard Giemsa procedure (see Cruickshank, R., *Handbook of Bacteriology*, E and S Livingstone Ltd., Edinburgh and London, 1961), whereby peripheral blood samples from the rats were examined under microscope. The number of  
30 *Trypanosoma* organisms in every blood sample was calculated and classified as follows (the numbers below are given for fields examined on a microscope slide):
- |      |   |                       |
|------|---|-----------------------|
| +++  | = | > 10 organisms        |
| ++   | = | 5-10 organisms        |
| 35 + | = | 1-4 organisms         |
| 0    | = | no organisms detected |

On day 1 post infection, each group of rats was subcutaneously injected with a single dose of tested compound in an amount of 50.0 mg/kg body weight. The following drugs were administered:

- 5       Group #1: JA 68
- Group #2: JA 74
- Group #3: JA 110
- Group #4: saline solution (control group)

The results of these trials are depicted in Table 9  
10 below:

Table 9: Antitrypanosomal effect of JA 68, JA 74  
and JA 110 on white rat

Tested animals		Number of <i>T. evansi</i> per examined field at different days post infection						
		1	3	5	7	9	11	13
Group #1 (JA 68)	Mouse #1	+	0	0	0	0	0	0
	2	+	++	++	0	0	0	0
	3	+	++	0	+++	0	0	0
	4	+	++	++	0	dead	dead	dead
	5	+	++	0	0	0	0	0
	6	+	++	0	0	0	0	0
	7	+	++	0	0	0	0	0
	8	+	++	0	0	0	0	0
	9	+	++	0	0	0	0	0
	10	+	++	0	0	0	0	0
Group #2 (JA 74)	Mouse #1	+	++	+++	dead	dead	dead	dead
	2	+	++	0	0	0	0	0
	3	+	++	++	0	0	0	0
	4	+	+++	++	0	0	0	0
	5	+	++	0	0	0	0	0
	6	+	++	0	0	0	0	0
	7	+	++	0	0	0	0	0
	8	+	++	0	0	0	0	0
	9	+	++	0	0	0	0	0
	10	+	++	+	0	0	0	0
Group #3 (JA 110)	Mouse #1	+	+++	++	++	+	+	0
	2	+	++	++	++	0	0	0
	3	+	++	++	++	0	0	0
	4	+	+++	++	++	0	0	0
	5	+	++	++	++	0	0	0
	6	+	++	++	++	0	0	0
	7	+	++	++	++	0	0	0
	8	+	++	++	++	0	0	0
	9	+	++	++	++	0	0	0
	10	+	++	++	++	0	0	0

90

Table 9 (cont.):

Group #4	Mouse #1	+	++	++	+++	+++	dead	All
(control)	2	++	++	+++	+++	dead	dead	animals
	3	+	+++	+++	+++	+++	+++	dead
	4	+	++	++	+++	+++	dead	
	5	+	+++	++	+++	+++	+++	
	6	+	++	++	+++	+++	+++	
	7	+	++	++	+++	+++	+++	
	8	+	++	++	+++	dead	dead	
	9	+	++	++	+++	+++	+++	
	10	+	++	++	+++	+++	+++	

As supported by the results obtained (*vide supra*),  
5 the tested compounds are all highly suitable for  
treatment of *Trypanosoma* infection as well.

In summary, it should be clear from the present  
disclosure that the compounds according to the present  
invention are versatile new agents for antibacterial  
10 and/or antiparasitic treatment.


15

20

25

## CLAIMS

1. A compound having the general formula (I):



5 wherein

X is selected from F, Cl, I, CN, SH, NO<sub>2</sub>, CF<sub>3</sub>, COOR<sub>1</sub>, CONR<sub>7</sub>R<sub>8</sub>, NH-aryl, NHSO<sub>2</sub>R<sub>15</sub> and (CH<sub>2</sub>)<sub>1-5</sub>NHSO<sub>2</sub>R<sub>15</sub>, wherein R<sub>1</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>15</sub> and aryl are as defined hereinbelow;

10 R<sub>2</sub>-R<sub>3</sub> are independently selected from a group of substituents (a)-(h) consisting of

- (a) H;
- (b) straight chain, branched or cyclic saturated or unsaturated alkyl, mono-, di- or trifluoroalkyl, hydroxyalkyl or alkoxyalkyl having 1-6 carbon atoms;
- 15 (c) (O-alkyl)<sub>z</sub>, (alkyl-O)<sub>z</sub>-alkyl, (S-alkyl)<sub>z</sub>, (alkyl-S)<sub>z</sub>-alkyl, (alkyl-S-S)<sub>z</sub>-alkyl, N-(alkyl)<sub>n</sub>, alkyl-N-(alkyl)<sub>n</sub>, alkyl-NH<sub>2</sub>, alkyl-NHSO<sub>2</sub>-alkyl or alkyl-NHSO<sub>2</sub>-aryl, where alkyl is as defined in (b) and optionally contains at least one substituent X, aryl is as defined in (e), z is an integer from 1 to 5 and n is 1 or 2;
- (d) (C(O)-alkyl)<sub>z</sub>, (O-C(O)-alkyl)<sub>z</sub>, (S-C(O)-alkyl)<sub>z</sub> or (NH-C(O)-alkyl)<sub>z</sub>, where alkyl is as defined in (b) and z as defined in (c);
- 25 (e) aryl, condensed aryl or aralkyl, optionally containing at least one heteroatom selected from N, S and O and/or at least one substituent selected from X and (a)-(d);
- (f) O-aryl, C(O)-aryl, C(O)-heteroaryl, O-aralkyl, N-(aryl)<sub>n</sub>, N-(aralkyl)<sub>n</sub> or N-(SO<sub>2</sub>-aryl)<sub>n</sub>, where aryl
- 30



is as defined in (e) and n is 1 or 2;

(g) X;

(h)  $\text{NR}_7\text{R}_8$ , wherein  $\text{R}_7$  and  $\text{R}_8$  independently are selected from the substituents (a)-(f), wherein  $\text{NR}_7\text{R}_8$  optionally may form a five- or six-membered saturated or unsaturated ring;

$\text{R}_1$  is selected from the substituents (a)-(b);

A is a radical selected from -N- and - $\text{CR}_9$ -, wherein

$\text{R}_9$  is selected from the substituents (a)-(h) or is a C-Y

10 bond to a radical - $\text{YCR}_{10}\text{R}_{11}\text{CR}_{12}\text{R}_{13}$ -, wherein

$\text{R}_{10}$ - $\text{R}_{13}$  are independently selected from the substituents (a)-(h) and Y is selected from S, O and  $\text{NR}_{14}$ ,

wherein  $\text{R}_{14}$  is selected from the substituents (a)-(h);

$\text{R}_4$  is selected from the substituents (a)-(h) or may

15 optionally be a C-C bond to said radical - $\text{YCR}_{10}\text{R}_{11}\text{CR}_{12}\text{R}_{13}$ -;

$\text{R}_5$  and  $\text{R}_6$  are either independently selected from the substituents (a)-(h) and a group of substituents (i)-(m) consisting of

(i) furanyl, furyl, pyranal, piperidinyl, morpholinyl, 20 pyridinyl, pyrazinyl, piperazinyl and pyrrolidinyl, optionally containing at least one substituent selected from X and (a)-(d);

(j) alkylfuranyl, -furyl, -pyranal, -piperidinyl, -morpholinyl, -pyridinyl, -pyrazinyl, -piperazinyl, 25 and -pyrrolidinyl, optionally containing at least one substituent selected from X and (a)-(d);

(k)  $\text{SO}_2\text{R}_{15}$ , where  $\text{R}_{15}$  is selected from the substituents (a)-(f) and (h)-(j);


(l)  $\text{C}(\text{S})-\text{NR}_{16}\text{R}_{17}$  or  $\text{C}(\text{O})-\text{NR}_{16}\text{R}_{17}$ , where  $\text{R}_{16}$  and  $\text{R}_{17}$  are 30 independently selected from the substituents (a)-(k);

(m) cycloalkyl- $\text{NR}_{16}\text{R}_{17}$ , alkylcycloalkyl- $\text{NR}_{16}\text{R}_{17}$ , cycloalkyl-X or alkylcycloalkyl-X, where  $\text{R}_{16}$  and  $\text{R}_{17}$  are as defined in (l) and the cycloalkyl moiety has 35 3-7 carbon atoms;

with the proviso that at least one of  $\text{R}_5$  and  $\text{R}_6$  is selected from the substituents (c)-(m) and that  $\text{R}_4$  is

selected from saturated cycloalkyl and aryl, optionally containing at least one heteroatom selected from N, S and O and/or at least one substituent selected from X and (a) - (d);


- 5 or taken together with the nitrogen atom to which they are attached form a group selected from (n) - (p) consisting of



- 10 wherein

R<sub>18</sub>-R<sub>21</sub> are independently selected from the substituents (a) - (b);

R<sub>22</sub> is selected from the substituents (c) - (m);



- 15

wherein

R<sub>23</sub> and R<sub>25</sub> are independently selected from the substituents (a) - (f) or may optionally be part of a C=N bond;

- 20 R<sub>24</sub> and R<sub>26</sub> are independently selected from the group of substituents (a) - (m) and a group of substituents (q) - (s) consisting of

(q) alkyl-NR<sub>27</sub>R<sub>28</sub>, where R<sub>27</sub>-R<sub>28</sub> are independently selected from the substituents (a) - (m);


- 25 (r) NR<sub>27</sub>R<sub>28</sub>, where R<sub>27</sub>-R<sub>28</sub> are as defined in (q);

(s) a =N-O-alkyl radical;

94

with the proviso that  $R_{23}$ - $R_{25}$  are not all H when  $R_{26}$  is  $NH_2$ , X is F, A is  $-CCl-$ ;  $R_1$ - $R_3$  are H and  $R_4$  is cyclopropyl;

- with the proviso that at least one of  $R_{27}$  and  $R_{28}$  in (q)  
 5 is selected from the substituents (c)-(m) when X is F, A is  $-COCH_3-$  or  $-N-$ ,  $R_1$ - $R_3$  are H and  $R_4$  is cyclopropyl;



wherein

- 10  $R_{27}$  and  $R_{28}$  are as defined in (q), with the proviso that at least one of  $R_{27}$  and  $R_{28}$  is selected from the substituents (c)-(m);

tautomers, solvates and radiolabelled derivatives thereof; and

- 15 pharmaceutically acceptable salts thereof.


2. A compound according to claim 1, wherein  $R_1$  is H.

3. A compound according to any one of claims 1-2, wherein X is F.

4. A compound according to any one of claims 1-3,  
 20 wherein A is  $-CR_5-$ .

5. A compound according to any one of claims 1-4, wherein  $R_5$  and  $R_6$  form said group (n).

6. A compound according to claim 5 having the general formula (II):



wherein R<sub>3</sub>, R<sub>4</sub>, R<sub>9</sub>, R<sub>19</sub>, R<sub>21</sub> and R<sub>22</sub> are as previously defined.

5           7. A compound according to claim 6, wherein R<sub>3</sub> is selected from a group of substituents consisting of H, CH<sub>3</sub>, NH<sub>2</sub>, (6-chloro-2-pyridinyl)amino, (6-chloro-2-pyrazinyl)amino, [(4-fluoro-phenyl)sulfonyl]amino and [(4-nitrophenyl)sulfonyl]amino.

10           8. A compound according to any one of claims 6-7, wherein R<sub>4</sub> is selected from a group of substituents consisting of cyclopropyl, ethyl, 2-fluoroethyl, 4-fluorophenyl and 2,4-difluorophenyl.

            9. A compound according to any one of claims 6-8,  
15           wherein R<sub>9</sub> is either H or F.

            10. A compound according to any one of claims 6-9, wherein R<sub>19</sub> and R<sub>21</sub> are independently either H or CH<sub>3</sub>.

            11. A compound according to any one of claims 6-10, wherein R<sub>22</sub> is selected from a group of substituents  
20           consisting of (4-nitroanilino)carbothioyl, anilinocarbothioyl, (4-fluoroanilino)carbothioyl, {4-nitro[(4-nitrophenyl)sulfonyl]anilino}carbothioyl, (4-nitroanilino)carbonyl, (4-fluoroanilino)carbonyl, (4-nitrophenyl)sulfonyl, 6-chloro-2-pyridinyl, 6-chloro-2-pyrazinyl, phenylsulfonyl, (4-methylphenyl)sulfonyl, (4-methoxyphenyl)sulfonyl, 2-naphthylsulfonyl, mesitylsulfonyl, propylsulfonyl, benzylsulfonyl, methylsulfonyl, (trifluoromethyl)sulfonyl, (5-bromo-2-thienyl)sulfonyl, (3,5-dichloro-2-hydroxyphenyl)sulfonyl, 5-bromo-2-pyridinyl, 3-chloro-2-sulfanylphenyl, (5-chloro-2-thienyl)sulfonyl, 2-pyrazinyl, {4-fluoro[(4-fluorophenyl)sulfonyl]anilino}carbothioyl, {4-fluoro[(4-nitrophenyl)sulfonyl]anilino}carbothioyl, [(6-chloro-2-pyrazinyl)-4-fluoroanilino]carbothioyl, [(6-chloro-2-pyridinyl)-4-fluoroanilino]carbothioyl, (4-fluorophenyl)sulfonyl, 6-{{(4-fluorophenyl)sulfonyl}amino}-2-pyridinyl, 4-pyridinylmethyl, 4-carboxycyclohexyl, 4-carboxybenzyl, tetrahydro-2-furan-

25  
30  
35

ylmethyl, 4-isopropylphenyl, 2-(1-piperidinyl)ethyl, 2-  
 [(2-{[(4-fluoro-phenyl)sulfonyl]amino}ethyl)disulfan-  
 yl]ethyl, 2-[(2-{[(4-nitrophenyl)sulfonyl]amino}ethyl)di-  
 sulfanyl]ethyl, 2-[2-({[(4-nitrophenyl)sulfonyl]ami-  
 5 no}methoxy)ethoxy]ethyl, 2-(2-{[(6-chloro-2-pyrazin-  
 yl)amino]methoxy}ethoxy)ethyl, 2-(1-pyrrolidinyl)ethyl,  
 (4-nitroanilino)carbothioyl, [3-({[(4-fluorophenyl)sul-  
 fonyl]amino}methyl)cyclohexyl]methyl, 3-[(3-aminoprop-  
 yl)(methyl)amino]propyl, 3-aminopropyl, 3-{[(trifluoro-  
 10 methyl)sulfonyl]amino}propyl, 3-{[(4-nitrophenyl)sul-  
 fonyl]amino}propyl, 3-(dimethylamino)-2,2-dimethylpropyl,  
 2-thienylcarbonyl, 2-aminocyclohexyl, 2-{[(trifluorometh-  
 yl)sulfonyl]amino}ethyl, 2-{[(4-nitrophenyl)sulfonyl]ami-  
 no}ethyl, 2,2-dimethyl-3-{[(trifluoromethyl)sulfon-  
 15 yl]amino}propyl, phenethylsulfonyl, acetoacetyl, 2-(4-  
 pyridinyl)ethyl, 2-(2-pyridinyl)ethyl and 2-methoxy-1-  
 methylethyl.

12. A compound according to any one of claims 6-11  
 selected from:


20 1-cyclopropyl-6-fluoro-4-oxo-7-{4-[(trifluoromethyl)-  
 sulfonyl]-1-piperazinyl}-1,4-dihydro-3-quinoline-  
 carboxylic acid;  
 7-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-1-cyclopropyl-  
 6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;  
 25 7-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]-1-cyclopropyl-  
 6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;  
 1-cyclopropyl-7-{3,5-dimethyl-4-[(4-nitrophenyl)sulfo-  
 nyl]-1-piperazinyl}-6,8-difluoro-5-{[(4-nitrophenyl)-  
 sulfonyl]amino}-4-oxo-1,4-dihydro-3-quinolinecarboxylic  
 30 acid;  
 5-[(6-chloro-2-pyrazinyl)amino]-7-[4-(6-chloro-2-  
 pyrazinyl)-3,5-dimethyl-1-piperazinyl]-1-cyclopropyl-6,8-  
 difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

13. A compound according to any one of claims 1-5,  
 35 wherein R<sub>9</sub> is a C-Y bond and R<sub>4</sub> is a C-C bond to said  
 radical -YCR<sub>10</sub>R<sub>11</sub>CR<sub>12</sub>R<sub>13</sub>-.

14. A compound according to claim 13, wherein  $R_{10}$ - $R_{13}$  are H.

15. A compound according to claim 13, wherein  $R_{10}$ - $R_{12}$  are H and  $R_{13}$  is methyl.

5 16. A compound according to claim 13 having the general formula (III):



wherein  $R_{12}$ ,  $R_{13}$  and  $R_{22}$  are as previously defined.

10 17. A compound according to claim 16, wherein Y is either S or O.

18. A compound according to any one of claims 16-17, wherein  $R_{12}$  and  $R_{13}$  are independently either H or  $CH_3$ .

19. A compound according to any one of claims 16-18, wherein  $R_{22}$  is as defined in claim 11.

15 20. A compound according to any one of claims 16-19 selected from

9-fluoro-3-methyl-10-{4-[(4-nitrophenyl)sulfonyl]-1-piperazinyl}-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;

20 10-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;


10-[4-(6-chloro-2-pyrazinyl)-1-piperazinyl]-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid.

25

21. A compound according to any one of claims 1-4, wherein  $R_5$  and  $R_6$  are selected from the group of substituents (a)-(m).

22. A compound according to claim 21, wherein  $R_4$  is cyclopropyl.

23. A compound according to claim 22 having the general formula (IV):



wherein  $R_5$  and  $R_6$  are as previously defined.

24. A compound according to any one of claims 21-23, wherein  $R_5$  and  $R_6$  are independently selected from H and at least one of the group of substituents as defined in claim 11.

25. A compound according to any one of claims 21-24 selected from


1-cyclopropyl-6-fluoro-4-oxo-7-[(4-pyridinylmethyl)-amino]-1,4-dihydro-3-quinolinecarboxylic acid;

1-cyclopropyl-6-fluoro-7-(4-isopropylanilino)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

7-[acetoacetyl(tetrahydro-2-furanylmethyl)amino]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

26. A compound according to any one of claims 1-3, wherein  $R_5$  and  $R_6$  form said group (o).

27. A compound according to claim 26 having the general formula (V):



wherein  $R_4$ , A and  $R_{23}$ - $R_{26}$  are as previously defined.

5        28. A compound according to claim 27, wherein A is selected from -CCl-, -COCH<sub>3</sub>- and -N-.

29. A compound according to any one of claims 27-28, wherein  $R_4$  is selected from a group of substituents consisting of cyclopropyl, ethyl, 2-fluoroethyl, 4-fluorophenyl and 2,4-difluorophenyl.

10

30. A compound according to any one of claims 27-29, wherein  $R_{23}$ - $R_{26}$  are independently selected from H and at least one of a group of substituents consisting of fluoromethyl, methoxyimino, (6-chloro-2-pyridinyl)amino, (6-chloro-2-pyridinyl)[(4-nitrophenyl)sulfonyl]amino, (6-chloro-2-pyrazinyl)[(4-nitrophenyl)sulfonyl]amino, [(4-nitroanilino)carbothioyl]amino, {(4-nitrophenyl)sulfonyl}amino}methyl, [(6-chloro-2-pyrazinyl)amino]methyl, [(6-chloro-2-pyridinyl)amino]methyl, {(4-fluoroanilino)carbothioyl}amino}methyl, {(4-fluoro[(4-nitrophenyl)sulfonyl]anilino)carbothioyl}[(4-nitrophenyl)sulfonyl]amino}methyl, {(4-fluoro[(4-methoxyphenyl)sulfonyl]anilino)carbothioyl}[(4-methoxyphenyl)sulfonyl]amino}methyl and the group of substituents as defined in claim 11.

15

20

25

31. A compound according to any one of claims 26-30 selected from 8-chloro-1-cyclopropyl-6-fluoro-7-(3-{[(4-nitroanilino)carbothioyl]amino}-1-pyrrolidinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;

30




100

8-chloro-7-{3-[(6-chloro-2-pyridinyl)amino]-1-pyrrolidinyl}-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid.

32. A compound according to any one of claims 1-4,  
5 wherein  $R_5$  and  $R_6$  form said group (p).

33. A compound according to claim 32 having the  
general formula (VI)



wherein A,  $R_4$ ,  $R_{27}$  and  $R_{28}$  are as previously defined.

34. A compound according to claim 33, wherein A is  
10 selected from  $-CCl-$ ,  $-COCH_3-$ , and  $-N-$ .

35. A compound according to any one of claims 33-34,  
wherein  $R_4$  is selected from a group of substituents  
consisting of cyclopropyl, ethyl, 2-fluoroethyl, 4-  
15 fluorophenyl and 2,4-difluorophenyl.

36. A compound according to any one of claims 33-35,  
wherein  $R_{27}$  and  $R_{28}$  are independently selected from H and  
at least one of the group of substituents as defined in  
claim 30.

37. A compound according to any one of claims 33-36  
20 selected from

7-{(1R,5S)-6-[(6-chloro-2-pyridinyl)amino]-3-  
azabicyclo[3.1.0]hex-3-yl}-1-(2,4-difluorophenyl)-6-  
fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic  
25 acid;

7-{(1R,5S)-6-[(6-chloro-2-pyrazinyl)amino]-3-  
azabicyclo[3.1.0]hex-3-yl}-1-(2,4-difluorophenyl)-6-  
fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic  
acid.

30

38. A compound according to claim 1 being  
7-(4-{[(anilinocarbothioyl)amino]methyl}-1-piperidinyl)-  
1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-3-quinoline-  
carboxylic acid.

5       39. A compound according to any one of claims 1-38  
for use as a pharmaceutical.

40. A pharmaceutical composition comprising a  
compound according to any one of claims 1-38 as active  
ingredient in association with a pharmaceutically  
10 acceptable adjuvant, diluent or carrier.

41. An animal feed, food concentrate or drinking  
water comprising a compound according to any one of  
claims 1-38.

42. Use of a compound according to any one of claims  
15 1-38 for the manufacture of a medicament for treatment of  
bacterial and parasitic disorders.

43. Use according to claim 42, wherein said  
parasitic disorder is caused by *Coccidia* or *Trypanosoma*.


44. A method for treatment of bacterial and  
20 parasitic disorders, wherein said method comprises  
administering to an animal of a therapeutically effective  
amount of a compound according to any one of claims 1-38.

45. A method according to claim 44, wherein said  
parasitic disorder is caused by *Coccidia* or *Trypanosoma*.

## AMENDED CLAIMS

[received by the International Bureau on 27 April 2001 (27.04.01);  
original claims 1-45 replaced by new claims 1-11 (4 pages)]

1. A compound having the general formula (I):



5

wherein

R<sub>1</sub> is selected from the group consisting of a cyclopropyl group and an ethyl group;

R<sub>2</sub> is selected from the group consisting of H and F;


10 R<sub>3</sub> is selected from the group consisting of a 4-carboxycyclohexyl group, a 4-pyridinylmethyl group, 4-carboxybenzyl group, a 4-carboxyphenyl group, a [(trifluoromethyl)sulfonyl]aminopropyl group, 2,2-dimethyl-3-[(trifluoromethyl)sulfonyl]aminopropyl group,  
15 a 2-[(trifluoromethyl)sulfonyl]aminoethyl group, a 5-bromo-2-pyridinyl group, a tetrahydro-2-furanylmethyl group, a 2-(1-pyrrolidinyl)ethyl group, a 2-naphtylsulfonyl group, a 2-(4-pyridinyl)ethyl group, and a 2-(2-pyridinyl)ethyl group;

20 R<sub>4</sub> is selected from the group consisting of a (trifluoromethyl)sulfonyl group, a 2-thiophenylcarbonyl group, an acetoacetyl group, a 4-fluorophenylsulfonyl group, a 4-nitrophenyl group, and a tetrahydro-2-furanylmethyl group; or

25 R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen to which they are attached, form a piperazinyl group substituted with a methyl group, a (4-nitrophenyl)sulfonyl group, an anilino-carbothioyl group, a 2-naphtylsulfonyl group, a (2,4,6-triisopropylphenyl)sulfonyl group, a (4-  
30 nitroanilino)carbothioyl group, a (4-

fluoroanilino)carbothioyl group, a (6-chloro-2-pyrazinyl)-4-fluoroanilino carbthioyl group, a mesitylsulfonyl group, a benzylsulfonyl group, a (5-chloro-2-thienyl)sulfonyl group, a (4-nitroanilino)carbonyl group, a (2-iodoanilino)carbothioyl group, a (4-cyanoanilino)carbothioyl group, a (4-chlorobenzothioyl) group, a (2,4-dichloroanilino)carbothionyl group, a (2-chloro-4-nitroanilino)carbothioyl group, a 6-chloro-2-pyridinyl group, a (6-chloro-2-pyridinyl)-4-fluoroanilino)carbothioyl group, a 6-chloro-2-pyrazinyl group, and a (trifluoromethyl)sulfonyl group; or R<sub>3</sub> and R<sub>4</sub>, together with the nitrogen to which they are attached, form a piperidinyl group substituted with a 4-{[anilinocarbothioyl)amino]methyl} group.

2. A compound according to claim 1, having the general formula (II)



wherein


R<sub>3</sub> is selected from the group consisting of a 4-carboxycyclohexyl group, a 4-pyridinylmethyl group, a 4-carboxybenzyl group, a 4-carboxyphenyl group, a [(trifluoromethyl)sulfonyl]aminopropyl group, 2,2-dimethyl-3-[(trifluoromethyl)sulfonyl]aminopropyl group, a 2-[(trifluoromethyl)sulfonyl]aminoethyl group, a 5-bromo-2-pyridinyl group, a tetrahydro-2-furanylmethyl group, a 2-(1-pyrrolidinyl)ethyl group, a 2-

naphtylsulfonyl group, a 2-(4-pyridinyl)ethyl group, a 2-(2-pyridinyl)ethyl group; and

R<sub>4</sub> is selected from the group consisting of a (trifluoromethyl)sulfonyl group, a 2-thiophenylcarbonyl group, an acetoacetyl group, a 4-fluorophenylsulfonyl group, a 4-nitrophenyl group, a tetrahydro-2-furanylmethyl group.

3. A compound according to claim 1, having the general formula (III)

10



wherein


R<sub>1</sub> is selected from the group consisting of a cyclopropyl group and an ethyl group;

15 R<sub>2</sub> is selected from the group consisting of H and F;

R<sub>5</sub> is selected from the group consisting of a (4-nitrophenyl)sulfonyl group, an anilinocarbothioyl group, a 2-naphtylsulfonyl group, a (2,4,6-triisopropylphenyl)sulfonyl group, a (4-nitroanilino)carbothioyl group, a (4-fluoroanilino)carbothioyl group, a (6-chloro-2-pyrazinyl)-4-fluoroanilino carbthioyl group, a mesitylsulfonyl group, a benzylsulfonyl group, a (5-chloro-2-thienyl)sulfonyl group, a (4-nitroanilino)carbonyl group, a (2-iodoanilino)carbothioyl group, a (4-cyanoanilino)carbothioyl group, a (4-chlorobenzothioyl) group, a (2,4-dichloroanilino)carbothionyl group, a (2-chloro-4-nitroanilino)carbothioyl group, a 6-chloro-2-pyridinyl group, a (6-chloro-2-pyridinyl)-4-

fluoroanilino)carbothioyl group, a 6-chloro-2-pyrazinyl group, and a (trifluoromethyl)sulfonyl group; and  $R_6$  is selected from the group consisting of H and a methyl group.

- 5        4. A compound according to claim 1, wherein said compound is



- 10        5. A compound according to any one of claims 1-4 for use as a medicament.

6. A pharmaceutical composition comprising a compound according to any one of claims 1-4 as active ingredient in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

- 15        7. An animal feed, food concentrate or drinking water comprising a compound according to any one of claims 1-4.

- 20        8. Use of a compound according to any one of claims 1-4 for the manufacture of a medicament for treatment of bacterial and parasitic disorders.

9. Use according to claim 8, wherein said parasitic disorder is caused by Coccidia or Trypanosoma.

- 25        10. A method for treatment of bacterial and parasitic disorders, wherein said method comprises administering to an animal of a therapeutically effective amount of a compound according to any one of claims 1-4.

11. A method according to claim 10, wherein said parasitic disorder is caused by Coccidia or Trypanosoma.

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/02217

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 401/02, C07D 401/14, C07D 405/12, C07D 498/06, C07D 215/56,  
A61K 31/495, A61K 31/5383, A61K 31/47, A61P 33/00, A61P 31/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D, A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Volume 43, No 8, August 1999, Elizabeth Nenortas et al, "Antitrypanosomal Activity of Fluoroquinolones" page 2066 - page 2068 --	1-45
X	DE 3637649 A1 (SPOHR, UWE), 14 April 1988 (14.04.88) --	1-45
X	GB 1598915 A (LABORATOIRE ROGER BELLON S.A.), 23 Sept 1981 (23.09.81) --	1-45
X	DE 3608745 A1 (BAYER AG), 29 January 1987 (29.01.87) --	1-45

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

27 February 2001

Date of mailing of the international search report

01 -03- 2001

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Nebil Gecer/ELY

Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/02217

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0049355 A1 (BAYER AG), 14 April 1982 (14.04.82) --	1-45
X	EP 0078362 A2 (BAYER AG), 11 May 1983 (11.05.83) --	1-45
X	DE 3632222 A1 (BAYER AG), 7 April 1988 (07.04.88) --	1-45
X	EP 0047005 A1 (DAIICHI SEIYAKU CO. LTD.), 10 March 1982 (10.03.82) --	1-45
X	EP 0131839 A1 (ABBOTT LABORATORIES), 23 January 1986 (23.01.86) --	1-45
X	EP 0154780 B1 (ABBOTT LABORATORIES), 18 Sept 1985 (18.09.85) --	1-45
X	EP 0140116 A1 (HOKURIKU PHARMACEUTICAL CO., LTD.), 8 May 1985 (08.05.85) --	1-45
X	GB 2093018 A (KYORIN SEIYAKU KABUSHIKI KAISHA), 25 August 1982 (25.08.82) --	1-45
X	GB 2057440 A (KYORIN SEIYAKU KABUHIKI KAISHA), 1 April 1981 (01.04.81) --	1-45
X	WO 9638417 A1 (BAYER AKTIENGESELLSCHAFT), 5 December 1996 (05.12.96) --	1-45



## INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 00/02217

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5225413 A (ARUNDEV H. NAIK ET AL), 6 July 1993 (06.07.93)  --	1-45
X	US 5266569 A (KATHERINE E. BRIGHTY), 30 November 1993 (30.11.93)  --	1-45
X	US 5164402 A (KATHERINE E. BRIGHTY), 17 November 1992 (17.11.92)  --	1-45
X	EP 0676199 A1 (PFIZER INC.), 11 October 1995 (11.10.95)  --	1-45
X	EP 0165375 A2 (MEDIOLANUM FARMACEUTICL S.R.L.), 27 December 1985 (27.12.85)  --	1-45
X	EP 0268223 A2 (HOEHCST AKTIENGESELLSCHAFT), 25 May 1988 (25.05.88)  --	1-45
X	EP 0354453 A2 (DAIICHI PHARMACEUTICAL CO., LTD.), 14 February 1990 (14.02.90)  -- -----	1-45

# INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/SE00/02217**

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: **44-45**  
because they relate to subject matter not required to be searched by this Authority, namely:  
**See extra sheet\***
2. ☒ Claims Nos.: **1-45**  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
**See extra sheet\*\***
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/SE00/02217**

\*Claims 44-45 relate to methods of treatment of the human or animal body by surgery or by therapy/diagnostic methods practised on the human or animal body/ Rule. 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compound(s)/composition(s).

\*\*An initial overview search revealed that a great number of documents could possibly be novelty destroying to the claimed invention. As the generic claims are unclear and broadly formulated because of the multitude of options, variables, provisos and broad expressions such as aryl, heteroaryl, aralkyl etc, it is not reasonable to make a meaningful novelty search over the whole of the claimed scope. Therefore, a limited search on the medical use has been made, mainly on the basis of claims 6-45. A selection of particularly relevant documents has been cited.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
DE	3637649	A1	14/04/88	NONE	
GB	1598915	A	23/09/81	AU 520458 B	04/02/82
				AU 3996278 A	27/03/80
				BE 870576 A	19/03/79
				CA 1175836 A	09/10/84
				DE 2840910 A	05/04/79
				ES 473486 A	01/11/79
				FR 2403339 A,B	13/04/79
				FR 2498931 A,B	06/08/82
				JP 1147604 C	26/05/83
				JP 54066686 A	29/05/79
				JP 57038581 B	16/08/82
				NL 190520 B,C	01/11/93
				NL 7809591 A	22/03/79
				SE 444566 B,C	21/04/86
				SE 7809411 A	21/03/79
				US 4292317 A	29/09/81
DE	3608745	A1	29/01/87	AT 52916 T	15/06/90
				AU 588045 B	07/09/89
				AU 6048086 A	29/01/87
				CA 1273579 A	04/09/90
				DE 3671370 D	00/00/00
				DK 166804 B	19/07/93
				DK 350386 A	25/01/87
				EP 0210513 A,B	04/02/87
				SE 0210513 T3	
				FI 863013 A	25/01/87
				GR 861925 A	24/11/86
				HK 78193 A	13/08/93
				HU 44173 A	29/02/88
				HU 198840 B	28/12/89
				IL 79462 A	31/08/90
				JP 2599126 B	09/04/97
				JP 62022716 A	30/01/87
				NZ 216907 A	28/06/89
				US 5145853 A	08/09/92
				ZA 8605483 A	25/03/87

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
EP	0049355	A1	14/04/82	SE	0049355 T3	
				AR	227063 A	15/09/82
				AT	9803 T	15/10/84
				AU	540242 B	08/11/84
				AU	7468081 A	11/03/82
				CY	1301 A	06/12/85
				DE	3033157 A	01/04/82
				DE	3166619 D	00/00/00
				DK	161460 B,C	08/07/91
				DK	387781 A	04/03/82
				ES	505138 A	16/08/82
				ES	8206523 A	16/11/82
				HK	61485 A	23/08/85
				IE	51541 B	07/01/87
				JP	1515648 C	24/08/89
				JP	1652227 C	30/03/92
				JP	1652228 C	30/03/92
				JP	3014811 B	27/02/91
				JP	3016344 B	05/03/91
				JP	57077683 A	15/05/82
				JP	62161728 A	17/07/87
				JP	62161763 A	17/07/87
				JP	63056224 B	07/11/88
				KE	3545 A	19/07/85
				KR	8700441 B	10/03/87
				MY	36387 A	31/12/87
				SG	44685 G	17/01/86
				US	4620007 A	28/10/86
				US	4670444 A,B	02/06/87
				US	5077429 A	31/12/91
				ZA	8106080 A	25/08/82

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0078362 A2	11/05/83	SE 0078362 T3	
		AT 23040 T	15/11/86
		AU 561103 B	30/04/87
		AU 573125 B	26/05/88
		AU 573126 B	26/05/88
		AU 7140587 A	06/08/87
		AU 7140687 A	30/07/87
		AU 8576882 A	05/05/83
		CA 1218067 A	17/02/87
		CA 1237431 C	31/05/88
		CA 1272210 A	31/07/90
		CA 1322334 A	21/09/93
		DD 202560 A	21/09/83
		DE 3142854 A	11/05/83
		DE 3273892 D	00/00/00
		DK 160491 B,C	18/03/91
		DK 162637 B,C	25/11/91
		DK 190890 A	10/08/90
		DK 306082 A	30/04/83
		ES 516921 A	16/07/83
		ES 8307787 A	01/11/83
		FI 78689 B,C	31/05/89
		FI 85369 B,C	31/12/91
		FI 85370 B,C	31/12/91
		FI 822442 A	30/04/83
		FI 882335 A	18/05/88
		FI 885277 A	15/11/88
		FI 885278 A	15/11/88
		GR 77707 A	25/09/84
		HU 187580 B	28/01/86
		IE 53709 B	18/01/89
		IL 66243 A	20/10/87
		IL 76998 A	20/10/87
		IL 76999 A	20/10/87
		IL 77000 A	20/10/87
		IL 80514 A	20/10/87
		JP 1510477 C	09/08/89
		JP 1626172 C	28/11/91
		JP 1768594 C	30/06/93
		JP 1783907 C	31/08/93
		JP 2044827 B	05/10/90
		JP 2109137 C	21/11/96
		JP 4057674 B	14/09/92
		JP 4063067 B	08/10/92
		JP 4253963 A	09/09/92
		JP 8024536 B	13/03/96
		JP 58074667 A	06/05/83
		JP 63022057 A	29/01/88
		JP 63022075 A	29/01/88
		JP 63022076 A	29/01/88
		JP 63062510 B	02/12/88
		KR 8700895 B	02/05/87
		LU 88325 A	04/05/94
		NO 158018 B,C	21/03/88
		NO 167800 B,C	02/09/91

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		NO 822346 A	02/05/83
		NO 871195 A	02/05/83
		NZ 202278 A	28/02/85
		PH 18803 A	27/09/85
		US 4620007 A	28/10/86
		US 4670444 A,B	02/06/87
		US 5077429 A	31/12/91
		ZA 8204829 A	25/05/83
DE	3632222 A1	07/04/88	NONE
EP	0047005 A1	10/03/82	SE 0047005 T3
		AT 10282 T	15/11/84
		AU 529263 B	02/06/83
		AU 7487881 A	11/03/82
		BA 97190 B	02/08/99
		CA 1167840 A	22/05/84
		DE 3167216 D	00/00/00
		DK 158267 B,C	23/04/90
		DK 204488 A	14/04/88
		DK 388981 A	03/03/82
		ES 505116 A	01/01/83
		ES 8301977 A	01/04/83
		FI 71155 B,C	14/08/86
		FI 812693 A	03/03/82
		GR 74637 A	29/06/84
		HK 82186 A	07/11/86
		HR 930087 A	31/10/96
		IL 63613 A	31/10/84
		IN 155680 A	23/02/85
		JP 1346589 C	13/11/86
		JP 57046986 A	17/03/82
		JP 61011955 B	05/04/86
		KR 8402141 B	23/11/84
		MY 71286 A	31/12/86
		NO 158507 B,C	13/06/88
		NO 812956 A	03/03/82
		NZ 198224 A	03/02/84
		PH 18276 A	17/05/85
		SI 8112109 A	30/06/97
		US 4382892 A	10/05/83
		YU 42422 B	31/08/88
		YU 74788 A	31/08/89
		YU 210981 A	30/06/83
		ZA 8105604 A	25/08/82

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
EP	0131839	A1	23/01/86	SE	0131839 T3	
				AT	40551 T	15/02/89
				AU	576323 B	25/08/88
				AU	3056384 A	24/01/85
				DE	3476540 D	00/00/00
				DK	168289 B	07/03/94
				DK	333984 A	19/01/85
				ES	533916 A	01/12/85
				ES	8602673 A	16/03/86
				GR	79948 A	31/10/84
				IE	58333 B	08/09/93
				IL	72100 A	30/09/88
				JP	1046512 B	09/10/89
				JP	1563283 C	12/06/90
				JP	60056959 A	02/04/85
				KR	9005025 B	18/07/90
				LU	90159 A	21/01/98
				MX	9202947 A	01/07/92
				NZ	208470 A	30/06/88
				ZA	8404599 A	27/02/85
				US	4730000 A	08/03/88
EP	0154780	B1	18/09/85	SE	0154780 T3	
				DE	3577089 D	00/00/00
				JP	1851736 C	21/06/94
				JP	5068466 B	29/09/93
				JP	60163866 A	26/08/85
				US	4774246 A	27/09/88



# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0140116 A1	08/05/85	SE 0140116 T3	
		AT 34573 T	15/06/88
		AU 553415 B	17/07/86
		AU 3298484 A	28/03/85
		CA 1238638 A	28/06/88
		DE 3433924 A,C	04/04/85
		DK 157997 B,C	12/03/90
		DK 445084 A	20/03/85
		ES 536004 A	01/02/86
		ES 545756 A	16/07/86
		ES 8604565 A	01/07/86
		ES 8609303 A	16/12/86
		FI 80033 B,C	29/12/89
		FI 843620 A	20/03/85
		FR 2555584 A,B	31/05/85
		HK 62191 A	16/08/91
		HR 930651 B	31/10/96
		HU 35666 A	29/07/85
		HU 193226 B	28/08/87
		JP 60190777 A	28/09/85
		KR 8701016 B	23/05/87
		SI 8411603 A	31/10/96
		US 4528287 A	09/07/85
		YU 45204 B	28/05/92
		YU 160384 A	28/02/87
		JP 61005075 A	10/01/86
		LV 5500 A	10/03/94
		SU 1694063 A	23/11/91
		HR 930652 B	31/10/96
		JP 1454541 C	25/08/88
		JP 60064979 A	13/04/85
		JP 62056151 B	24/11/87
		LT 2516 R	15/02/94
		SI 8611958 A	31/10/96
		YU 45379 B	28/05/92
		YU 195886 A	31/10/87
		ZA 8407059 A	24/04/85
<hr/>			
GB 2093018 A	25/08/82	JP 1316075 C	15/05/86
		JP 57031454 A	19/02/82
		JP 60012147 B	30/03/85
<hr/>			

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report				Publication date		Patent family member(s)	Publication date
GB	2057440	A	01/04/81	AU	533141	B	03/11/83
				AU	6112280	A	26/02/81
				BE	884824	A	16/12/80
				BE	887574	A	15/06/81
				CA	1159454	A	27/12/83
				CH	645641	A	15/10/84
				DE	3031767	A,C,R	26/03/81
				ES	494352	D	00/00/00
				ES	8104233	A	01/07/81
				FR	2463771	A,B	27/02/81
				HK	98486	A	24/12/86
				HU	184817	B	29/10/84
				IT	1132392	B	02/07/86
				IT	8024111	D	00/00/00
				JP	56030964	A	28/03/81
				MY	15587	A	31/12/87
				SE	440353	B,C	29/07/85
				SE	8005534	A	23/02/81
				SG	71386	G	27/03/87
				SU	978727	A	30/11/82
				SU	1015827	A	30/04/83
				CA	1159831	A	03/01/84
				CH	650501	A	31/07/85
				DE	3106013	A,C	09/09/82
				FR	2499990	A,B	20/08/82
				FR	2507183	A,B	10/12/82
				SE	440354	B,C	29/07/85
				SE	8100978	A	13/08/82
				US	4398029	A,B	09/08/83
WO	9638417	A1	05/12/96	AU	707628	B	15/07/99
				AU	5900596	A	18/12/96
				BR	9608593	A	05/01/99
				CA	2222552	A	05/12/96
				CN	1190958	A	19/08/98
				CZ	9703748	A	18/03/98
				DE	19519822	A	05/12/96
				EP	0828715	A	18/03/98
				HU	9802076	A	28/12/98
				JP	11505855	T	25/05/99
				NO	975464	A	27/11/97
				NZ	309074	A	30/08/99
				PL	323622	A	14/04/98
				SK	160397	A	06/05/98
				US	6114351	A	05/09/00
				ZA	9604414	A	09/12/96

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5225413	A	06/07/93	AU 613238 B	25/07/91
				AU 4139589 A	22/03/90
				CA 1340487 A	06/04/99
				DE 3831514 A	22/03/90
				DE 58906552 D	00/00/00
				EP 0359076 A,B	21/03/90
				JP 2121971 A	09/05/90
				JP 2728516 B	18/03/98
				ZA 8907044 A	27/06/90
-----					

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report			Publication date	Patent family member(s)	Publication date
US	5266569	A	30/11/93	US 5391763 A	21/02/95
				AT 124040 T	15/07/95
				AU 623801 B	21/05/92
				AU 6104290 A	21/02/91
				CA 2023217 A,C	17/02/91
				CA 2127561 A	17/02/91
				CN 1025192 B	29/06/94
				CN 1049501 A	27/02/91
				CY 1969 A	05/09/97
				CZ 281127 B	12/06/96
				CZ 9004027 A	17/04/96
				DD 298399 A	20/02/92
				DE 69020262 D,T	26/10/95
				DK 413455 T	14/08/95
				EG 19251 A	29/09/94
				EP 0413455 A,B	20/02/91
				SE 0413455 T3	
				ES 2074131 T	01/09/95
				FI 103879 B	00/00/00
				FI 920632 D	00/00/00
				FI 964520 A	11/11/96
				GR 3017072 T	30/11/95
				HK 1000207 A	00/00/00
				HU 211681 B	28/12/95
				HU 9500380 A	28/08/95
				IE 66202 B	13/12/95
				IE 902950 A	27/02/91
				IL 95331 A	31/07/95
				JP 1975517 C	27/09/95
				JP 3086875 A	11/04/91
				JP 7002734 B	18/01/95
				JP 7149758 A	13/06/95
				JP 8019099 B	28/02/96
				KR 9304844 B	09/06/93
				LU 90310 A	25/01/99
				LU 90311 A	25/01/99
				NO 300214 B	28/04/97
				NO 920599 D	00/00/00
				NZ 234920 A	25/06/92
				PL 166381 B	31/05/95
				PT 94998 A,B	18/04/91
				RU 2049777 C	10/12/95
				US 5164402 A	17/11/92
				US 5229396 A	20/07/93
				WO 9102526 A	07/03/91
				ZA 9006450 A	25/03/92

# INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/01

International application No.

PCT/SE 00/02217

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5164402 A	17/11/92	AT 124040 T	15/07/95
		AU 623801 B	21/05/92
		AU 6104290 A	21/02/91
		CA 2023217 A,C	17/02/91
		CA 2127561 A	17/02/91
		CN 1025192 B	29/06/94
		CN 1049501 A	27/02/91
		CY 1969 A	05/09/97
		CZ 281127 B	12/06/96
		CZ 9004027 A	17/04/96
		DD 298399 A	20/02/92
		DE 69020262 D,T	26/10/95
		DK 413455 T	14/08/95
		EG 19251 A	29/09/94
		EP 0413455 A,B	20/02/91
		SE 0413455 T3	
		ES 2074131 T	01/09/95
		FI 103879 B	00/00/00
		FI 920632 D	00/00/00
		FI 964520 A	11/11/96
		GR 3017072 T	30/11/95
		HK 1000207 A	00/00/00
		HU 211681 B	28/12/95
		HU 9500380 A	28/08/95
		IE 66202 B	13/12/95
		IE 902950 A	27/02/91
		IL 95331 A	31/07/95
		JP 1975517 C	27/09/95
		JP 3086875 A	11/04/91
		JP 7002734 B	18/01/95
		JP 7149758 A	13/06/95
		JP 8019099 B	28/02/96
		KR 9304844 B	09/06/93
		LU 90310 A	25/01/99
		LU 90311 A	25/01/99
		NO 300214 B	28/04/97
		NO 920599 D	00/00/00
		NZ 234920 A	25/06/92
		PL 166381 B	31/05/95
		PT 94998 A,B	18/04/91
		RU 2049777 C	10/12/95
		US 5229396 A	20/07/93
		US 5266569 A	30/11/93
		WO 9102526 A	07/03/91
		ZA 9006450 A	25/03/92
		US 5391763 A	21/02/95

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE 00/02217

Patent document cited in search report			Publication date		Patent family member(s)		Publication date	
EP	0676199	A1	11/10/95	SE	0676199	T3		
				AT	170400	T	15/09/98	
				DE	69504392	D,T	11/02/99	
				DK	676199	T	08/02/99	
				ES	2121293	T	16/11/98	
				US	5463035	A	31/10/95	
<hr/>								
EP	0165375	A2	27/12/85	SE	0165375	T3		
				AT	57532	T	15/11/90	
				AU	573780	B	23/06/88	
				AU	3914285	A	05/09/85	
				DE	3580124	D	00/00/00	
				DK	81885	A	25/08/85	
				EG	17585	A	30/08/93	
				ES	541170	A	01/03/88	
				ES	557331	A	16/06/88	
				ES	557332	A	16/06/88	
				ES	8801923	A	16/05/88	
				ES	8802455	A	01/10/88	
				ES	8802456	A	01/10/88	
				FI	83327	B,C	15/03/91	
				FI	850741	A	25/08/85	
				FI	890310	A	20/01/89	
				GR	850482	A	26/06/85	
				IE	57974	B	02/06/93	
				IN	165142	A	19/08/89	
				IN	168676	A	18/05/91	
				IN	168740	A	25/05/91	
				IT	1173374	B	24/06/87	
				IT	8419790	D	00/00/00	
				JP	1640418	C	18/02/92	
				JP	1729172	C	29/01/93	
				JP	2059153	B	11/12/90	
				JP	3027389	A	05/02/91	
				JP	4013326	B	09/03/92	
				JP	60208987	A	21/10/85	
				KR	8800024	B	15/02/88	
				MX	162343	A	26/04/91	
				MX	172472	B	17/12/93	
				MX	172473	B	17/12/93	
				MX	173934	B	11/04/94	
				MX	9203608	A	01/07/92	
				NO	171163	B,C	26/10/92	
				NO	850710	A	26/08/85	
				NZ	211224	A	26/03/92	
				NZ	233955	A	26/03/92	
				PH	22239	A	01/07/88	
				PH	23882	A	18/12/89	
				PT	80003	A,B	01/03/85	
				US	4668784	A	26/05/87	
				US	4684647	A	04/08/87	
				YU	29085	A	31/12/87	
				YU	43401	B	30/06/89	
				ZA	8501379	A	30/10/85	
				ZA	8508046	A	25/06/86	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/SE 00/02217

Patent document cited in search report				Publication date		Patent family member(s)	Publication date
EP	0268223	A2	25/05/88	AU	602024	B	27/09/90
				AU	8128587	A	19/05/88
				DE	3639465	A	19/05/88
				DK	602987	A	19/05/88
				FI	875055	A	19/05/88
				HU	199848	B	28/03/90
				IL	84508	D	00/00/00
				JP	63135372	A	07/06/88
				NO	874786	A	19/05/88
				NZ	222571	A	28/11/89
				PT	86153	A,B	01/12/87
				ZA	8708593	A	09/05/88
EP	0354453	A2	14/02/90	AU	625066	B	02/07/92
				AU	3927689	A	15/02/90
				CN	1040200	A	07/03/90
				CN	1042732	B	31/03/99
				DE	68920794	D,T	29/06/95
				ES	2070150	T	01/06/95
				JP	2138219	A	28/05/90
				JP	2821912	B	05/11/98
				KR	137767	B	15/05/98
				NZ	230130	A	25/06/92
				PH	26316	A	29/04/92
				US	5175160	A	29/12/92